Clinical Trials
Abraxane in Treatment of Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: nab-paclitaxel Sponsor: Celgene Completed Mon, 21 Sep 2015 12:00:00 EDT Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast CancerConditions: Breast Cancer; Triple Negative Breast Cancer; Stage IV Breast Cancer; Metastatic Breast CancerInterventions: Drug: Abraxane alone; Drug: Abraxane + Tigatuzumab Sponsors: University of Alabama at Birmingham; Susan G. Komen Breast Cancer Foundation; Daiichi Sankyo UK Ltd.; Triple Negative Breast Cancer Foundation Completed Thu, 03 Mar 2011 12:00:00 EST Abraxane in CIMP-High Colorectal and Small Bowel AdenocarcinomasConditions: Colorectal Cancer; Cancer of Gastrointestinal TractIntervention: Drug: Abraxane Sponsors: M.D. Anderson Cancer Center; Celgene Completed Wed, 21 Nov 2012 12:00:00 EST Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast CancerCondition: Breast Cancer StageIntervention: Drug: nab-paclitaxel Sponsor: Jilin University Not yet recruiting Wed, 22 May 2019 12:00:00 EDT Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine TherapyCondition: Pancreatic CancerIntervention: Drug: Abraxane Sponsor: University of Miami Completed Thu, 05 Jun 2008 12:00:00 EDT Study of Gemcitabine and Abraxane for Pancreas CancerCondition: Pancreatic CancerIntervention: Drug: Gemcitabine and Abraxane Sponsor: Georgetown University Terminated Wed, 17 Sep 2014 12:00:00 EDT A Combination of Abraxane and Cisplatin in Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: Abraxane and Cisplatin combination Sponsor: Fudan University Completed Thu, 24 Jun 2010 12:00:00 EDT PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: PU-H71; Drug: Nab-paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; Samus Therapeutics, Inc. Active, not recruiting Wed, 24 May 2017 12:00:00 EDT The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)Conditions: Esophageal Cancer; ToxicityIntervention: Drug: Nab-paclitaxel Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Celgene Corporation Completed Fri, 24 Oct 2014 12:00:00 EDT Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric CancerCondition: Stomach and Gastro-Esophageal Junction (GEJ) CancerIntervention: Drug: nab-Paclitaxel Sponsor: Hellenic Oncology Research Group Completed Mon, 29 Sep 2014 12:00:00 EDT 
S-1 in Combination With Abraxane in Treating CholangiocarcinomaCondition: CholangiocarcinomaIntervention: Drug: S-1 plus Abraxane Sponsor: Yuhong Li Completed Wed, 16 Oct 2013 12:00:00 EDT Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerCondition: Breast CancerInterventions: Drug: Abraxane; Drug: Xeloda Sponsor: Zhejiang Cancer Hospital Unknown status Mon, 27 Aug 2018 12:00:00 EDT Treatment of Pancreatic Cancer With AbraxaneCondition: Metastatic Pancreatic CancerInterventions: Drug: Abraxane; Drug: Gemcitabine Sponsor: Celgene Completed Tue, 22 Sep 2015 12:00:00 EDT Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast CancerCondition: Breast CancerInterventions: Drug: Abraxane; Drug: Paclitaxel Sponsor: Fondazione Michelangelo Active, not recruiting Tue, 02 Apr 2013 12:00:00 EDT Treatment With Nab-paclitaxel in Cutaneous SCCCondition: Cutaneous Squamous Cell CarcinomaIntervention: Drug: nab-paclitaxel Sponsors: Icahn School of Medicine at Mount Sinai; Celgene Corporation Terminated Mon, 03 Mar 2014 12:00:00 EST IST Neoadjuvant Abraxane in Newly Diagnosed Breast CancerCondition: Breast CancerIntervention: Drug: Nab-Paclitaxel Sponsor: Barwon Health Unknown status Fri, 12 Apr 2013 12:00:00 EDT Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyConditions: Non-Small Cell Lung Cancer; Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Large Cell; Lung NeoplasmInterventions: Drug: nab-paclitaxel; Drug: Carboplatin Sponsor: Celgene Completed Fri, 30 May 2014 12:00:00 EDT The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerCondition: Breast CancerInterventions: Drug: Abraxane; Drug: Epirubicin Sponsor: Zhejiang Cancer Hospital Unknown status Mon, 27 Aug 2018 12:00:00 EDT Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast CancerCondition: Breast CancerIntervention: Drug: Abraxane Sponsor: Tianjin Medical University Unknown status Mon, 23 Jul 2012 12:00:00 EDT Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial CancerConditions: Urothelial Cancer; Bladder CancerIntervention: Drug: ABI-007 (Abraxane®) Sponsors: University of Michigan Rogel Cancer Center; Celgene Corporation Terminated Thu, 15 Oct 2009 12:00:00 EDT
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerIntervention: Drug: RX-3117 Sponsor: Rexahn Pharmaceuticals, Inc. Completed Fri, 16 Jun 2017 12:00:00 EDT A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck CancerCondition: Head and Neck CancerIntervention: Drug: ABI-007 Sponsors: University Health Network, Toronto; Celgene Corporation Completed Mon, 11 Aug 2008 12:00:00 EDT Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerCondition: Ovarian CancerIntervention: Drug: Fostamatinib and Paclitaxel Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Rigel Pharmaceuticals; Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Recruiting Fri, 11 Aug 2017 12:00:00 EDT Endoscopic Abraxane Injection Into Pancreatic CystsCondition: Pancreatic CystsIntervention: Drug: Albumin bound paclitaxel Sponsor: Massachusetts General Hospital Terminated Wed, 03 Oct 2012 12:00:00 EDT Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDACCondition: Metastatic Pancreatic Ductal AdenocarcinomaInterventions: Drug: Palbociclib; Drug: Nab-Paclitaxel Sponsors: Pfizer; Celgene Completed Fri, 17 Jul 2015 12:00:00 EDT Single Arm on the Tolerability of Weekly Nab-paclitaxelCondition: Non Small Cell Lung Cancer (NSCLC)Intervention: Drug: Nab-Paclitaxel Sponsors: UNC Lineberger Comprehensive Cancer Center; Celgene Completed Mon, 08 Oct 2012 12:00:00 EDT Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung CancerCondition: Squamous Cell Carcinoma of LungIntervention: Drug: nanoparticle albumin-bound paclitaxel Sponsor: Chinese Academy of Medical Sciences Unknown status Fri, 25 Oct 2013 12:00:00 EDT The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung CancerCondition: Small Cell Lung CancerIntervention: Drug: Nab-paclitaxel Sponsor: Tongji University Unknown status Mon, 13 Oct 2014 12:00:00 EDT Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal CancerCondition: Colorectal NeoplasmsIntervention: Drug: ABI-007 Sponsor: Celgene Completed Thu, 03 Apr 2014 12:00:00 EDT Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCTCondition: Breast CancerInterventions: Drug: nab-Paclitaxel+carboplatin; Drug: Paclitaxel+carboplatin Sponsor: Shengjing Hospital Recruiting Thu, 24 Oct 2019 12:00:00 EDT
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast CancerCondition: Breast CancerIntervention: Drug: Nab-paclitaxel Sponsors: Spanish Breast Cancer Research Group; Celgene Completed Wed, 28 Mar 2012 12:00:00 EDT Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic CancerCondition: Resectable Pancreatic CancerIntervention: Drug: Gemcitabine and Abraxane Sponsors: Pancreatic Cancer Research Team; Celgene Corporation Completed Thu, 17 Feb 2011 12:00:00 EST Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic CancerCondition: Advanced Pancreatic CancerIntervention: Drug: Nab-paclitaxel and S-1 Sponsor: Aiping Zhou Completed Tue, 30 Jan 2018 12:00:00 EST Pembrolizumab and Paclitaxel in Refractory Small Cell Lung CancerCondition: Small Cell Lung CancerIntervention: Drug: pembrolizumab, paclitaxel Sponsor: Seoul National University Hospital Completed Wed, 16 Sep 2015 12:00:00 EDT Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic MelanomaCondition: Metastatic MelanomaIntervention: Drug: Abraxane Sponsor: Celgene Corporation Withdrawn Fri, 30 Aug 2013 12:00:00 EDT Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Abraxane; Drug: Carboplatin Sponsors: Duke University; Celgene Corporation Terminated Wed, 22 Sep 2010 12:00:00 EDT Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast CancerInterventions: Drug: nab-Paclitaxel; Drug: Paclitaxel Sponsors: German Breast Group; Celgene Corporation; Roche Pharma AG Completed Tue, 24 Apr 2012 12:00:00 EDT Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder CancerCondition: Bladder CancerIntervention: Drug: Paclitaxel, nanoparticle albumin-bound Sponsors: Columbia University; Celgene Corporation Unknown status Mon, 31 Dec 2007 12:00:00 EST Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial DiseaseCondition: Peripheral Arterial DiseaseIntervention: Drug: Paclitaxel Sponsors: Lahey Clinic; National Evaluation System for health Technology Coordinating Center (NESTcc); Society for Vascular Surgery Patient Safety Organization Active, not recruiting Tue, 01 Dec 2020 12:00:00 EST Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: Abraxane Sponsor: Fudan University Completed Mon, 22 Feb 2016 12:00:00 EST
A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: Abraxane and Gemcitabine Sponsor: Fudan University Completed Mon, 12 Mar 2012 12:00:00 EDT Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and TrastuzumabConditions: Breast Cancer; HER-2 Positive Breast Cancer; Effects of ChemotherapyIntervention: Drug: Nab-paclitaxel Sponsor: Osaka Medical College Completed Mon, 12 Sep 2011 12:00:00 EDT Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic CancerConditions: Pancreatic Adenocarcinoma Resectable; Pancreatic Adenocarcinoma Locally Advanced; Pancreatic Adenocarcinoma MetastaticInterventions: Drug: Gemcitabine; Drug: Abraxane Sponsors: Jean-Luc Van Laethem; Celgene Corporation Completed Fri, 26 Oct 2012 12:00:00 EDT Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy ResponseCondition: Breast Neoplasm FemaleIntervention: Drug: Paclitaxel Sponsor: University of Wisconsin, Madison Recruiting Thu, 30 Mar 2017 12:00:00 EDT Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric CancerCondition: Advanced Gastric CancerIntervention: Drug: Albumin-paclitaxel, Apatinib, Camrelizumab Sponsor: China Medical University, China Not yet recruiting Thu, 27 Feb 2020 12:00:00 EST Hepatic Arterial Infusion (HAI) of AbraxaneConditions: Liver Cancer; Advanced Cancers; Solid TumorsInterventions: Drug: HAI Abraxane; Procedure: Hepatic Artery Catheter; Drug: IV Abraxane Sponsors: M.D. Anderson Cancer Center; National Comprehensive Cancer Network Completed Tue, 12 Aug 2008 12:00:00 EDT Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord CompressionCondition: Cord CompressionInterventions: Radiation: Radiation therapy; Drug: nab-Paclitaxel Sponsors: Washington University School of Medicine; Celgene Recruiting Fri, 31 Aug 2018 12:00:00 EDT Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing SarcomaConditions: Tumor, Desmoplastic Small Round Cell, Adult; Tumor, Desmoplastic Small Round Cell, Childhood; Sarcoma, Ewing; Sarcoma; DesmoidIntervention: Drug: nab paclitaxel Sponsor: Grupo Espanol de Investigacion en Sarcomas Active, not recruiting Fri, 08 Sep 2017 12:00:00 EDT Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric CancerCondition: Gastric CanerInterventions: Drug: Albumin Bound Paclitaxel; Drug: 5-FU Sponsor: Sun Yat-sen University Unknown status Fri, 29 Aug 2014 12:00:00 EDT Schedules of Nab-Paclitaxel in Metastatic Breast CancerCondition: Metastatic BreastcancerIntervention: Drug: nab-Paclitaxel Sponsors: International Breast Cancer Study Group; Breast International Group Active, not recruiting Mon, 10 Dec 2012 12:00:00 EST
Abraxane/BevacizumabConditions: Ovarian Cancer; Peritoneal CancerInterventions: Drug: Abraxane; Drug: Bevacizumab Sponsor: OHSU Knight Cancer Institute Terminated Mon, 01 Apr 2013 12:00:00 EDT First Line Therapy for Patients With Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: ABI-007 Sponsor: Celgene Terminated Thu, 05 Apr 2007 12:00:00 EDT Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic CancerConditions: Pancreatic Cancer; Metastatic Pancreatic CancerIntervention: Drug: nab paclitaxel plus gemcitabine Sponsors: Asan Medical Center; Bundang CHA Hospital; Ulsan University Hospital Completed Mon, 21 Oct 2019 12:00:00 EDT Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaConditions: Urothelial Carcinoma; Bladder Cancer; Transitional Cell CarcinomaInterventions: Drug: nab-paclitaxel; Drug: Gemcitabine Sponsors: SCRI Development Innovations, LLC; Celgene Terminated Fri, 02 Sep 2016 12:00:00 EDT Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of EsophagusCondition: Squamous Cell Carcinoma of EsophagusIntervention: Drug: nanoparticle albumin-bound paclitaxel Sponsor: Zhejiang University Withdrawn Fri, 10 Jan 2014 12:00:00 EST Abraxane and Alimta in Advanced Solid TumorsConditions: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: Abraxane; Drug: Alimta Sponsors: University of California, Davis; Celgene; Eli Lilly and Company Terminated Mon, 07 May 2007 12:00:00 EDT A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate CancerCondition: Castration-resistant Prostate CancerInterventions: Drug: nab-paclitaxel; Drug: carboplatin Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Unknown status Mon, 04 Nov 2019 12:00:00 EST Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic ResponseCondition: Breast CancerInterventions: Drug: Paclitaxel; Radiation: Radiation therapy Sponsor: NYU Langone Health Completed Fri, 31 Oct 2014 12:00:00 EDT Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerConditions: HER2-negative Breast Cancer; Inflammatory Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast CancerInterventions: Drug: Romidepsin; Drug: Abraxane Sponsors: Sidney Kimmel Cancer Center at Thomas Jefferson University; Celgene Corporation Terminated Tue, 10 Sep 2013 12:00:00 EDT Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative ResectionConditions: Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic AdenocarcinomaInterventions: Drug: nab-paclitaxel; Drug: gemcitabine Sponsor: Xian-Jun Yu Completed Mon, 30 Dec 2013 12:00:00 EST
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: ABI-007; Drug: Bevacizumab Sponsor: Celgene Completed Tue, 31 Oct 2006 12:00:00 EST NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric AdenocarcinomaCondition: Cancer of StomachInterventions: Drug: nab-paclitaxel; Drug: FOLFOX Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group; Celgene Corporation Recruiting Wed, 01 Jul 2015 12:00:00 EDT Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast CancerCondition: Breast CancerInterventions: Drug: Mifepristone; Other: Placebo; Drug: Nab-Paclitaxel Sponsor: University of Chicago Recruiting Thu, 02 Jun 2016 12:00:00 EDT Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric CancerCondition: Gastric CancerInterventions: Drug: Albumin Bound Paclitaxel; Drug: S-1 Sponsor: Sun Yat-sen University Completed Fri, 29 Aug 2014 12:00:00 EDT Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer PatientsCondition: Gastric AdenocarcinomaIntervention: Drug: nanoparticle Albumin-Bound paclitaxel Sponsor: Yanqiao Zhang Unknown status Tue, 17 Jul 2012 12:00:00 EDT Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaCondition: Metastatic Pancreatic Ductal AdenocarcinomaInterventions: Drug: Relacorilant, 100 mg and 25 mg; Drug: Nab paclitaxel Sponsor: Corcept Therapeutics Active, not recruiting Wed, 01 Apr 2020 12:00:00 EDT Phase I/II Study of Abraxane in Recurrent and Refractory LymphomaConditions: Lymphoma, Non-Hodgkin; Hodgkin DiseaseIntervention: Drug: Abraxane Sponsor: Washington University School of Medicine Terminated Fri, 16 Mar 2012 12:00:00 EDT Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: Bevacizumab, Abraxane Sponsors: Abramson Cancer Center of the University of Pennsylvania; Genentech, Inc. Completed Mon, 14 May 2007 12:00:00 EDT Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With CetuximabCondition: Head and Neck CancerInterventions: Drug: Abraxane; Drug: Cetuximab Sponsor: University of California, Irvine Terminated Thu, 27 Apr 2006 12:00:00 EDT Single Agent Abraxane as Second Line Therapy in Bladder CancerCondition: Transitional Cell CarcinomaIntervention: Drug: Paclitaxel Sponsors: Sunnybrook Health Sciences Centre; Celgene Corporation Completed Fri, 23 May 2008 12:00:00 EDT
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the UterusCondition: Endometrial CancerInterventions: Drug: Carboplatin AUC; Drug: Abraxane Sponsor: NYU Langone Health Completed Wed, 20 Apr 2016 12:00:00 EDT A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCCondition: Non-Small Cell Lung CancerInterventions: Drug: Camrelizumab; Drug: nb-Paclitaxel Sponsors: Sun Yat-sen University; Jiangsu HengRui Medicine Co., Ltd. Recruiting Tue, 19 Nov 2019 12:00:00 EST A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)Condition: Advanced Gastric CancerInterventions: Combination Product: fruquintinib +paclitaxel; Combination Product: fruquintinib placebo + paclitaxel Sponsors: Hutchison Medipharma Limited; Sun Yat-sen University Recruiting Fri, 21 Jul 2017 12:00:00 EDT Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer PatientsCondition: Metastatic Pancreatic CancerIntervention: Drug: Nab paclitaxel / gemcitabine Sponsor: Helse Stavanger HF Unknown status Mon, 14 Mar 2016 12:00:00 EDT Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable AngiosarcomaCondition: Angiosarcoma MetastaticIntervention: Drug: Abraxane combined with liposomal doxorubicin Sponsor: Sun Yat-sen University Not yet recruiting Mon, 26 Apr 2021 12:00:00 EDT Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid TumorsCondition: CancerInterventions: Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: Emory University; Celgene Corporation Recruiting Wed, 25 Apr 2018 12:00:00 EDT Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple MyelomaCondition: Relapsed or Refractory Multiple MyelomaInterventions: Drug: Lenalidomide; Drug: nab-paclitaxel Sponsors: NYU Langone Health; Celgene Corporation Terminated Mon, 03 Mar 2014 12:00:00 EST Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV MelanomaConditions: Stage III Melanoma; Stage IV Melanoma; Unresectable MelanomaIntervention: Drug: Pazopanib and Paclitaxel Sponsors: University of California, Irvine; GlaxoSmithKline Completed Wed, 21 Apr 2010 12:00:00 EDT Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell CancerCondition: Small Cell Lung Cancer (SCLC)Interventions: Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsors: Muhammad Furqan; Celgene Corporation Active, not recruiting Thu, 12 May 2016 12:00:00 EDT Phase I Study of the Combination of Satraplatin and Abraxane in Advanced CancersCondition: Advanced CancersInterventions: Drug: Satraplatin; Drug: Abraxane Sponsors: Yale University; Agennix Completed Tue, 15 May 2007 12:00:00 EDT
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast CancerCondition: Breast NeoplasmsIntervention: Drug: Cirmtuzumab + Paclitaxel Sponsors: Barbara Parker, MD; Oncternal Therapeutics, Inc Active, not recruiting Wed, 18 May 2016 12:00:00 EDT Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerCondition: Pancreatic CancerIntervention: Drug: SHR-1020+albumin-bound paclitaxel Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting Wed, 24 Mar 2021 12:00:00 EDT NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue SarcomaCondition: Soft Tissue SarcomaInterventions: Drug: Nab-Paclitaxel; Drug: gemcitabine Sponsor: Swiss Group for Clinical Cancer Research Active, not recruiting Tue, 15 May 2018 12:00:00 EDT A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCondition: Gastric CancerIntervention: Drug: fruquintinib+paclitaxel Sponsor: Hutchison Medipharma Limited Completed Tue, 14 Apr 2015 12:00:00 EDT Study of Abraxane and Carboplatin to Treat Small Cell Lung CancerCondition: Small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Abraxane Sponsors: UNC Lineberger Comprehensive Cancer Center; Celgene Corporation Terminated Fri, 30 Mar 2007 12:00:00 EDT An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Nanoparticle albumin-bound paclitaxel; Drug: Phenelzine Sulfate Sponsors: EpiAxis Therapeutics; The Canberra Hospital; Southern Medical Day Care Centre; Liverpool Cancer Therapy Centre Completed Mon, 23 Apr 2018 12:00:00 EDT Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Abraxane; Radiation: Radiation Therapy Sponsor: Olugbenga Olowokure Terminated Wed, 26 Sep 2012 12:00:00 EDT Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric CancerCondition: Gastric CancerIntervention: Drug: Paclitaxel + S-1 + Oxaliplatin Sponsor: Affiliated Hospital of Qinghai University Unknown status Mon, 28 Aug 2017 12:00:00 EDT Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsConditions: Neuroblastoma; Rhabdomyosarcoma; Ewing's Sarcoma; Ewing's Tumor; Sarcoma, Ewing's; Sarcomas, Epitheliod; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell; Melanoma; Malignant Melanoma; Clinical Oncology; Oncology, Medical; Pediatrics, Osteosarcoma; Osteogenic Sarcoma; Osteosarcoma Tumor; Sarcoma, Osteogenic; Tumors; Cancer; Neoplasia; Neoplasm; Histiocytoma; Fibrosarcoma; DermatofibrosarcomaIntervention: Drug: nab-paclitaxel Sponsor: Celgene Completed Mon, 14 Oct 2013 12:00:00 EDT Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerCondition: Gastroesophageal CancerInterventions: Drug: nab-paclitaxel; Biological: ramucirumab Sponsors: SCRI Development Innovations, LLC; Celgene Completed Wed, 17 Dec 2014 12:00:00 EST
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL CancerCondition: Lung CancerInterventions: Drug: Carboplatin; Drug: Abraxane Sponsors: Kathryn Mileham; Celgene Completed Wed, 31 Dec 2014 12:00:00 EST Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the LiverConditions: Melanoma; Liver MetastasisIntervention: Drug: Nab-Paclitaxel (Abraxane) Sponsors: M.D. Anderson Cancer Center; Celgene Corporation Completed Mon, 02 Feb 2009 12:00:00 EST A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine CarcinomasCondition: Gastrointestinal Neuroendocrine CarcinomasInterventions: Drug: NAB paclitaxel; Drug: Carboplatin Sponsors: Barwon Health; Specialised Therapeutics Australia; Deakin University; Australasian Gastro-Intestinal Trials Group Unknown status Wed, 13 Aug 2014 12:00:00 EDT Paclitaxel-Avelumab for AngiosarcomaCondition: Angiosarcoma MetastaticInterventions: Drug: Avelumab; Drug: Paclitaxel Sponsors: Sung Yong Oh; Merck KGaA, Darmstadt, Germany Recruiting Tue, 01 May 2018 12:00:00 EDT Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast CancerCondition: Recurrent or Metastatic Breast CancerInterventions: Drug: DHP107; Drug: IV Paclitaxel Sponsor: Daehwa Pharmaceutical Co., Ltd. Recruiting Mon, 30 Oct 2017 12:00:00 EDT Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical CancerCondition: Uterine Cervical CancerIntervention: Drug: albumin-bound paclitaxel plus nedaplatin Sponsor: Chinese Academy of Medical Sciences Unknown status Fri, 17 Aug 2012 12:00:00 EDT Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung CancerCondition: Non Small Cell Lung CancerIntervention: Drug: nanoparticle albumin-bound paclitaxel Sponsor: Zhejiang University Unknown status Thu, 19 Dec 2013 12:00:00 EST Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)Condition: Ovarian CarcinomaInterventions: Device: NovoTTF-100L(O); Drug: Paclitaxel Sponsor: NovoCure Ltd. Unknown status Fri, 19 Sep 2014 12:00:00 EDT Dose Dense Abraxane in Adjuvant Chemotherapy for Breast CancerCondition: Breast CancerIntervention: Drug: Abraxane Sponsors: Harold J. Burstein, MD, PhD; Celgene Corporation; Beth Israel Deaconess Medical Center; Massachusetts General Hospital Completed Wed, 29 Mar 2006 12:00:00 EST Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid TumorsCondition: Solid TumorsIntervention: Drug: CORT125134 with nab-paclitaxel Sponsor: Corcept Therapeutics Completed Thu, 05 May 2016 12:00:00 EDT
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)Condition: Penile Squamous Cell Carcinoma Stage IVInterventions: Drug: Pazopanib; Drug: Paclitaxel Sponsor: Spanish Oncology Genito-Urinary Group Terminated Fri, 31 Oct 2014 12:00:00 EDT Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic CancerCondition: Advanced Pancreatic CancerInterventions: Drug: nanoparticle albumin-bound paclitaxel; Drug: S-1 Sponsor: Chinese PLA General Hospital Unknown status Mon, 28 Apr 2014 12:00:00 EDT A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC PatientsCondition: Metastatic Pancreatic Ductal AdenocarcinomaIntervention: Drug: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine Sponsors: Pancreatic Cancer Action Network; Novartis Pharmaceuticals Recruiting Fri, 09 Oct 2020 12:00:00 EDT Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung CancerCondition: Lung CancerInterventions: Biological: Pembrolizumab; Drug: Nab-Paclitaxel Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Merck Canada Inc.; Celgene; Jewish General Hospital Completed Mon, 11 Apr 2016 12:00:00 EDT Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing HemodialysisCondition: Hemodialysis Graft DysfunctionIntervention: Drug: ABI-007 Sponsor: Celgene Terminated Mon, 07 Nov 2005 12:00:00 EST Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate CancerCondition: Prostate CancerIntervention: Drug: Abraxane Sponsors: Kaiser Permanente; Celgene Corporation Completed Wed, 01 Feb 2006 12:00:00 EST The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract AdenocarcinomaCondition: Biliary Tract CancerIntervention: Drug: Nab-paclitaxel,S-1 Sponsor: Aiping Zhou Completed Tue, 05 Feb 2019 12:00:00 EST A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and CisplatinCondition: Esophageal CancerIntervention: Drug: paclitaxel and cisplatin Sponsors: Chinese Academy of Medical Sciences; Beijing Municipal Science & Technology Commission Unknown status Fri, 30 Sep 2011 12:00:00 EDT Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic CancerCondition: Pancreatic NeoplasmsInterventions: Drug: nab-paclitaxel; Drug: Gemcitabine Sponsor: Celgene Completed Fri, 20 Dec 2013 12:00:00 EST Effects of Paclitaxel on Intimal HyperplasiaCondition: Peripheral Vascular DiseaseIntervention: Drug: Paclitaxel Sponsor: Patrick Kelly Completed Wed, 19 Oct 2011 12:00:00 EDT
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaCondition: MelanomaInterventions: Drug: ABI-007; Drug: Ipilimumab; Behavioral: Phone Call Sponsors: M.D. Anderson Cancer Center; Celgene Completed Tue, 09 Apr 2013 12:00:00 EDT Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver InvolvementCondition: Advanced CancerIntervention: Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Completed Fri, 27 Jul 2007 12:00:00 EDT Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: ABI-007; Drug: Docetaxel Sponsor: Celgene Completed Wed, 11 Jan 2006 12:00:00 EST Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Pembrolizumab; Drug: Paclitaxel Sponsors: Queen Mary University of London; Merck Sharp & Dohme Corp.; European Institute of Oncology Not yet recruiting Fri, 15 Feb 2019 12:00:00 EST A Study of KX2-391 With Paclitaxel in Patients With Solid TumorsConditions: Unspecified Adult Solid Tumor, Protocol Specific; Gastric Cancer; Breast CancerIntervention: Drug: KX2-391 and Paclitaxel Sponsor: Hanmi Pharmaceutical Company Limited Unknown status Wed, 09 Jan 2013 12:00:00 EST Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.Condition: Pancreatic Cancer Stage IIInterventions: Drug: Nab-paclitaxel and Gemcitabine; Drug: Gemcitabine Sponsors: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente; Unità Sperimentazioni cliniche; Istituto Nazionale Tumori di Napoli Completed Thu, 23 Jan 2014 12:00:00 EST A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerCondition: Triple-Negative Breast CancerInterventions: Drug: Atezolizumab; Drug: Nab-Paclitaxel Sponsor: Hoffmann-La Roche Recruiting Mon, 04 Nov 2019 12:00:00 EST The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic CancerConditions: Pancreatic Cancer; Chemotherapy EffectInterventions: Drug: raltitrexed for injection; Drug: nab-paclitaxel Sponsor: Fudan University Recruiting Fri, 09 Oct 2020 12:00:00 EDT Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial CancerCondition: Urothelial CarcinomaInterventions: Drug: Pembrolizumab; Drug: Abraxane Sponsor: University of Michigan Rogel Cancer Center Recruiting Fri, 04 Aug 2017 12:00:00 EDT Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced AngiosarcomasCondition: AngiosarcomaInterventions: Drug: Paclitaxel; Drug: Bevacizumab Sponsors: Centre Oscar Lambret; French Sarcoma Group; Study Group of Bone Tumors Completed Thu, 24 Feb 2011 12:00:00 EST
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell CarcinomaCondition: Esophageal CancerIntervention: Drug: paclitaxel; cisplatin Sponsor: Chinese Academy of Medical Sciences Completed Thu, 08 May 2014 12:00:00 EDT LDE225 and Paclitaxel in Solid TumorsConditions: Solid Tumor; Ovarian CancerInterventions: Drug: LDE225; Drug: Paclitaxel Sponsor: Swiss Group for Clinical Cancer Research Completed Tue, 01 Oct 2013 12:00:00 EDT A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCondition: Malignant MelanomaInterventions: Drug: ABI-007; Drug: Dacarbazine Sponsors: Celgene; University of Arizona Completed Wed, 18 Mar 2009 12:00:00 EDT Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisConditions: Breast Cancer; HER2-positive Breast CancerInterventions: Drug: Pyrotinib Plus And; Drug: Trastuzumab; Drug: Abraxane Sponsor: Shandong Cancer Hospital and Institute Not yet recruiting Fri, 20 Nov 2020 12:00:00 EST Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial CarcinomaCondition: Bladder CancerInterventions: Drug: paclitaxel; Drug: RAD001 Sponsor: Heinrich-Heine University, Duesseldorf Terminated Tue, 07 Jul 2009 12:00:00 EDT T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: T-DM1; Drug: Lapatinib; Drug: Abraxane Sponsors: Jenny C. Chang, MD; The Methodist Hospital Research Institute Completed Thu, 27 Feb 2014 12:00:00 EST A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line ChemotherapyCondition: Stage IV Gastric CancerIntervention: Drug: Paclitaxel Sponsor: Daehwa Pharmaceutical Co., Ltd. Completed Thu, 25 Apr 2013 12:00:00 EDT Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line TherapyCondition: Recurrent or Metastatic Breast CancerInterventions: Drug: Oral paclitaxel; Drug: Paclitaxel injection Sponsor: Daehwa Pharmaceutical Co., Ltd. Recruiting Fri, 20 Oct 2017 12:00:00 EDT Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast CaCondition: Breast CancerInterventions: Drug: everolimus; Drug: abraxane Sponsors: Rutgers, The State University of New Jersey; National Cancer Institute (NCI) Terminated Wed, 08 Jul 2009 12:00:00 EDT A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic CancerConditions: Pancreatic Cancer; Metastatic Pancreatic CancerIntervention: Drug: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel Sponsors: Atlantic Health System; Rafael Pharmaceuticals Inc. Unknown status Mon, 19 Feb 2018 12:00:00 EST
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous AngiosarcomaCondition: Cutaneous AngiosarcomaInterventions: Drug: Paclitaxel; Radiation: Radiation therapy; Procedure: Research blood draw Sponsor: Washington University School of Medicine Recruiting Fri, 19 Apr 2019 12:00:00 EDT Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric AdenocarcinomaCondition: Gastric AdenocarcinomaIntervention: Drug: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 Sponsor: Beijing Cancer Hospital Recruiting Wed, 07 Aug 2019 12:00:00 EDT Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic NeoplasmConditions: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of PancreasIntervention: Drug: Ethanol and Paclitaxel Injection Sponsors: Lawson Health Research Institute; University of Western Ontario, Canada Terminated Fri, 03 Feb 2012 12:00:00 EST Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ CarcinomaCondition: Gastric CarcinomaInterventions: Drug: Albumin-Bound Paclitaxel; Drug: Toripalimab Sponsor: China Medical University, China Recruiting Tue, 23 Jun 2020 12:00:00 EDT Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2Condition: Carcinoma, Non-Small-Cell LungInterventions: Drug: nab-Paclitaxel; Drug: Carboplatin Sponsor: Celgene Completed Thu, 13 Nov 2014 12:00:00 EST Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: Paclitaxel for Injection（Albumin Bound）; Drug: Gemcitabine Sponsors: Fudan University; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Fri, 26 Apr 2019 12:00:00 EDT Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic CancerConditions: Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: nab-Paclitaxel Sponsor: Western Regional Medical Center Terminated Fri, 10 May 2013 12:00:00 EDT Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer PatientsCondition: Esophageal Squamous Cell CarcinomaIntervention: Drug: albumin-bound paclitaxel plus cisplatin Sponsors: Zhejiang Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University Completed Fri, 10 Dec 2010 12:00:00 EST Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerConditions: Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Recurrent Ovarian CarcinomaIntervention: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Wed, 11 Jul 2007 12:00:00 EDT Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)Conditions: Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, AntineoplasticInterventions: Drug: nab-Paclitaxel; Drug: Gemcitabine Sponsor: Celgene Active, not recruiting Thu, 17 Oct 2013 12:00:00 EDT
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerCondition: Squamous Cell Carcinoma, Non-Small-Cell LungInterventions: Drug: Abraxane (Induction); Drug: Carboplatin (Induction); Drug: Abraxane (Maintenance); Other: Best Supportive Care (Maintenance) Sponsor: Celgene Completed Mon, 06 Jan 2014 12:00:00 EST Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer PatientsConditions: Stomach Cancer; Stomach Neoplasm; Gastric Cancer; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Ramucirumab; Drug: Paclitaxel Sponsors: Federation Francophone de Cancerologie Digestive; Eli Lilly and Company Recruiting Fri, 30 Nov 2018 12:00:00 EST Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the LungCondition: Non-small Cell Lung CancerIntervention: Drug: nanoparticle albumin-bound paclitaxel/carboplatin Sponsor: The First Affiliated Hospital of Guangzhou Medical University Unknown status Fri, 07 Jun 2013 12:00:00 EDT VQI DELTA Paclitaxel Device Safety AnalysisCondition: Peripheral Vascular DiseaseInterventions: Drug: Paclitaxel; Device: Non-drug coated Device Treatment Sponsors: Lahey Clinic; Society for Vascular Surgery Patient Safety Organization Completed Tue, 01 Oct 2019 12:00:00 EDT Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.Condition: Advanced Solid TumorsInterventions: Drug: Paclitaxel Micelles for Injection; Drug: Paclitaxel injection Sponsors: First Affiliated Hospital of Zhejiang University; Hangzhou Dihua Biotechnology Co., LTD. Not yet recruiting Wed, 03 Mar 2021 12:00:00 EST Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer PatientsCondition: Breast CancerIntervention: Drug: Paclitaxel 80mg/m2 weekly x 12 weeks Sponsor: University of Michigan Rogel Cancer Center Completed Wed, 14 Jan 2015 12:00:00 EST Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Pazopanib; Drug: Paclitaxel Sponsors: ARCAGY/ GINECO GROUP; Novartis Completed Mon, 09 Mar 2015 12:00:00 EDT Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerCondition: Pancreatic CancerIntervention: Drug: gemcitabine and nab paclitaxel Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Novartis; Celgene Corporation Completed Fri, 06 Feb 2015 12:00:00 EST Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic CancerCondition: Advanced Pancreatic CancerInterventions: Drug: nanoparticle albumin-bound paclitaxel; Drug: gemcitabine Sponsor: Chinese PLA General Hospital Unknown status Mon, 12 May 2014 12:00:00 EDT Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorCondition: Metastatic Head-and-neck Squamous-cell CarcinomaInterventions: Drug: nab-paclitaxel; Drug: Nivolumab Sponsors: Washington University School of Medicine; Bristol-Myers Squibb Recruiting Mon, 05 Apr 2021 12:00:00 EDT
Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic AdenocarcinomaCondition: Pancreatic Carcinoma MetastaticInterventions: Drug: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4; Drug: Gemcitabine 1000 weeks 1,2,3/4 Sponsors: Asociación de Oncología Médica del Hospital de Cruces; Apices Soluciones S.L.; Celgene Completed Wed, 18 Mar 2015 12:00:00 EDT Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLCCondition: Efficacy and SafetyIntervention: Drug: Albumin paclitaxel combined with cisplatin Sponsor: Guizhou Medical University Active, not recruiting Tue, 25 Feb 2020 12:00:00 EST EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT CancerCondition: Breast CancerIntervention: Drug: Nab-paclitaxel Sponsor: Fondazione Sandro Pitigliani Completed Thu, 26 May 2016 12:00:00 EDT Study of Trametinib and Nab-paclitaxel in Patients With MelanomaCondition: MelanomaInterventions: Drug: trametinib; Drug: nab-paclitaxel Sponsors: SCRI Development Innovations, LLC; Celgene; GlaxoSmithKline Withdrawn Tue, 25 Nov 2014 12:00:00 EST A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Nab-Paclitaxel Sponsor: Osaka Medical Center for Cancer and Cardiovascular Diseases Completed Thu, 23 Oct 2014 12:00:00 EDT Observational Post-authorization Studies Carboplatin, Paclitaxel and BevacizumabCondition: Nonsquamous Nonsmall Cell Neoplasm of LungIntervention: Drug: paclitaxel, carboplatin and bevacizumab Sponsor: Spanish Lung Cancer Group Completed Tue, 19 Mar 2013 12:00:00 EDT Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With CholangiocarcinomaCondition: CholangiocarcinomaIntervention: Drug: Nab-Paclitaxel and Gemcitabine Sponsors: PrECOG, LLC.; Celgene Corporation Completed Fri, 04 Jul 2014 12:00:00 EDT A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Paclitaxel; Drug: Lovastatin Sponsor: University of Iowa Terminated Wed, 02 Jan 2008 12:00:00 EST Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerConditions: Breast Cancer; Breast Carcinoma; Breast Tumors; Malignant Neoplasm of BreastInterventions: Drug: Paclitaxel; Drug: Alisertib Sponsors: US Oncology Research; Millennium Pharmaceuticals, Inc. Active, not recruiting Fri, 11 Jul 2014 12:00:00 EDT Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º ChemotherapyCondition: Head and Neck CancerInterventions: Drug: Paclitaxel; Drug: Cetuximab + Paclitaxel Sponsors: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Merck Sharp & Dohme Corp.; Pivotal S.L. Terminated Mon, 25 Mar 2019 12:00:00 EDT
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.Condition: Advanced CancerInterventions: Drug: AZD2014 3 on/4 off & weekly paclitaxel; Drug: AZD2014 2 on/5 off & weekly paclitaxel Sponsors: Royal Marsden NHS Foundation Trust; Institute of Cancer Research, United Kingdom; AstraZeneca Completed Thu, 17 Jul 2014 12:00:00 EDT Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer PatientsCondition: Breast CancerInterventions: Device: Elasto-Gel™; Drug: Paclitaxel Sponsors: National Cancer Centre, Singapore; Terry Fox Foundation; Duke-NUS Academic Medicine Research Institute; Singapore General Hospital Unknown status Mon, 12 Feb 2018 12:00:00 EST Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: nanoparticle albumin-bound paclitaxel; Drug: S1; Drug: Gemcitabine Sponsor: Peking University Unknown status Fri, 17 Aug 2018 12:00:00 EDT Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast CancerConditions: Breast Neoplasms; Neoplasm MetastasisInterventions: Drug: ABI-007 (Abraxane); Drug: bevacizumab Sponsor: Celgene Terminated Wed, 25 Jan 2006 12:00:00 EST Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin Sponsors: Duke University; Genentech, Inc.; Celgene Corporation Completed Mon, 28 May 2007 12:00:00 EDT Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic AdenocarcinomaConditions: Pancreatic Neoplasms; Pancreatic Cancer; AdenocarcinomaIntervention: Drug: nab-paclitaxel, gemcitabine, capecitabine Sponsors: University of California, San Francisco; Celgene Corporation Completed Tue, 13 Jul 2010 12:00:00 EDT Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast CancerCondition: Breast CancerIntervention: Drug: Paclitaxel/Gemcitabine Sponsor: National Cancer Center, Korea Terminated Thu, 20 Sep 2007 12:00:00 EDT FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCondition: Squamous Cell Carcinoma of the Head and NeckIntervention: Drug: Durvalumab with Carboplatin/Paclitaxel Sponsor: Centre Leon Berard Recruiting Tue, 30 Oct 2018 12:00:00 EDT Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPCCondition: Nasopharyngeal CarcinomaIntervention: Drug: Nab-paclitaxel Sponsor: Fuzhou General Hospital Recruiting Thu, 11 Jul 2019 12:00:00 EDT Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)Condition: Metastatic Breast CancerIntervention: Drug: Nab-Paclitaxel Sponsor: German Breast Group Terminated Mon, 15 Aug 2011 12:00:00 EDT
Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.Conditions: Gastric Cancer; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Rivoceranib; Drug: Paclitaxel Sponsor: Elevar Therapeutics Recruiting Tue, 16 Oct 2018 12:00:00 EDT Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate CancerCondition: Prostate CancerInterventions: Drug: Hormone Suppressors; Drug: Paclitaxel; Radiation: Radiation Therapy Sponsor: NYU Langone Health Completed Thu, 22 Sep 2016 12:00:00 EDT Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: ABI-007; Drug: Gemcitabine; Drug: simplified LV5FU2 Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group; Celgene Corporation Unknown status Thu, 17 Oct 2013 12:00:00 EDT Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By SurgeryCondition: Intraocular MelanomaIntervention: Drug: nab-paclitaxel Sponsors: Ohio State University Comprehensive Cancer Center; National Comprehensive Cancer Network; Celgene Corporation Completed Wed, 20 Aug 2008 12:00:00 EDT Paclitaxel-trastuzumab in EGFR-mutated NSCLC PatientsConditions: NSCLC; HER2-expression; EGFR-mutationIntervention: Drug: Paclitaxel-trastzumab Sponsor: VU University Medical Center Unknown status Wed, 27 Aug 2014 12:00:00 EDT Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian CancerConditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Mixed Tumor, MesodermalInterventions: Drug: Paclitaxel; Drug: Carboplatin Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital Terminated Mon, 08 May 2006 12:00:00 EDT Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal CytologyCondition: Pancreatic AdenocarcinomaInterventions: Drug: Gemcitabine; Drug: nab-paclitaxel Sponsor: Benaroya Research Institute Recruiting Thu, 11 Oct 2018 12:00:00 EDT Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLCCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Nab-Paclitaxel; Drug: Carboplatin Sponsors: iOMEDICO AG; Bristol-Myers Squibb Completed Wed, 15 Jun 2016 12:00:00 EDT Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line TreatmentConditions: HER-2 Positive Gastric Cancer; Gastrooesophageal Cancer; Esophageal CancerInterventions: Drug: Afatinib; Drug: Paclitaxel Sponsors: Columbia University; Boehringer Ingelheim Withdrawn Fri, 24 Oct 2014 12:00:00 EDT Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableConditions: High-Risk; Non-Muscle Invasive Bladder Urothelial CarcinomaInterventions: Drug: Tislelizumab; Drug: Nab-paclitaxel Sponsor: Tianjin Medical University Second Hospital Recruiting Fri, 29 Jan 2021 12:00:00 EST
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: paclitaxel; Drug: sorafenib tosylate Sponsor: University of Texas Southwestern Medical Center Terminated Mon, 25 Feb 2008 12:00:00 EST Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerCondition: Metastatic Triple Negative Breast CancerInterventions: Drug: Carboplatin; Drug: Nab-paclitaxel; Drug: Pembrolizumab Sponsor: Case Comprehensive Cancer Center Active, not recruiting Thu, 20 Apr 2017 12:00:00 EDT Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: DOXIL; Drug: Abraxane Sponsors: West Virginia University; Ortho Biotech, Inc. Completed Thu, 01 Mar 2007 12:00:00 EST A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersConditions: Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,; Primary Peritoneal Cancer or Endometrial Cancer; Locally Advanced/Metastatic Her2 Non Overexpressing Breast CancerInterventions: Drug: MM-121; Drug: Paclitaxel Sponsors: Merrimack Pharmaceuticals; Sanofi Completed Mon, 27 Sep 2010 12:00:00 EDT Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid TumorsCondition: Solid TumorsInterventions: Drug: ABT-263; Drug: paclitaxel Sponsors: AbbVie; Genentech, Inc. Completed Fri, 01 May 2009 12:00:00 EDT Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.Condition: Gastrointestinal Stromal TumorsIntervention: Drug: Paclitaxel Sponsor: Asan Medical Center Recruiting Thu, 09 May 2019 12:00:00 EDT Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)Condition: Pancreatic NeoplasmsInterventions: Drug: nab-Paclitaxel; Drug: Gemcitabine; Drug: Chemoradiation; Drug: Capecitabine; Procedure: Surgery Sponsor: Celgene Completed Tue, 25 Nov 2014 12:00:00 EST Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)Condition: HEAD & NECK CancerIntervention: Other: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®) Sponsors: Memorial Sloan Kettering Cancer Center; Celgene Corporation; National Comprehensive Cancer Network Completed Mon, 18 Aug 2008 12:00:00 EDT Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent RestenosisCondition: Coronary RestenosisIntervention: Drug: Nanoparticle Paclitaxel Sponsor: Celgene Corporation Completed Fri, 29 Jul 2005 12:00:00 EDT Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial CancerConditions: Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableInterventions: Drug: Pazopanib (GW786034); Drug: Paclitaxel Sponsors: Sandy Srinivas; GlaxoSmithKline Completed Wed, 21 Apr 2010 12:00:00 EDT
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Demcizumab; Drug: Abraxane®; Drug: Gemcitabine Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Limited Completed Fri, 27 Aug 2010 12:00:00 EDT Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast CancerCondition: Breast CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Wed, 02 Dec 2009 12:00:00 EST AMG 386 Drug-Drug Interaction Study With PaclitaxelCondition: Advanced Solid TumorsInterventions: Drug: AMG 386; Drug: Paclitaxel Sponsor: Amgen Completed Mon, 25 Nov 2013 12:00:00 EST Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast CancerCondition: Breast CancerInterventions: Drug: lapatinib ditosylate; Drug: paclitaxel albumin-stabilized nanoparticle formulation Sponsors: Northwestern University; GlaxoSmithKline; Celgene Corporation Completed Wed, 31 May 2006 12:00:00 EDT An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With CarboplatinCondition: Non-Small Cell Lung Cancer (NSCLC)Intervention: Drug: ABI-007 (Abraxane) and Carboplatin Sponsor: Celgene Completed Wed, 11 Jan 2006 12:00:00 EST Reirradiation With Concurrent Paclitaxel for Breast CancerCondition: Breast CancerIntervention: Radiation: Paclitaxel+Initial Radiation+Boost Sponsor: University of Kentucky Withdrawn Mon, 10 Feb 2014 12:00:00 EST Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck CancerCondition: Head and Neck CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Fri, 04 Sep 2009 12:00:00 EDT Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast CancerCondition: Breast CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Fri, 04 Sep 2009 12:00:00 EDT Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)Condition: Non-Small Cell Lung CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Wed, 02 Dec 2009 12:00:00 EST Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast CancerConditions: Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxelInterventions: Drug: Nab-paclitaxel + Carboplatin; Drug: Nab-paclitaxel + Epirubicin Sponsors: Hebei Medical University Fourth Hospital; Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Thu, 24 Oct 2019 12:00:00 EDT
Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast CancerCondition: Breast CancerIntervention: Drug: carboplatin and paclitaxel and or without trastuzumab Sponsor: Guangdong Provincial People's Hospital Unknown status Tue, 11 Feb 2014 12:00:00 EST Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal CancerCondition: Esophageal CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Fri, 04 Sep 2009 12:00:00 EDT Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.Condition: Non-small Cell Lung CancerInterventions: Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsors: West Virginia University; Celgene Corporation Withdrawn Wed, 01 Apr 2015 12:00:00 EDT Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic CancerCondition: Pancreatic CancerIntervention: Drug: Gemcitabine plus nab-paclitaxel Sponsor: Grupo Hospital de Madrid Completed Thu, 29 Sep 2011 12:00:00 EDT Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic CholangiocarcinomaCondition: Cholangiocarcinoma, IntrahepaticIntervention: Drug: combined therapy using nab-paclitaxel and gemcitabine chemotherapy Sponsor: Shanghai Zhongshan Hospital Not yet recruiting Wed, 04 Sep 2019 12:00:00 EDT Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck CancerCondition: Head and Neck CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Wed, 02 Dec 2009 12:00:00 EST Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical CarcinomaCondition: Recurrent, Persistent or Metastasized Cervical CancerInterventions: Drug: Paclitaxel; Drug: Cisplatin/Paclitaxel Sponsors: Institut fuer Frauengesundheit; GlaxoSmithKline; Schantl Pharma Service, Germany Unknown status Fri, 29 Jul 2011 12:00:00 EDT Paclitaxel for the Treatment of Gastric or Gastroesophageal CancerConditions: Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Peritoneal Carcinomatosis; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Intervention: Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting Tue, 07 Jan 2020 12:00:00 EST Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Albumin-bound paclitaxel Sponsor: Celgene Completed Fri, 10 Nov 2006 12:00:00 EST A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCondition: CancerInterventions: Drug: BBI608; Drug: Paclitaxel Sponsor: Sumitomo Dainippon Pharma Oncology, Inc Completed Tue, 29 Mar 2011 12:00:00 EDT
Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional TreatmentsCondition: Solid TumorsInterventions: Drug: Paclitaxel liposome injection; Drug: Paclitaxel injection Sponsor: Nanjing Luye Sike Pharmaceutical Co., Ltd. Unknown status Mon, 25 Nov 2013 12:00:00 EST Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerCondition: Head and Neck CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Wed, 04 Mar 2009 12:00:00 EST Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0Condition: Gynecologic MalignanciesInterventions: Drug: Paclitaxel; Drug: Carboplatin Sponsor: Case Comprehensive Cancer Center Terminated Fri, 29 Apr 2016 12:00:00 EDT Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder CancerCondition: Bladder CancerIntervention: Drug: Paclitaxel-binding albumin Sponsor: Third Military Medical University Recruiting Mon, 19 Aug 2019 12:00:00 EDT Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Condition: Non-small Cell Lung CancerInterventions: Drug: ramucirumab; Drug: nab-paclitaxel Sponsor: Liza Villaruz, MD Completed Wed, 06 Apr 2016 12:00:00 EDT Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung CancerCondition: Extensive Stage Small Cell Lung CancerInterventions: Drug: nab-paclitaxel; Drug: Topotecan Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting Mon, 30 Dec 2019 12:00:00 EST The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic CancerConditions: Pancreatic Adenocarcinoma; Chemotherapy EffectIntervention: Drug: Chemotherapy (Gemcitabine + nab-paclitaxel) Sponsor: Seoul National University Hospital Unknown status Wed, 17 Jan 2018 12:00:00 EST Paclitaxel and TAK-228 in Urothelial CarcinomaCondition: Metastatic Urothelial CancerIntervention: Combination Product: Paclitaxel and TAK-228 Sponsors: Associació per a la Recerca Oncologica, Spain; Takeda; Pivotal S.L. Unknown status Mon, 19 Nov 2018 12:00:00 EST Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung CancerCondition: Non Small Cell Lung CancerInterventions: Drug: carboplatin paclitaxel bevacizumab; Drug: Standard treatment plus nitroglycerin Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis Completed Wed, 28 Jul 2010 12:00:00 EDT A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerCondition: Neoplasms, Breast Neoplasms, Head and Neck NeoplasmsInterventions: Drug: BYL719; Drug: Paclitaxel Sponsor: Novartis Pharmaceuticals Completed Fri, 31 Jan 2014 12:00:00 EST
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerCondition: Breast CancerInterventions: Drug: Pembrolizumab; Drug: Nab-Paclitaxel; Procedure: Biopsy Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme Corp. Recruiting Wed, 21 Dec 2016 12:00:00 EST Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic CancerConditions: Locally Advanced Pancreatic Cancer; Borderline Pancreatic Inoperable Cancer; Pancreatic CancerInterventions: Drug: Folfirinox; Drug: Gemcitabine nab-Paclitaxel Sponsor: University of Alabama at Birmingham Terminated Thu, 26 Jul 2018 12:00:00 EDT Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic HyperbilirubinemiaConditions: Pancreatic Neoplasms; CholestasisInterventions: Drug: nab-paclitaxel; Drug: Gemcitabine Sponsor: Celgene Terminated Fri, 17 Oct 2014 12:00:00 EDT Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: Ficlatuzumab Sponsors: Dana-Farber Cancer Institute; AVEO Pharmaceuticals, Inc. Completed Fri, 20 Oct 2017 12:00:00 EDT Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ CancerConditions: Esophageal Cancer; Induction ChemotherapyIntervention: Drug: carboplatin paclitaxel Sponsor: Instituto Nacional de Cancer, Brazil Unknown status Wed, 05 Oct 2016 12:00:00 EDT Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Avastin; Drug: Gemcitabine; Drug: Abraxane Sponsor: University of Miami Completed Thu, 19 Jul 2007 12:00:00 EDT Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian CancerConditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CancerIntervention: Drug: Abraxane Sponsors: Southeastern Gynecologic Oncology; Celgene Corporation Completed Fri, 27 Apr 2007 12:00:00 EDT Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical CancerConditions: Locally Advanced Cancer; Cervical CancerIntervention: Drug: Carboplatin-Paclitaxel adjuvant chemotherapy Sponsor: Centre Oscar Lambret Recruiting Thu, 11 Jul 2019 12:00:00 EDT Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent RestenosisCondition: Coronary In-stent RestenosisInterventions: Device: Paclitaxel eluting PTCA balloon; Device: SeQuent® Please paclitaxel eluting balloon Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University; West China Hospital; First Affiliated Hospital of Wenzhou Medical University; Second Affiliated Hospital of Wenzhou Medical University; The Third Xiangya Hospital of Central South University; Hebei Medical University Third Hospital; TEDA International Cardiovascular Hospital; Tianjin People's Hospital; The Second Hospital of Shandong University; Hainan People's Hospital; The First Affiliated Hospital of Xiamen University; Shanghai Chest Hospital; Renmin Hospital of Wuhan University; Taizhou Hospital Recruiting Mon, 30 Dec 2019 12:00:00 EST Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung CancerCondition: Non-small Cell Lung CancerInterventions: Drug: Imatinib mesylate; Drug: Paclitaxel Sponsors: New Mexico Cancer Care Alliance; Fred Hutchinson Cancer Research Center; Novartis Completed Wed, 11 Nov 2009 12:00:00 EST
Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck CancerConditions: Head and Neck Neoplasms; Squamous Cell CarcinomaInterventions: Drug: metformin up to 2500mg/d; Drug: paclitaxel 175mg/m² q21d; Drug: placebo Sponsors: Lucas Vieira dos Santos; Fundação de Amparo à Pesquisa do Estado de São Paulo; University of Campinas, Brazil Terminated Tue, 12 Apr 2011 12:00:00 EDT TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerConditions: Epithelial Ovarian; Fallopian Tube; Primary Peritoneal CancerInterventions: Drug: Paclitaxel/Bev (control); Drug: Paclitaxel/Bev + ZA (experimental) Sponsors: M.D. Anderson Cancer Center; Gateway for Cancer Research; National Cancer Institute (NCI) Not yet recruiting Wed, 22 Sep 2021 12:00:00 EDT Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)Condition: Breast CancerIntervention: Drug: paclitaxel, gemcitabine, lapatinib Sponsors: Jungsil Ro; GlaxoSmithKline; HK inno.N Corporation Completed Mon, 31 May 2010 12:00:00 EDT Paclitaxel Releasing Balloon in Patients Presenting With In-Stent RestenosisCondition: In-stent Coronary Artery RestenosisIntervention: Device: Paclitaxel Releasing Balloon Sponsor: Biotronik AG Completed Tue, 18 Aug 2009 12:00:00 EDT A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationCondition: Breast CancerInterventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120 Sponsor: Novartis Pharmaceuticals Completed Fri, 06 Apr 2012 12:00:00 EDT Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast CancerConditions: Triple Negative Breast Cancer; Nab-paclitaxelInterventions: Drug: Nab-paclitaxel + Carboplatin; Drug: Nab-paclitaxel + Capecitabine Sponsors: Hebei Medical University Fourth Hospital; Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Tue, 12 Nov 2019 12:00:00 EST Cisplatin vs Paclitaxel for Triple Negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Cisplatin; Drug: Paclitaxel Sponsors: Dana-Farber Cancer Institute; Myriad Genetics, Inc.; Translational Breast Cancer Research Consortium Active, not recruiting Wed, 13 Nov 2013 12:00:00 EST A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCondition: Ovarian CancerInterventions: Drug: CRLX101; Drug: Paclitaxel Sponsor: NewLink Genetics Corporation Terminated Tue, 17 Mar 2015 12:00:00 EDT Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2)Condition: Arteriovenous Access Fistula StenosisInterventions: Drug: Paclitaxel; Procedure: Standard Therapy Sponsor: Englewood Hospital and Medical Center Withdrawn Mon, 20 Jan 2014 12:00:00 EST Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic CancerCondition: Pancreatic NeoplasmsIntervention: Drug: Nab paclitaxel and S-1 Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting Mon, 22 Mar 2021 12:00:00 EDT
HAI Abraxane With Gemcitabine and BevacizumabCondition: Advanced CancersInterventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim Sponsor: M.D. Anderson Cancer Center Completed Wed, 27 Jan 2010 12:00:00 EST Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Genetic: SGT-53; Drug: nab-paclitaxel; Drug: Gemcitabine Sponsor: SynerGene Therapeutics, Inc. Recruiting Fri, 16 Jan 2015 12:00:00 EST F16IL2 Plus Paclitaxel in Metastatic Merkel Cell CarcinomaCondition: Merkel Cell CarcinomaInterventions: Drug: Arm A: F16IL2 in combination with paclitaxel; Drug: Arm B: Paclitaxel Sponsors: Philogen S.p.A.; immatics Biotechnologies GmbH Terminated Tue, 04 Feb 2014 12:00:00 EST Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: nab-paclitaxel IV; Drug: CC-486; Drug: Duravalumab Sponsor: Celgene Active, not recruiting Fri, 26 Sep 2014 12:00:00 EDT A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCondition: Carcinoma, Pancreatic DuctalInterventions: Drug: Napabucasin; Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsor: Sumitomo Dainippon Pharma Oncology, Inc Completed Thu, 15 Dec 2016 12:00:00 EST Lenalidomide and Paclitaxel in Prostate CancerCondition: Prostate CancerInterventions: Drug: Lenalidomide; Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; Celgene Corporation Terminated Tue, 07 Jul 2009 12:00:00 EDT Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula StenosisCondition: Fistula StenosisInterventions: Drug: Paclitaxel; Procedure: Standard Therapy Sponsors: Englewood Hospital and Medical Center; Spectranetics Corporation Terminated Wed, 05 Jun 2013 12:00:00 EDT Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk WomenConditions: Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Duct Carcinoma of BreastInterventions: Drug: Paclitaxel, Cisplatin; Drug: EC to docetaxel or paclitaxel Sponsor: RenJi Hospital Recruiting Wed, 28 Jun 2017 12:00:00 EDT Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung CancerCondition: Non-Small Cell Lung CarcinomaInterventions: Drug: Albumin-bound paclitaxel; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Celgene Completed Mon, 08 Oct 2007 12:00:00 EDT Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaConditions: Malignant Melanoma of Skin Stage III; Metastatic MelanomaIntervention: Drug: Rituxan Sponsor: California Cancer Assocaties for Research & Excellence Unknown status Tue, 20 May 2014 12:00:00 EDT
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)Condition: Pancreatic AdenocarcinomaInterventions: Drug: Abraxane; Drug: Gemcitabine Sponsors: CCTU- Cancer Theme; Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK; Celgene Terminated Mon, 28 Apr 2014 12:00:00 EDT Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast CancerCondition: Breast NeoplasmsInterventions: Drug: paclitaxel; Drug: BKM120 Sponsor: Washington University School of Medicine Withdrawn Tue, 01 Oct 2013 12:00:00 EDT Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung CancerCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: PF-3512676 + Paclitaxel + Carboplatin; Drug: Paclitaxel + Carboplatin Sponsor: Pfizer Terminated Thu, 17 Nov 2005 12:00:00 EST Lapatinib and Paclitaxel in Treating Patients With Advanced Solid TumorsConditions: Bladder Cancer; Brain and Central Nervous System Tumors; Breast Cancer; Esophageal Cancer; Extragonadal Germ Cell Tumor; Gastric Cancer; Lung Cancer; Ovarian Cancer; Prostate CancerInterventions: Drug: lapatinib; Drug: paclitaxel Sponsors: University of California, San Francisco; National Cancer Institute (NCI) Completed Wed, 12 Apr 2006 12:00:00 EDT Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: LCL161; Drug: Gemcitabine; Drug: nab-Paclitaxel Sponsors: US Oncology Research; Novartis Pharmaceuticals; Delta Clinical Research, LLC Unknown status Wed, 04 Sep 2013 12:00:00 EDT Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial CancerCondition: Urologic NeoplasmInterventions: Drug: Cetuximab; Drug: Paclitaxel Sponsors: Fox Chase Cancer Center; Bristol-Myers Squibb Completed Mon, 10 Jul 2006 12:00:00 EDT Feasibility Study of Intraperitoneal PaclitaxelCondition: Gastric CancerIntervention: Drug: IP Paclitaxel Sponsor: National University Hospital, Singapore Unknown status Tue, 04 Dec 2012 12:00:00 EST Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal CancerConditions: Epithelial Ovarian Cancer; Primary Peritoneal CarcinomaInterventions: Drug: Bevacizumab; Drug: Abraxane Sponsors: Accelerated Community Oncology Research Network; Genentech, Inc.; Celgene Corporation Completed Tue, 05 Dec 2006 12:00:00 EST Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic CancerCondition: Borderline Resectable Pancreatic CancerIntervention: Drug: nab-paclitaxel and S-1 Sponsor: Peking Union Medical College Hospital Recruiting Fri, 22 Feb 2019 12:00:00 EST Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory SarcomaConditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Soft Tissue SarcomaInterventions: Drug: nab-Paclitaxel; Drug: Gemcitabine Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Pediatric Cancer Foundation Recruiting Wed, 26 Oct 2016 12:00:00 EDT
Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging CorrelatesCondition: Breast CancerInterventions: Drug: BIBF + Paclitaxel; Drug: Paclitaxel Sponsors: Centro Nacional de Investigaciones Oncologicas CARLOS III; Hospital Universitario de Fuenlabrada; M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge; Grupo Espanol de Investigacion del Cancer de Mama Completed Fri, 02 Dec 2011 12:00:00 EST Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric CancerCondition: Gastric CancerIntervention: Drug: Nab-paclitaxel combined with S-1 Sponsor: Shanghai Zhongshan Hospital Not yet recruiting Thu, 06 Jun 2019 12:00:00 EDT Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical CancerConditions: Cervical Cancer; Chemotherapy Effect; Programmed Cell Death 1 Receptor / Antagonists & Inhibitors; Neoadjuvant TherapyIntervention: Drug: Sindilimab +paclitaxel+ cisplantin Sponsor: Sun Yat-sen University Not yet recruiting Tue, 16 Mar 2021 12:00:00 EDT Study of Weekly LOC-paclitaxel Injection for MelanomaCondition: MelanomaIntervention: Drug: LOC-paclitaxel Sponsors: M.D. Anderson Cancer Center; American Regent, Inc. Terminated Fri, 25 Dec 2009 12:00:00 EST Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the PancreasCondition: Metastatic Pancreatic CancerInterventions: Drug: Albumin-bound paclitaxel (ABI-007); Drug: Gemcitabine Sponsor: Celgene Completed Mon, 16 Feb 2009 12:00:00 EST A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane); Drug: Sorafenib (Nexavar) Sponsors: Veeda Oncology; Bayer; Celgene Corporation Terminated Tue, 05 Feb 2008 12:00:00 EST Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)Condition: Ovarian CancerInterventions: Device: NovoTTF-100L(O); Drug: Paclitaxel Sponsor: NovoCure Ltd. Recruiting Tue, 07 May 2019 12:00:00 EDT Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Oraxol; Drug: IV paclitaxel Sponsor: Athenex, Inc. Active, not recruiting Tue, 03 Nov 2015 12:00:00 EST Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic CancerCondition: Locally Advanced Pancreatic CancerIntervention: Drug: Nab-paclitaxel and S-1 Sponsor: Peking Union Medical College Hospital Recruiting Thu, 21 Mar 2019 12:00:00 EDT Local Paclitaxel Delivery for SFA DiseaseConditions: Atherosclerosis; Angioplasty; Peripheral Arterial DiseaseIntervention: Drug: Paclitaxel Sponsor: University of Oklahoma Completed Mon, 12 Jan 2009 12:00:00 EST
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerCondition: Early Breast CancerIntervention: Drug: Nab-paclitaxel in combination with pyrotinib Sponsors: Peking Union Medical College Hospital; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting Wed, 09 Dec 2020 12:00:00 EST Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial TractCondition: Carcinoma, Transitional CellInterventions: Drug: nanoparticle albumin-bound paclitaxel, S-1; Drug: Gemcitabine, cisplatin Sponsor: Chinese PLA General Hospital Completed Mon, 13 Feb 2017 12:00:00 EST Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian OriginCondition: Ovarian CancerIntervention: Drug: Gleevec/Paclitaxel Sponsors: NYU Langone Health; Novartis Terminated Tue, 10 Feb 2009 12:00:00 EST A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCondition: Carcinoma, Non-Small Cell Lung Cancer (NSCLC)Interventions: Drug: Necitumumab; Drug: Nab-Paclitaxel; Drug: Carboplatin Sponsors: Eli Lilly and Company; Celgene Completed Thu, 19 Mar 2015 12:00:00 EDT Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II StudyCondition: Metastatic Malignant MelanomaInterventions: Drug: Avastin; Drug: Abraxane Sponsors: Lynn E. Spitler, MD; Celgene Corporation; Genentech, Inc. Completed Thu, 19 Apr 2007 12:00:00 EDT Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast CancerCondition: Triple-Negative Breast CancerInterventions: Biological: Magrolimab; Drug: Nab-Paclitaxel; Drug: Paclitaxel Sponsor: Gilead Sciences Not yet recruiting Mon, 12 Jul 2021 12:00:00 EDT QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic CancerCondition: Pancreatic Cancer, AdultInterventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: NPC-1C Sponsor: Precision Biologics, Inc Terminated Wed, 17 Apr 2013 12:00:00 EDT Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast CancerCondition: Breast CancerIntervention: Drug: nab-paclitaxel Sponsor: Shanghai Cancer Hospital, China Unknown status Thu, 21 Jun 2012 12:00:00 EDT Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerCondition: Anaplastic Thyroid CancerInterventions: Drug: Trametinib; Drug: Paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; Novartis Recruiting Tue, 21 Mar 2017 12:00:00 EDT A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic CancerCondition: Stage IV Pancreatic CancerInterventions: Drug: OMP-59R5; Drug: Gemcitabine; Drug: Placebo; Drug: Nab-Paclitaxel Sponsor: OncoMed Pharmaceuticals, Inc. Completed Tue, 24 Jul 2012 12:00:00 EDT
Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)Condition: Locally Advanced, Squamous Cell Carcinoma of the VulvaIntervention: Drug: Paclitaxel and Carboplatin Sponsor: The Netherlands Cancer Institute Recruiting Tue, 10 Dec 2019 12:00:00 EST A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial CarcinomaCondition: Advanced Urothelial CarcinomaInterventions: Drug: anti-PD-L1 antibody; Drug: albumin bound paclitaxel Sponsor: Lee's Pharmaceutical Limited Recruiting Tue, 27 Oct 2020 12:00:00 EDT Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal MetastasisConditions: Stomach Neoplasms; Paclitaxel; Peritoneal MetastasesIntervention: Drug: Paclitaxel Sponsor: Seoul St. Mary's Hospital Recruiting Tue, 29 Jun 2021 12:00:00 EDT Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerCondition: Anaplastic Thyroid CancerInterventions: Drug: Fosbretabulin + paclitaxel + carboplatin; Drug: Placebo + paclitaxel + carboplatin Sponsor: Mateon Therapeutics Withdrawn Fri, 05 Oct 2012 12:00:00 EDT Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the UterusCondition: Mixed Tumor, MullerianInterventions: Drug: Carboplatin; Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Completed Tue, 17 Jul 2007 12:00:00 EDT Gleevec/Taxol for Patients With Uterine Papillary Serous CarcinomaCondition: Uterine CancerInterventions: Drug: Imatinib Mesylate; Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Terminated Wed, 25 Jul 2007 12:00:00 EDT A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid CancersCondition: Advanced Solid CancersInterventions: Drug: Rapamune; Drug: Abraxane Sponsors: Yale University; Celgene Corporation Terminated Thu, 15 Jun 2006 12:00:00 EDT Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine CarcinomaCondition: Neuroendocrine CarcinomaIntervention: Drug: Nab-paclitaxel Combined With Bevacizumab Sponsors: Peking University; Qilu Pharmaceutical Co., Ltd. Recruiting Tue, 12 Jan 2021 12:00:00 EST Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerCondition: Ovarian CancerInterventions: Drug: defactinib; Drug: Paclitaxel Sponsor: Verastem, Inc. Completed Tue, 29 Jan 2013 12:00:00 EST Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel ChemotherapyCondition: Metastatic Squamous Cell Carcinoma of the VulvaIntervention: Drug: Paclitaxel and Carboplatin Sponsor: The Netherlands Cancer Institute Recruiting Wed, 13 Nov 2019 12:00:00 EST
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the CervixConditions: Cervical Cancer; Uterine CancerInterventions: Drug: Bevacizumab; Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Terminated Fri, 29 Feb 2008 12:00:00 EST Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian CancerCondition: Ovarian CancerInterventions: Biological: Intraperitoneal tgDCC-E1A; Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI) Terminated Tue, 01 Feb 2005 12:00:00 EST A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)Condition: Triple Negative Breast CancerInterventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Drug: Nab-Paclitaxel; Drug: Placebo Sponsor: Hoffmann-La Roche Active, not recruiting Fri, 24 Apr 2015 12:00:00 EDT M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: nab-paclitaxel; Drug: gemcitabine; Drug: placebo; Drug: Necuparanib Sponsor: Momenta Pharmaceuticals, Inc. Terminated Mon, 18 Jun 2012 12:00:00 EDT Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of LungCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Albumin paclitaxel plus carboplatin; Drug: Gemcitabine plus carboplatin Sponsor: Chinese Society of Lung Cancer Completed Tue, 09 Nov 2010 12:00:00 EST Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.Condition: Hemodialysis Access FailureIntervention: Device: Paclitaxel-eluting graft Sponsor: Samsung Medical Center Recruiting Wed, 26 Feb 2020 12:00:00 EST Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical HysterectomyCondition: Cervical CancerInterventions: Drug: paclitaxel; Drug: cisplatin; Procedure: Radical hysterectomy and bilateral pelvic lymphadenectomy Sponsors: Chang Gung Memorial Hospital; Asian Gynecologic Oncology Group; Taiwanese Gynecologic Oncology Group Recruiting Mon, 04 May 2015 12:00:00 EDT Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerCondition: Advanced Gastric CancerIntervention: Drug: CM082 plus paclitaxel Sponsor: AnewPharma Unknown status Mon, 18 Sep 2017 12:00:00 EDT Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Pembrolizumab; Drug: Nab-Paclitaxel Sponsor: NYU Langone Health Recruiting Wed, 27 Apr 2016 12:00:00 EDT Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic CancerCondition: Pancreatic CancerIntervention: Drug: albumin-bound paclitaxel Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting Sun, 05 Sep 2021 12:00:00 EDT
Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic CancerConditions: Pancreatic Cancer; Neoadjuvant ChemotherapyInterventions: Drug: S1,; Drug: Paclitaxel-albumin Sponsor: Zhejiang Provincial People's Hospital Terminated Thu, 12 Jul 2018 12:00:00 EDT Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI TrialCondition: Coronary Artery Bypass GraftingIntervention: Device: Paclitaxel eluting stent Sponsors: Laval University; Boston Scientific Corporation Completed Fri, 10 Feb 2006 12:00:00 EST ABI-007 in Treating Patients With Persistent or Recurrent Cervical CancerConditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical CarcinomaInterventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Other: Laboratory Biomarker Analysis Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Mon, 03 Apr 2006 12:00:00 EDT Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast CancerCondition: Breast CancerIntervention: Drug: Paclitaxel, Carboplatin Sponsors: Shanghai Jiao Tong University School of Medicine; Fudan University; Ruijin Hospital Completed Thu, 16 Sep 2010 12:00:00 EDT A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous PaclitaxelCondition: Solid TumorIntervention: Drug: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules Sponsors: Athenex, Inc.; PharmaEssentia; Zenith Technology Corporation Limited Completed Mon, 29 Jul 2019 12:00:00 EDT Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric CancerCondition: Advanced Gastric AdenocarcinomaIntervention: Other: Camrelizumab, Albumin-bound paclitaxel, S-1 Sponsor: Henan Cancer Hospital Not yet recruiting Sat, 19 Dec 2020 12:00:00 EST BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast CancerCondition: Breast CancerInterventions: Drug: BYL-719 (alpelisib); Drug: Nab-paclitaxel Sponsors: Priyanka Sharma; Novartis Pharmaceuticals Active, not recruiting Wed, 04 Mar 2015 12:00:00 EST Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194Condition: Breast CancerIntervention: Drug: Dasatinib and Paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb Completed Mon, 12 Jan 2009 12:00:00 EST Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior TherapyCondition: Squamous Cell Carcinoma of the EsophagusInterventions: Drug: Ramucirumab; Drug: Paclitaxel Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Eli Lilly and Company; Trium Analysis Online GmbH Active, not recruiting Mon, 03 Dec 2018 12:00:00 EST Pazopanib and Paclitaxel for Non-Small Cell Lung CancerCondition: Non-small Cell Lung CancerIntervention: Drug: Pazopanib plus Paclitaxel Sponsors: Loyola University; GlaxoSmithKline Withdrawn Wed, 11 Aug 2010 12:00:00 EDT
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular CorrelatesConditions: Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreas Ductal AdenocarcinomaInterventions: Drug: Nab-paclitaxel and gemcitabine for R-PDAC Patients; Drug: Nab-paclitaxel and gemcitabine for BR-PDAC Patients Sponsors: Academic Thoracic Oncology Medical Investigators Consortium; Celgene Corporation; Criterium, Inc.; University of Colorado, Denver Recruiting Wed, 30 Mar 2016 12:00:00 EDT Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal InterventionConditions: Restenosis; Peripheral Arterial DiseaseInterventions: Drug: Paclitaxel; Drug: Placebo Sponsors: Midwest Cardiovascular Research Foundation; Spectranetics Corporation Unknown status Tue, 15 May 2012 12:00:00 EDT PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Paclitaxel; Drug: AZD5363; Drug: Placebo Sponsors: Queen Mary University of London; AstraZeneca; Cancer Research UK Active, not recruiting Wed, 22 Apr 2015 12:00:00 EDT Phase I Abraxane Weekly and Three Weekly Schedule With VandetanibCondition: Solid TumorsInterventions: Drug: Weekly Abraxane and Daily Vandetanib; Drug: Abraxane every three weeks and daily vandetanib Sponsors: University of Southern California; AstraZeneca; Celgene Corporation Completed Fri, 25 Apr 2008 12:00:00 EDT Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical StudyCondition: Dialysis Access MalfunctionIntervention: Device: Cutting balloon followed by paclitaxel coated balloon Sponsors: Singapore General Hospital; Boston Scientific Corporation Completed Tue, 24 Aug 2021 12:00:00 EDT Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer PatientsCondition: Cancer of PancreasInterventions: Drug: Nab-paclitaxel plus Gemcitabine; Drug: Gemcitabine monotherapy; Drug: S-1 monotherapy Sponsor: Chinese PLA General Hospital Unknown status Mon, 11 Sep 2017 12:00:00 EDT Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell LineCondition: Squamous Cell CarcinomaInterventions: Dietary Supplement: Licochalcone A; Drug: Paclitaxel Sponsor: Cairo University Unknown status Tue, 26 Sep 2017 12:00:00 EDT Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug MonitoringCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Paclitaxel dosing according to SmPC; Drug: Individualized pharmacokinetically driven paclitaxel dosing Sponsors: Central European Society for Anticancer Drug Research; Saladax Biomedical, Inc.; Cantonal Hospital of St. Gallen; University Hospital, Basel, Switzerland; Assign Data Management and Biostatistics GmbH; Wake Forest University; University Hospital, Essen Completed Thu, 31 Mar 2011 12:00:00 EDT Pharmacokinetics Study of Liposomal Paclitaxel in HumansCondition: CancerInterventions: Drug: Liposomal paclitaxel; Drug: Paclitaxel Sponsors: Shandong Luye Pharmaceutical Co., Ltd.; Nanjing Sike Pharmaceutical Co., Ltd. Completed Mon, 04 Feb 2008 12:00:00 EST A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract CancerCondition: Biliary Tract CancerInterventions: Drug: Nab-paclitaxel + Cisplatin; Drug: Gemcitabine + Cisplatin Sponsors: Huazhong University of Science and Technology; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Thu, 31 Dec 2020 12:00:00 EST
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid CancerConditions: Anaplastic Thyroid Cancer; Recurrent Thyroid CancerInterventions: Drug: efatutazone; Drug: paclitaxel Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Daiichi Sankyo, Inc. Active, not recruiting Mon, 02 Jun 2014 12:00:00 EDT Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract CancerCondition: CholangiocarcinomaIntervention: Drug: nab-paclitaxel Sponsor: Istituto Clinico Humanitas Recruiting Thu, 09 May 2019 12:00:00 EDT Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascularCondition: Peripheral Arterial DiseaseIntervention: Device: Luminor-14 Paclitaxel eluting balloon Sponsor: ID3 Medical Recruiting Tue, 19 Feb 2019 12:00:00 EST A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaCondition: Pancreatic Ductal CarcinomaInterventions: Other: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20); Drug: Placebo; Drug: nab-Paclitaxel; Drug: Gemcitabine Sponsor: Halozyme Therapeutics Terminated Tue, 22 Mar 2016 12:00:00 EDT First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and GemcitabineConditions: Metastatic Pancreatic Cancer; Adenocarcinoma of the PancreasInterventions: Drug: nab-paclitaxel and gemcitabine; Drug: gemcitabine mono and nab-paclitaxel and gemcitabine Sponsors: AIO-Studien-gGmbH; ClinAssess GmbH; Celgene Corporation Active, not recruiting Wed, 30 Sep 2015 12:00:00 EDT Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast CancerCondition: Breast CancerIntervention: Drug: LY2780301 + paclitaxel Sponsor: Institut Paoli-Calmettes Terminated Fri, 08 Nov 2013 12:00:00 EST Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric CancerConditions: Esophageal Cancer; Gastric CancerIntervention: Drug: Afatinib and Paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; Boehringer Ingelheim; University of Southern California; Dana-Farber Cancer Institute; United States Department of Defense Active, not recruiting Wed, 01 Feb 2012 12:00:00 EST The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total OcclusionsConditions: Coronary Artery Disease; Chronic Total Occlusion; Native Coronary ArteryInterventions: Device: paclitaxel eluting PTCA balloon catheter (SeQuent Please); Device: paclitaxel eluting Taxus stent (Boston Scientific) Sponsors: University of Ulm; B. Braun Melsungen AG Completed Thu, 01 May 2008 12:00:00 EDT PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal CancerConditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerIntervention: Drug: Dasatinib, Paclitaxel, and Carboplatin Sponsor: AA Secord Completed Tue, 06 May 2008 12:00:00 EDT Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction AdenocarcinomaConditions: Gastric Cancer; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Raltitrexed; Drug: Paclitaxel Sponsor: Chinese Academy of Medical Sciences Completed Mon, 20 Mar 2017 12:00:00 EDT
Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer PatientsCondition: Unresectable Pancreatic CarcinomaInterventions: Drug: Tocilizumab; Drug: Gemcitabine; Drug: nab-Paclitaxel Sponsors: Herlev Hospital; Celgene Active, not recruiting Tue, 10 May 2016 12:00:00 EDT Prospective Phase I Study of GAX for Metastatic Pancreatic CancerCondition: Pancreatic CancerIntervention: Drug: GAX - Gemcitabine, Abraxane and Xeloda Sponsor: Stamford Hospital Withdrawn Wed, 21 Oct 2015 12:00:00 EDT An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)Condition: Muscle-Invasive Bladder CarcinomaInterventions: Drug: Nivolumab + Nab-paclitaxel; Drug: Nivolumab Sponsors: IRCCS San Raffaele; Bristol-Myers Squibb Not yet recruiting Thu, 06 May 2021 12:00:00 EDT Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract CancersCondition: Advanced Biliary Tract CancersIntervention: Drug: cisplatin and nab-paclitaxel Sponsors: Henan Provincial People's Hospital; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Tue, 01 Oct 2019 12:00:00 EDT A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerConditions: Non-Small-Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Nonsmall Cell Lung Cancer; Non Small Cell Lung Cancer RecurrentInterventions: Drug: Nivolumab; Drug: nab-paclitaxel Sponsors: Alliance Foundation Trials, LLC.; Celgene Corporation; Bristol-Myers Squibb Unknown status Fri, 18 Nov 2016 12:00:00 EST Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Paclitaxel; Drug: Durvalumab Sponsors: King Faisal Specialist Hospital & Research Center; AstraZeneca Completed Fri, 11 Dec 2015 12:00:00 EST Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLCCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: paclitaxel + carboplatin + bevacizumab; Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676 Sponsor: Pfizer Terminated Wed, 12 Apr 2006 12:00:00 EDT A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction AdenocarcinomaInterventions: Biological: pembroliziumab; Drug: paclitaxel Sponsor: Merck Sharp & Dohme Corp. Completed Wed, 25 Feb 2015 12:00:00 EST Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerCondition: Small Cell Lung CancerInterventions: Drug: APG-1252; Drug: Paclitaxel Sponsor: Ascentage Pharma Group Inc. Active, not recruiting Tue, 24 Dec 2019 12:00:00 EST Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerConditions: Ovarian Cancer; Relapsed or Refractory; Chiauranib; PaclitaxelInterventions: Drug: chiauranib; Drug: Placebo; Drug: Paclitaxel Sponsor: Chipscreen Biosciences, Ltd. Not yet recruiting Thu, 10 Jun 2021 12:00:00 EDT
Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Paclitaxel; Radiation: LDWART (Low Dose Whole Abdominal Radiation Therapy) Sponsor: National University Hospital, Singapore Unknown status Wed, 09 Sep 2015 12:00:00 EDT Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).Conditions: Fallopian Tube Cancer; Peritoneum Cancer; Epithelial Ovarian CancerInterventions: Drug: Pembrolizumab; Drug: Paclitaxel; Drug: Carboplatin Sponsors: Marilyn Huang, MD, MS; Merck Sharp & Dohme Corp. Recruiting Fri, 15 Jul 2016 12:00:00 EDT Genetic Testing in Predicting Response to Paclitaxel in Women With Breast CancerCondition: Breast CancerInterventions: Drug: paclitaxel; Genetic: microarray analysis; Procedure: biopsy; Procedure: neoadjuvant therapy; Drug: Paclitaxel Sponsors: Georgetown University; National Cancer Institute (NCI) Terminated Thu, 05 Aug 2004 12:00:00 EDT A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: Vantictumab combined with paclitaxel Sponsor: OncoMed Pharmaceuticals, Inc. Completed Thu, 31 Oct 2013 12:00:00 EDT Paclitaxel Detection in NSCLC Treated With TC RegimenCondition: Non-small Cell Lung CancerIntervention: Drug: Paclitaxel and Carboplatin regimen Sponsor: Sun Yat-sen University Terminated Thu, 14 Apr 2016 12:00:00 EDT First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC PatientsCondition: Breast CancerIntervention: Drug: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1) Sponsor: Fudan University Recruiting Thu, 03 Sep 2020 12:00:00 EDT Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Paclitaxel, Carboplatin; Drug: Paclitaxel, Epirubicin Sponsor: Tianjin Medical University Cancer Institute and Hospital Unknown status Mon, 04 Aug 2014 12:00:00 EDT A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic CancerConditions: Advanced Adenocarcinoma; Metastatic AdenocarcinomaInterventions: Drug: Hydroxychloroquine (HCQ); Drug: Gemcitabine; Drug: Abraxane Sponsor: Abramson Cancer Center of the University of Pennsylvania Active, not recruiting Tue, 10 Jan 2012 12:00:00 EST A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerCondition: Breast CancerInterventions: Drug: LCL161; Drug: paclitaxel Sponsor: Novartis Pharmaceuticals Completed Tue, 12 Jun 2012 12:00:00 EDT Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic CancerCondition: Borderline Resectable Pancreatic CancerInterventions: Drug: gemcitabine/nab-paclitaxel; Drug: mFOLFIRINOX Sponsor: Nathan Bahary, MD Terminated Tue, 16 Sep 2014 12:00:00 EDT
Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLCCondition: Small Cell Lung CancerIntervention: Drug: Nabpaclitaxel Sponsors: Gruppo Oncologico Italiano di Ricerca Clinica; Temas srl; Clirest s.r.l.; Mipharm S.p.A.; Istituto Toscano Tumori Unknown status Tue, 18 Jul 2017 12:00:00 EDT Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)Condition: Colorectal CancerIntervention: Drug: Abraxane Sponsors: Mt. Sinai Medical Center, Miami; Celgene Corporation Completed Thu, 28 Feb 2008 12:00:00 EST Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck CancerCondition: Head and Neck CancerIntervention: Drug: Panitumumab + paclitaxel Sponsors: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Amgen; Trial Form Support S.L. Completed Tue, 21 Dec 2010 12:00:00 EST Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and SunitinibCondition: Gastrointestinal Stromal TumorsIntervention: Drug: Paclitaxel Sponsor: Asan Medical Center Completed Wed, 18 Nov 2015 12:00:00 EST Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)Condition: Non-Small Cell Lung CancerIntervention: Other: dosage of paclitaxel Sponsor: Caicun Zhou Unknown status Mon, 10 Feb 2014 12:00:00 EST Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung CancerCondition: Non Small Cell Lung CancerInterventions: Drug: Paclitaxel/Carboplatin/Gefitinib; Drug: Paclitaxel/Carboplatin Sponsors: Asan Medical Center; AstraZeneca Completed Wed, 08 Sep 2010 12:00:00 EDT Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer PatientsCondition: Gastric AdenocarcinomaIntervention: Drug: Nanoparticle Albumin-Bound Paclitaxel Sponsor: Peking University Completed Fri, 15 Apr 2011 12:00:00 EDT The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal CarcinomaCondition: Nasopharyngeal CarcinomaIntervention: Combination Product: Paclitaxel（Albumin-bound） Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting Wed, 24 Feb 2021 12:00:00 EST QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-PaclitaxelCondition: Advanced Pancreatic CancerInterventions: Biological: Gemcitabine; Biological: Nab-paclitaxel; Biological: ALT-803 Sponsor: Altor BioScience Completed Thu, 24 Sep 2015 12:00:00 EDT Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Albumin-bound paclitaxel plus capecitabine; Drug: capecitabine Sponsor: Fudan University Recruiting Wed, 03 Mar 2021 12:00:00 EST
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)Condition: Breast CancerInterventions: Drug: Pre operativeTrastuzumab; Drug: ABI-007 (Abraxane); Drug: Vinorelbine Sponsor: Emory University Completed Thu, 19 Jul 2007 12:00:00 EDT Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial CancerConditions: Urothelial Cancer; Bladder CancerIntervention: Drug: Lapatinib and Paclitaxel Sponsors: University of Michigan Rogel Cancer Center; GlaxoSmithKline Withdrawn Thu, 04 Oct 2012 12:00:00 EDT A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of PaclitaxelCondition: Metastatic Breast CancerInterventions: Drug: Eftilagimod Alpha; Drug: Paclitaxel Sponsor: Immutep S.A.S. Not yet recruiting Wed, 05 Feb 2020 12:00:00 EST Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: Paricalcitol; Other: Placebo Sponsors: Dana-Farber Cancer Institute; Stand Up To Cancer; Lustgarten Foundation; American Association for Cancer Research Recruiting Fri, 11 May 2018 12:00:00 EDT Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: TOCOSOL(R) Paclitaxel Sponsor: Achieve Life Sciences Completed Mon, 15 Nov 2004 12:00:00 EST Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaCondition: Metastatic MelanomaInterventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Everolimus Sponsors: SCRI Development Innovations, LLC; Novartis Completed Tue, 17 Nov 2009 12:00:00 EST Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple MyelomaCondition: Refractory Plasma Cell MyelomaInterventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Other: Laboratory Biomarker Analysis Sponsors: Mayo Clinic; National Cancer Institute (NCI) Terminated Fri, 20 Jul 2012 12:00:00 EDT Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerCondition: Advanced Gastric CancerIntervention: Drug: Camrelizumab, Apatinib and Nab-paclitaxel Sponsor: Chinese PLA General Hospital Recruiting Mon, 02 Dec 2019 12:00:00 EST A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior ChemotherapyConditions: Advanced Gastric Cancer; Esophagogastric Junction CancerInterventions: Drug: Paclitaxel; Drug: RAD001 Sponsor: Krankenhaus Nordwest Completed Thu, 25 Nov 2010 12:00:00 EST Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric CarcinomaConditions: Esophageal Neoplasms; Stomach Neoplasms; Neoplasm MetastasisInterventions: Drug: Regorafenib; Drug: Paclitaxel Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Completed Thu, 02 Apr 2015 12:00:00 EDT
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung CancerCondition: Non-Small Cell Lung CancerIntervention: Drug: BIIB022 With Paclitaxel and Carboplatin Sponsor: Biogen Completed Wed, 02 Sep 2009 12:00:00 EDT A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast CancerConditions: Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast CancerInterventions: Drug: Azacitidine (Vidaza); Drug: Nab-paclitaxel (Abraxane) Sponsors: University of Utah; Celgene Corporation Completed Mon, 08 Sep 2008 12:00:00 EDT Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsCondition: Advanced Solid TumorsInterventions: Drug: TAS-119; Drug: Paclitaxel Sponsor: Taiho Oncology, Inc. Terminated Thu, 08 May 2014 12:00:00 EDT Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor FailureCondition: Head and Neck Squamous Cell CarcinomaInterventions: Drug: Paclitaxel; Drug: Cetuximab Sponsor: Medical University of Vienna Recruiting Thu, 20 Feb 2020 12:00:00 EST Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLCCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: MPDL3280A; Drug: Carboplatin; Drug: Nab-paclitaxel Sponsors: Columbia University; Genentech, Inc.; Celgene Corporation Active, not recruiting Tue, 22 Mar 2016 12:00:00 EDT CDK4/6 Tumor, Abemaciclib, PaclitaxelCondition: TumorsIntervention: Drug: abemaciclib+paclitaxel Sponsor: Yonsei University Recruiting Tue, 20 Oct 2020 12:00:00 EDT Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent GlioblastomaConditions: Glioblastoma; Gliosarcoma; GBM; Glioblastoma Multiforme; Glioblastoma, IDH-wildtype; Recurrent GlioblastomaInterventions: Device: Sonication for opening of blood-brain barrier; Drug: Chemotherapy, albumin-bound paclitaxel Sponsors: Northwestern University; CarThera; Bristol-Myers Squibb; Lantheus Medical Imaging Recruiting Thu, 27 Aug 2020 12:00:00 EDT Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerConditions: Chemotherapeutic Agent Toxicity; Endometrial Adenocarcinoma; Fallopian Tube Carcinoma; Gastrointestinal Complication; Malignant Ovarian Mixed Epithelial Tumor; Neurotoxicity Syndrome; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Stage II Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Undifferentiated Ovarian CarcinomaInterventions: Drug: Paclitaxel; Drug: Cisplatin Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Tue, 23 Dec 2008 12:00:00 EST Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic CancerCondition: Carcinoma, Pancreatic DuctalIntervention: Drug: Paclitaxel and gemcitabine Sponsor: New York Presbyterian Brooklyn Methodist Hospital Withdrawn Tue, 27 Sep 2005 12:00:00 EDT Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerCondition: Breast CancerInterventions: Biological: bevacizumab; Drug: Carboplatin; Drug: ABI-007 Sponsors: Loyola University; Genentech, Inc.; Celgene Corporation Completed Wed, 09 Apr 2008 12:00:00 EDT
Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic CancerConditions: Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal AdenocarcinomaInterventions: Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: L-glutamine Sponsors: Jun Gong, MD; Emmaus Medical, Inc. Recruiting Wed, 18 Nov 2020 12:00:00 EST A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenCondition: CancerIntervention: Drug: Custirsen, paclitaxel and carboplatin Sponsors: Achieve Life Sciences; Teva Pharmaceutical Industries Completed Thu, 22 Dec 2011 12:00:00 EST Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerConditions: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Drug: Relacorilant, 100mg QD; Drug: Nab-paclitaxel, 80mg/m^2; Drug: Nab-paclitaxel, 100mg/m^2; Drug: Relacorilant, 150mg QD Sponsor: Corcept Therapeutics Active, not recruiting Mon, 17 Dec 2018 12:00:00 EST Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract CancerCondition: Advanced Biliary Tract CancerIntervention: Drug: Toripalimab Combined With S1 and Albumin Paclitaxel Sponsor: Dai, Guanghai Unknown status Mon, 22 Jul 2019 12:00:00 EDT A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerConditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer PatientsInterventions: Drug: MM-121; Drug: Paclitaxel Sponsors: Merrimack Pharmaceuticals; Sanofi Completed Mon, 22 Aug 2011 12:00:00 EDT Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)Condition: Advanced Non-small Cell Lung CancerIntervention: Drug: paclitaxel poliglumex, pemetrexed Sponsors: Dartmouth-Hitchcock Medical Center; CTI BioPharma Completed Mon, 18 Jun 2007 12:00:00 EDT Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic PatientsCondition: Metastatic Pancreatic Ductal AdenocarcinomaInterventions: Drug: PF-04136309; Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsor: Pfizer Terminated Mon, 11 Apr 2016 12:00:00 EDT A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Napabucasin; Drug: Paclitaxel Sponsor: Sumitomo Dainippon Pharma Oncology, Inc Terminated Thu, 07 Jul 2016 12:00:00 EDT Clinical Study of Liposomal Paclitaxel in Chinese PatientsCondition: Solid TumorIntervention: Drug: Liposomal paclitaxel Sponsor: Nanjing Sike Pharmaceutical Co., Ltd. Unknown status Wed, 15 Apr 2009 12:00:00 EDT Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyCondition: HER2-positive Breast CancerIntervention: Combination Product: pyrotinib maleate tablets+nab-paclitaxel Sponsor: Hebei Medical University Fourth Hospital Not yet recruiting Thu, 18 Apr 2019 12:00:00 EDT
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBCCondition: Triple Negative Breast CancerInterventions: Drug: JS001，an engineered anti-PD-1 antibody; Drug: Nab-Paclitaxel; Drug: Placebo Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Suspended Mon, 17 Dec 2018 12:00:00 EST Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal CancerCondition: Esophageal CancerIntervention: Drug: nab-paclitaxel group Sponsor: Tianjin Medical University Cancer Institute and Hospital Unknown status Thu, 05 May 2016 12:00:00 EDT Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCondition: Metastatic Urothelial CarcinomaIntervention: Drug: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Completed Wed, 14 Mar 2018 12:00:00 EDT SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerCondition: Triple-negative Breast CancerIntervention: Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin Sponsor: Henan Cancer Hospital Not yet recruiting Mon, 30 Dec 2019 12:00:00 EST PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian CancerConditions: Peritoneal Carcinomatosis; Ovarian Cancer Stage IIIB; Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Breast Cancer Stage IV; Stomach Cancer Stage III; Stomach Cancer Stage IV With Metastases; Pancreas Cancer, Stage III; Pancreas Cancer, Stage IVIntervention: Drug: PIPAC with Abraxane Sponsors: University Hospital, Ghent; Kom Op Tegen Kanker; University Ghent; Hopital Lariboisière; University Women's Hospital Tübingen; Candiolo Cancer Institute - IRCCS; Centre Hospitalier Universitaire Vaudois Completed Fri, 06 Oct 2017 12:00:00 EDT Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic CancerCondition: Pancreatic AdenocarcinomaIntervention: Drug: Nab-paclitaxel + Gemcitabine Sponsor: Institut Paoli-Calmettes Completed Thu, 26 Jun 2014 12:00:00 EDT Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric CancerConditions: Surgically-Created Resection Cavity; Drug SafetyIntervention: Drug: S-1 + Paclitaxel Chemotherapy Sponsor: Zhejiang Cancer Hospital Unknown status Tue, 25 Dec 2012 12:00:00 EST DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCCondition: Breast CancerInterventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Pertuzumab Sponsors: Dana-Farber Cancer Institute; Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation; Terri Brodeur Breast Cancer Foundation Active, not recruiting Tue, 23 Oct 2018 12:00:00 EDT Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaConditions: Muscle Invasive Bladder Cancer; Urothelial CarcinomaInterventions: Drug: Tislelizumab; Drug: Nab paclitaxel Sponsor: Tianjin Medical University Second Hospital Recruiting Fri, 29 Jan 2021 12:00:00 EST Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory CancerCondition: Refractory CancerInterventions: Drug: AZD6738; Drug: Paclitaxel Sponsor: Samsung Medical Center Recruiting Tue, 15 Dec 2015 12:00:00 EST
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerConditions: Fallopian Tube Carcinoma; Recurrent Ovarian Cancer; Primary Peritoneal Carcinoma; Recurrent Endometrial CancerInterventions: Drug: Lenvatinib Mesylate; Drug: Paclitaxel; Other: Pharmacological Study Sponsors: Floor Backes; Eisai Inc. Active, not recruiting Thu, 02 Jun 2016 12:00:00 EDT Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical CancerCondition: Locally Advanced Cervical CancerInterventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Taxol Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Merck Sharp & Dohme Corp. Recruiting Thu, 23 Jan 2020 12:00:00 EST Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsConditions: Salivary Gland Malignant Neoplasms; Salivary Gland TumorsIntervention: Drug: Sintilimab , Carboplatin, Nab-paclitaxel Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting Wed, 11 Aug 2021 12:00:00 EDT Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCondition: Solid TumorsInterventions: Drug: PLX3397; Drug: Paclitaxel Sponsors: Daiichi Sankyo, Inc.; Plexxikon Completed Fri, 03 Feb 2012 12:00:00 EST Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer PatientsCondition: Advanced Pancreatic CancerInterventions: Drug: Paclitaxel liposome; Drug: S-1 Sponsor: Fudan University Not yet recruiting Fri, 03 Jan 2020 12:00:00 EST Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line TherapyCondition: Gastric CancerInterventions: Drug: Paclitaxel; Drug: Irinotecan Sponsors: Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd Unknown status Wed, 20 Oct 2010 12:00:00 EDT Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal CarcinomaCondition: Nasopharyngeal CarcinomaIntervention: Drug: Albumin-Bound Paclitaxel Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting Tue, 23 Feb 2021 12:00:00 EST Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCondition: Malignant Neoplasm of BreastInterventions: Drug: Pembrolizumab; Drug: nab-paclitaxel; Drug: Epirubicin; Drug: Cyclophosphamide Sponsors: Institut fuer Frauengesundheit; Merck Sharp & Dohme Corp.; Celgene Corporation Completed Thu, 21 Sep 2017 12:00:00 EDT Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsConditions: Salivary Gland Malignant Neoplasms; Salivary Gland TumorsIntervention: Drug: Toripalimab , Carboplatin, Nab-paclitaxel Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting Thu, 01 Apr 2021 12:00:00 EDT A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Condition: Triple Negative Breast CancerInterventions: Drug: SG001; Drug: Nab-paclitaxel Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting Tue, 05 Oct 2021 12:00:00 EDT
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCCondition: Stage IIIA Non-Small Cell Lung CancerInterventions: Drug: Neoadjuvant Cisplatin, nab-paclitaxel; Drug: Adjuvant Cisplatin,nab-paclitaxel; Drug: Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine Sponsor: UNC Lineberger Comprehensive Cancer Center Terminated Tue, 28 Oct 2014 12:00:00 EDT Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour PatientsConditions: Solid Tumour,; Breast Cancer,; Metastatic Melanoma,; Non-small Cell Lung Cancer (NSCLC),Intervention: Drug: F16IL2 in combination with paclitaxel Sponsor: Philogen S.p.A. Unknown status Mon, 31 May 2010 12:00:00 EDT A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersConditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal CancerInterventions: Drug: MM-121; Drug: Paclitaxel Sponsors: Merrimack Pharmaceuticals; Sanofi Completed Thu, 06 Oct 2011 12:00:00 EDT Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric CancerCondition: Gastric CancerIntervention: Drug: paclitaxel-albumin and S-1 Sponsor: Beijing Friendship Hospital Not yet recruiting Thu, 06 Feb 2020 12:00:00 EST Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Conditions: Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast CancerInterventions: Drug: nab-Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine Sponsor: Celgene Completed Wed, 19 Jun 2013 12:00:00 EDT Study of Vemurafenib, Carboplatin, and PaclitaxelCondition: Advanced CancersInterventions: Drug: Vemurafenib; Drug: Carboplatin; Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Completed Tue, 10 Jul 2012 12:00:00 EDT Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCondition: Esophageal Squamous Cell CarcinomaInterventions: Drug: Sintilimab; Drug: Nab paclitaxel; Drug: Cisplatin Sponsors: Sun Yat-sen University; Innovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group Limited Recruiting Mon, 14 Sep 2020 12:00:00 EDT A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: FOLFIRINOX or gemcitabine/abraxane; Radiation: SBRT Sponsor: University of Colorado, Denver Active, not recruiting Fri, 19 Aug 2016 12:00:00 EDT Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly PaclitaxelCondition: CancerInterventions: Drug: Paclitaxel dose escalation; Drug: Paclitaxel; Drug: Cyclophosphamide; Biological: Blood collection Sponsor: Centre Oscar Lambret Completed Thu, 16 Jun 2011 12:00:00 EDT Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast CancerCondition: Breast CancerInterventions: Drug: Adriamycin and Cytoxan (AC); Drug: ABI-007; Drug: Taxol; Drug: Bevacizumab; Drug: pegfilgrastim Sponsor: Celgene Completed Tue, 31 Oct 2006 12:00:00 EST
Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous TummorCondition: Squamous Cell Carcinoma of Head and NeckIntervention: Drug: albumin-bound paclitaxel Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting Tue, 23 Feb 2021 12:00:00 EST Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid TumorsCondition: Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: gemcitabine hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI) Completed Mon, 27 Mar 2006 12:00:00 EST Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like NanoparticlesConditions: Coronary Artery Disease; Atherosclerosis; InflammationInterventions: Drug: LDE-Paclitaxel; Drug: LDE-Placebo Sponsor: University of Sao Paulo General Hospital Active, not recruiting Mon, 04 Nov 2019 12:00:00 EST Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate CancerCondition: Prostatic NeoplasmsInterventions: Drug: Abraxane; Drug: Leuprolide; Drug: Bicalutamide Sponsors: The Methodist Hospital Research Institute; Celgene Corporation Terminated Tue, 28 Aug 2007 12:00:00 EDT Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st ChemotherapyCondition: Small Cell Lung CancerInterventions: Drug: Albumin Paclitaxel; Drug: Simvastatin Sponsors: Shanghai Pulmonary Hospital, Shanghai, China; Chinese Academy of Sciences Recruiting Thu, 07 Jan 2021 12:00:00 EST Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerConditions: Ovarian Neoplasms; Fallopian Tube Neoplasms; Neoplasms by Site; Genital Neoplasms, Female; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Genital Diseases, Female; Endocrine System Diseases; Carcinoma; Anlotinib; Angiogenesis; Antineoplastic Agents; Tyrosine Kinase InhibitorInterventions: Drug: Drug: Anlotinib; Drug: Drug: Carboplatin/Paclitaxel Sponsor: Wenjun Cheng Not yet recruiting Fri, 19 Mar 2021 12:00:00 EDT SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic CancerCondition: Pancreatic Cancer Stage IVIntervention: Drug: Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin Sponsors: RenJi Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting Fri, 29 Nov 2019 12:00:00 EST Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian CancerCondition: Recurrent Ovarian CancerIntervention: Drug: LDE225 Sponsors: University of Alabama at Birmingham; Novartis Pharmaceuticals Completed Mon, 21 Jul 2014 12:00:00 EDT Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast CancerCondition: Breast CancerIntervention: Drug: Paclitaxel + Carboplatin + ASLAN001 Sponsor: National University Hospital, Singapore Unknown status Tue, 24 Mar 2015 12:00:00 EDT Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal CancerCondition: Esophageal CancerInterventions: Drug: S-1 and Paclitaxel; Drug: Paclitaxel and Cisplatin; Drug: 5-FU and Cisplatin Sponsor: Peking University Terminated Thu, 11 Oct 2012 12:00:00 EDT
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast CancerConditions: Metastatic Breast Cancer; Locally Recurrent Breast CancerInterventions: Drug: Nab-paclitaxel; Drug: IG-001 Sponsor: Sorrento Therapeutics, Inc. Completed Mon, 17 Feb 2014 12:00:00 EST Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical CancerConditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical CancerInterventions: Drug: Paclitaxel; Drug: Oxaliplatin Sponsor: National Cancer Institute (NCI) Completed Wed, 09 Apr 2003 12:00:00 EDT Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors ProgressionCondition: Metastatic Breast CancerInterventions: Drug: Pembrolizumab; Drug: Paclitaxel Sponsors: SOLTI Breast Cancer Research Group; Merck Sharp & Dohme Corp. Recruiting Fri, 31 Jan 2020 12:00:00 EST BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic CancerConditions: Pancreatic Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas CancerInterventions: Drug: BVD-523; Drug: Nab-paclitaxel; Drug: Gemcitabine; Procedure: Tumor biopsy Sponsors: Washington University School of Medicine; BioMed Valley Discoveries, Inc; National Cancer Institute (NCI) Terminated Wed, 18 Nov 2015 12:00:00 EST Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable AngiosarcomaConditions: Angiosarcomas; Soft Tissue SarcomaInterventions: Drug: Bevacizumab; Drug: Paclitaxel Sponsors: Stanford University; Genentech, Inc. Terminated Mon, 25 Jan 2010 12:00:00 EST Afatinib, Paclitaxel, 2nd Line, Advanced Gastric CancerConditions: Gastric Cancer; Gastroesophageal Junction CancerInterventions: Drug: afatinib; Drug: paclitaxel Sponsor: Yonsei University Active, not recruiting Fri, 17 Jul 2015 12:00:00 EDT A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and PaclitaxelCondition: Breast CancerInterventions: Drug: Bevacizumab; Drug: Paclitaxel Sponsor: Theodoros Foukakis Completed Wed, 07 Nov 2012 12:00:00 EST Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerConditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung CancerInterventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation Sponsors: University of Washington; National Cancer Institute (NCI); Celgene Corporation Completed Fri, 15 Jun 2012 12:00:00 EDT Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)Condition: Non-small-cell Lung CancerIntervention: Drug: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy) Sponsor: Taipei Veterans General Hospital, Taiwan Completed Thu, 29 May 2008 12:00:00 EDT Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerConditions: Metastatic Pancreatic Adenocarcinoma; Metastatic Pancreatic CancerInterventions: Drug: Nab-Paclitaxel; Drug: Gemcitabine; Drug: Indoximod Sponsor: NewLink Genetics Corporation Completed Tue, 04 Mar 2014 12:00:00 EST
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: nab-paclitaxel Sponsor: Chinese Academy of Medical Sciences Not yet recruiting Wed, 11 Dec 2019 12:00:00 EST ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid TumorsConditions: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Recurrent Breast Carcinoma; TP53 wt Allele; Unresectable Malignant Solid NeoplasmInterventions: Drug: MDM2/MDMX Inhibitor ALRN-6924; Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting Wed, 31 Oct 2018 12:00:00 EDT A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)Condition: Recurrent Platinum Resistant Ovarian CancerInterventions: Drug: VB-111 + Paclitaxel; Drug: Placebo + Paclitaxel Sponsors: Vascular Biogenics Ltd. operating as VBL Therapeutics; GOG Foundation, Inc. Recruiting Fri, 12 Jan 2018 12:00:00 EST Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerConditions: Gastric Cancer; GastroEsophageal CancerInterventions: Drug: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor); Drug: Albumin-bound Paclitaxel Sponsor: Huazhong University of Science and Technology Not yet recruiting Wed, 04 Mar 2020 12:00:00 EST Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast CancerCondition: Breast CancerIntervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc.; University of Pennsylvania Completed Thu, 13 Jan 2011 12:00:00 EST Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLCCondition: STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCERInterventions: Drug: NAB-PACLITAXEL; Drug: PACLITAXEL Sponsors: University of Texas Southwestern Medical Center; Celgene Completed Fri, 28 Dec 2012 12:00:00 EST Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast CancerCondition: Neoplasms, BreastInterventions: Drug: Lapatinib oral tablets; Drug: Paclitaxel infusion Sponsor: GlaxoSmithKline Completed Wed, 26 Jul 2006 12:00:00 EDT POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerCondition: Advanced Breast CancerInterventions: Drug: POL6326; Drug: Eribulin; Drug: Nab paclitaxel Sponsor: MedSIR Not yet recruiting Thu, 01 Apr 2021 12:00:00 EDT Study of Afuresertib Combined With Paclitaxel in Gastric CancerCondition: CancerInterventions: Drug: Afuresertib; Drug: Paclitaxel Sponsor: Novartis Pharmaceuticals Completed Mon, 15 Sep 2014 12:00:00 EDT S 81694 Plus Paclitaxel in Metastatic Breast CancerConditions: Metastatic Breast Cancer; Metastatic Triple Negative Breast CancerInterventions: Drug: Combination therapy (S81694 + paclitaxel) phase I; Drug: Paclitaxel; Drug: Combination therapy (S81694 + paclitaxel) phase II Sponsors: Institut de Recherches Internationales Servier; ADIR, a Servier Group company Completed Fri, 26 Jan 2018 12:00:00 EST
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Pembrolizumab; Drug: Paclitaxel Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme Corp. Active, not recruiting Tue, 12 May 2015 12:00:00 EDT Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and TrastuzumabCondition: Breast CancerIntervention: Drug: Paclitaxel/Gemcitabine/Trastuzumab Sponsor: Jungsil Ro Completed Thu, 20 Sep 2007 12:00:00 EDT Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung CancerCondition: Non-small Cell Lung CancerInterventions: Drug: nab-paclitaxel; Drug: Paclitaxel; Drug: Carboplatin Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown status Mon, 28 Aug 2017 12:00:00 EDT Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerConditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)Interventions: Drug: BEZ235; Drug: Paclitaxel Sponsor: Novartis Pharmaceuticals Terminated Mon, 19 Dec 2011 12:00:00 EST A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: Nab-paclitaxel; Radiation: Radiation Therapy; Procedure: Surgical Resection Sponsor: University Health Network, Toronto Active, not recruiting Thu, 25 Jun 2015 12:00:00 EDT Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast CancerCondition: Breast CancerIntervention: Drug: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab Sponsor: West China Hospital Recruiting Tue, 08 Jun 2021 12:00:00 EDT Taxol Carboplatin and ErythropoetinCondition: Ovarian CancerIntervention: Drug: Paclitaxel Sponsor: North Eastern German Society of Gynaecological Oncology Completed Mon, 12 Sep 2005 12:00:00 EDT Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the BonesConditions: Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor-Positive Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8Interventions: Drug: Paclitaxel; Radiation: Radium Ra 223 Dichloride Sponsor: National Cancer Institute (NCI) Recruiting Mon, 16 Sep 2019 12:00:00 EDT Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal MelanomaCondition: MelanomaInterventions: Drug: Genasense; Drug: Paclitaxel; Drug: Carboplatin Sponsors: M.D. Anderson Cancer Center; Genta Incorporated Terminated Mon, 13 Sep 2010 12:00:00 EDT Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: nab-Paclitaxel; Drug: Gemcitabine; Radiation: Intensity modulated radiation Sponsor: Washington University School of Medicine Completed Wed, 05 Nov 2014 12:00:00 EST
A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)Condition: Unknown Primary TumorsInterventions: Drug: nab-paclitaxel; Drug: Carboplatin; Drug: Gemcitabine Sponsor: Fondazione del Piemonte per l'Oncologia Unknown status Tue, 17 Nov 2015 12:00:00 EST Paclitaxel in Treating Older Patients With Solid TumorsCondition: Unspecified Adult Solid Tumor, Protocol SpecificIntervention: Drug: paclitaxel Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Mon, 27 Jan 2003 12:00:00 EST A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLCConditions: Lung Cancer Stage II; PD-1 Antibody; Non-small Cell Lung CancerInterventions: Drug: SHR-1210; Drug: Carboplatin and Paclitaxel-albumin Sponsor: Xuanwu Hospital, Beijing Unknown status Fri, 27 Sep 2019 12:00:00 EDT Paclitaxel in Treating Women With Recurrent Solid TumorsCondition: Unspecified Adult Solid Tumor, Protocol SpecificIntervention: Drug: paclitaxel Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Tue, 25 Nov 2003 12:00:00 EST Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossCondition: Triple Negative Breast NeoplasmsInterventions: Drug: alpelisib; Drug: placebo; Drug: nab-paclitaxel Sponsor: Novartis Pharmaceuticals Recruiting Wed, 05 Feb 2020 12:00:00 EST Carboplatin Combined With Paclitaxel in Treating Patients With Advanced ThymomaConditions: Thymoma; Thymic CarcinomaInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI) Completed Mon, 27 Jan 2003 12:00:00 EST AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCondition: Lung CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: AZD1775 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting Fri, 31 Jul 2015 12:00:00 EDT Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian CancerCondition: Ovarian CancerIntervention: Drug: Paclitaxel for injection (albumin-bound) Sponsor: Huazhong University of Science and Technology Not yet recruiting Mon, 28 Jan 2019 12:00:00 EST Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic MalignanciesCondition: Advanced Nonhaematologic MalignanciesInterventions: Drug: BOS172722; Drug: Paclitaxel Sponsor: Boston Pharmaceuticals Completed Wed, 01 Nov 2017 12:00:00 EDT Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)Conditions: Squamous Cell Cancer; Head and Neck CancerIntervention: Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin Sponsors: Memorial Sloan Kettering Cancer Center; NATL COMP CA NETWORK; Pfizer Completed Thu, 19 Nov 2009 12:00:00 EST
A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic CancerCondition: Pancreatic Cancer (Unresectable)Interventions: Drug: FG-3019; Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsor: FibroGen Active, not recruiting Wed, 06 Aug 2014 12:00:00 EDT Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer PatientsCondition: Adenocarcinoma PancreasInterventions: Drug: Nab-paclitaxel; Drug: Gemcitabine; Other: Best Supportive Care Sponsor: AIO-Studien-gGmbH Completed Fri, 24 Jun 2016 12:00:00 EDT Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal CancerCondition: Esophageal Squamous Cell CarcinomaIntervention: Drug: Paclitaxel+Nedaplatin+Endostar Sponsor: Yuhong Li Recruiting Thu, 29 Jan 2015 12:00:00 EST Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaConditions: NSCLC, Recurrent; Adenocarcinoma of LungInterventions: Drug: Vargatef; Drug: Abraxane; Other: placebo Sponsors: Royal Marsden NHS Foundation Trust; Boehringer Ingelheim; Celgene Withdrawn Mon, 04 Dec 2017 12:00:00 EST PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric AdenocarcinomaCondition: Advanced Gastric AdenocarcinomaInterventions: Drug: GSK2636771; Drug: Paclitaxel Sponsor: Yonsei University Completed Thu, 26 Nov 2015 12:00:00 EST Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian CancerConditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; No Prior ChemotherapyInterventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab Sponsors: David O'Malley; Genentech, Inc. Unknown status Wed, 13 Oct 2010 12:00:00 EDT Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric CarcinomaCondition: Advanced Gastric CarcinomaIntervention: Drug: Liposomal paclitaxel plus capecitabine Sponsor: Nanjing Sike Pharmaceutical Co., Ltd. Unknown status Wed, 15 Apr 2009 12:00:00 EDT A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast CancerCondition: Breast CancerIntervention: Drug: paclitaxel Sponsors: University of Kansas; Novartis Withdrawn Fri, 16 Jul 2010 12:00:00 EDT Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaCondition: Nasopharyngeal CarcinomaInterventions: Drug: Paclitaxel; Drug: Cisplatin Sponsor: Sun Yat-sen University Active, not recruiting Wed, 08 Feb 2017 12:00:00 EST Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)Condition: Pancreatic AdenocarcinomaInterventions: Device: NovoTTF-100L; Drug: Gemcitabine; Drug: nab-Paclitaxel Sponsor: NovoCure Ltd. Unknown status Tue, 29 Oct 2013 12:00:00 EDT
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerConditions: Breast Cancer; Estrogen Receptor Negative Neoplasm; HER-2 Positive Breast CancerInterventions: Drug: nab-paclitaxel; Drug: Trastuzumab Sponsor: Osaka Medical College Terminated Thu, 05 Nov 2015 12:00:00 EST Combination Chemotherapy With CS-1008 to Treat Ovarian CancerConditions: Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IVInterventions: Drug: CS-1008; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Daiichi Sankyo, Inc. Completed Fri, 24 Jul 2009 12:00:00 EDT Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian CancerCondition: Ovarian CancerInterventions: Drug: albumin-bound paclitaxel; Drug: Apatinib Sponsor: Henan Cancer Hospital Unknown status Wed, 08 May 2019 12:00:00 EDT S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary TractConditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral CancerInterventions: Drug: gemcitabine hydrochloride; Drug: paclitaxel Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Terminated Mon, 27 Jan 2003 12:00:00 EST Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced MalignanciesCondition: Advanced CancerInterventions: Drug: Nab-paclitaxel; Drug: Bevacizumab; Drug: Gemcitabine Sponsor: M.D. Anderson Cancer Center Unknown status Fri, 30 Apr 2010 12:00:00 EDT Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung CancerCondition: Lung CancerIntervention: Drug: paclitaxel Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Wed, 17 Dec 2003 12:00:00 EST Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast CarcinomaCondition: Breast NeoplasmsIntervention: Drug: cetuximab paclitaxel Sponsor: Hadassah Medical Organization Unknown status Wed, 19 Jul 2006 12:00:00 EDT Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct ObstructionCondition: Bile Duct ObstructionIntervention: Device: Paclitaxel eluting covered metal stent and control covered metal stent Sponsor: Asan Medical Center Completed Wed, 28 Mar 2007 12:00:00 EDT Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell CarcinomaCondition: Esophageal Squamous Cell CarcinomaIntervention: Drug: Paclitaxel+Cisplatin+5fluorouracil Sponsor: Yuhong Li Unknown status Tue, 29 Nov 2016 12:00:00 EST Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and SunitinibCondition: Breast CancerIntervention: Drug: Paclitaxel,Gemcitabine,Sunitinib Sponsors: Jungsil Ro; Pfizer; HK inno.N Corporation Completed Thu, 18 Feb 2010 12:00:00 EST
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Gemcitabine; Drug: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) Sponsors: Mayo Clinic; National Cancer Institute (NCI) Completed Wed, 04 May 2005 12:00:00 EDT Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell CarcinomaCondition: Squamous Cell CarcinomaInterventions: Drug: Onivyde; Drug: Paclitaxel Sponsors: Federation Francophone de Cancerologie Digestive; Shire Recruiting Thu, 25 Oct 2018 12:00:00 EDT Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerConditions: Breast Cancer; Breast Adenocarcinoma; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Recurrent Breast Carcinoma; Stage IV Breast CancerInterventions: Drug: Rebastinib; Drug: Paclitaxel; Drug: Eribulin Mesylate Sponsors: Montefiore Medical Center; Deciphera Pharmaceuticals LLC; Albert Einstein College of Medicine Recruiting Wed, 06 Jul 2016 12:00:00 EDT Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung CancerCondition: Lung CancerIntervention: Drug: Paclitaxel, Carboplatin and Irinotecan Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Terminated Wed, 25 Apr 2007 12:00:00 EDT Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon CatheterCondition: In-stent RestenosisInterventions: Device: paclitaxel controlled release balloon catheter Vasoguard TM; Device: paclitaxel release coronary balloon catheter SeQuent Please Sponsors: Shandong Branden Med.Device Co.,Ltd; Fudan University Unknown status Wed, 07 Sep 2016 12:00:00 EDT Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to CisplatinCondition: Neoplasms, Germ Cell and EmbryonalIntervention: Drug: Oxaliplatin, Paclitaxel Sponsor: Sanofi Completed Mon, 11 Feb 2008 12:00:00 EST Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in ChinaCondition: Coronary DiseaseIntervention: Device: Paclitaxel Eluting Balloon Catheter Sponsors: Xijing Hospital; The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhejiang University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Second Hospital of Jilin University; First Affiliated Hospital of Xinjiang Medical University; Tang-Du Hospital; China-Japan Union Hospital, Jilin University; Xuzhou Third People's Hospital Unknown status Thu, 15 Mar 2018 12:00:00 EDT Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By SurgeryCondition: SarcomaIntervention: Drug: paclitaxel Sponsor: UNICANCER Completed Thu, 22 Sep 2005 12:00:00 EDT Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid TumorConditions: Breast Cancer; NSCLC; Ovary Cancer; Endometrial Cancer; Small Cell Lung Cancer (SCLC); Head and Neck (HNSCC)Interventions: Drug: PF-05212384; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Cristiana Sessa Completed Mon, 24 Feb 2014 12:00:00 EST Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the PancreasCondition: Adenocarcinoma PancreasInterventions: Procedure: Surgery; Genetic: Genetic Expression; Drug: Chemotherapy Sponsor: Medical University of South Carolina Terminated Mon, 04 Feb 2013 12:00:00 EST
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic AnalysisConditions: Gastric Adenocarcinoma; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Ramucirumab; Drug: Paclitaxel Sponsor: Samsung Medical Center Completed Fri, 11 Dec 2015 12:00:00 EST A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid TumorsCondition: Malignant Solid TumorInterventions: Biological: ramucirumab (IMC-1121B); Drug: paclitaxel Sponsor: Eli Lilly and Company Completed Tue, 24 Jan 2012 12:00:00 EST S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionConditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity CancerIntervention: Drug: paclitaxel Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Completed Fri, 20 Feb 2004 12:00:00 EST A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)Condition: Squamous Cell Carcinoma of Head and NeckInterventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel Sponsor: Merck Sharp & Dohme Corp. Recruiting Tue, 28 Jul 2020 12:00:00 EDT Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal AdenocarcinomaCondition: Pancreatic Ductal AdenocarcinomaInterventions: Drug: nab-paclitaxel; Drug: gemcitabine Sponsor: Samsung Medical Center Unknown status Fri, 24 Apr 2015 12:00:00 EDT Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaCondition: Advanced Gastric and Gastro-esophageal Junction AdenocarcinomaInterventions: Drug: sintilimab; Drug: nab-paclitaxel Sponsors: Chinese Academy of Medical Sciences; Chinese PLA General Hospital; Beijing Friendship Hospital; Beijing Hospital Recruiting Fri, 25 Oct 2019 12:00:00 EDT Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast CancerConditions: Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer; Inflammatory Breast CancerInterventions: Drug: Paclitaxel; Drug: Cisplatin Sponsor: RenJi Hospital Completed Thu, 24 Jul 2014 12:00:00 EDT TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Tak-228 & Tak-117; Drug: Cisplatin & Nab Paclitaxel Sponsors: Baylor Research Institute; Takeda Active, not recruiting Wed, 21 Jun 2017 12:00:00 EDT Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based ChemotherapyCondition: Patients With Stage IV or Recurrent Adenocarcinoma of the LungInterventions: Drug: Abraxane; Drug: Gemcitabine Sponsor: Abramson Cancer Center of the University of Pennsylvania Completed Mon, 01 Dec 2014 12:00:00 EST Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast CancerConditions: Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7Interventions: Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Active, not recruiting Tue, 01 Nov 2011 12:00:00 EDT
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)Condition: Carcinoma, Non-Small-Cell LungInterventions: Drug: CS-7017; Drug: Carboplatin; Drug: Paclitaxel Sponsors: Daiichi Sankyo Co., Ltd.; ICON Clinical Research Completed Fri, 10 Sep 2010 12:00:00 EDT Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Epirubicin; Drug: Paclitaxel; Drug: Capecitabine Sponsor: Thomas Hatschek Completed Wed, 14 Sep 2011 12:00:00 EDT ACY-1215 + Nab-paclitaxel in Metastatic Breast CancerConditions: Metastatic Breast Cancer; Breast CarcinomaInterventions: Drug: ACY-1215; Drug: Nab-paclitaxel Sponsors: Columbia University; Acetylon Pharmaceuticals Incorporated; National Cancer Institute (NCI) Completed Wed, 16 Dec 2015 12:00:00 EST Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral ArteryCondition: Peripheral Artery DiseaseInterventions: Device: Paclitaxel Eluting Stent; Device: Paclitaxel Eluting Balloon Sponsors: Provascular GmbH; William Cook Europe Completed Mon, 19 Nov 2012 12:00:00 EST Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerCondition: Advanced Triple Negative Breast CancerInterventions: Drug: Apatinib Mesylate; Drug: Albumin-Bound Paclitaxel Sponsor: Fujian Cancer Hospital Not yet recruiting Wed, 25 Aug 2021 12:00:00 EDT A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer PatientsCondition: Solid TumorIntervention: Drug: Oraxol Sponsors: Athenex, Inc.; Zenith Technology Corporation Limited; PharmaEssentia Completed Wed, 27 Nov 2019 12:00:00 EST Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic AdenocarcinomaCondition: Pancreatic CancerInterventions: Drug: Chemotherapy; Drug: Chemotherapy + ChemoRadiotherapy Sponsor: University of Florida Completed Fri, 11 Nov 2011 12:00:00 EST Prevention of Paclitaxel Neuropathy With CryotherapyCondition: Breast CancerInterventions: Other: Cryotherapy; Drug: Paclitaxel Sponsors: Medical Oncology & Hematology Associates of Northern Virginia; Inova Health System Unknown status Wed, 03 Sep 2014 12:00:00 EDT Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal CavityConditions: Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Other: laboratory biomarker analysis Sponsors: City of Hope Medical Center; National Cancer Institute (NCI); National Comprehensive Cancer Network Completed Mon, 19 Jan 2009 12:00:00 EST Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast CancerCondition: Breast NeoplasmInterventions: Drug: Taxol; Drug: TOCOSOL Paclitaxel Sponsor: Achieve Life Sciences Terminated Wed, 09 Nov 2005 12:00:00 EST
Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB AngioplastyCondition: IschemiaInterventions: Device: Angiogram, Medtronic DCB (paclitaxel)/stent; Device: Angiogram, Bard DCB (paclitaxel)/stent Sponsor: Rabih A. Chaer Recruiting Tue, 03 May 2016 12:00:00 EDT Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic CancerCondition: Locally Advanced Pancreatic CancerIntervention: Drug: Nab-paclitaxel and S-1 Sponsor: Chinese Academy of Medical Sciences Not yet recruiting Thu, 24 Jan 2019 12:00:00 EST FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + GemcitabineCondition: Metastatic Pancreatic CancerInterventions: Drug: FOLFIRI.3; Drug: nab-paclitaxel+ gemcitabine Sponsors: Federation Francophone de Cancerologie Digestive; UNICANCER; GERCOR - Multidisciplinary Oncology Cooperative Group Active, not recruiting Mon, 11 Jul 2016 12:00:00 EDT AZD8186 and Paclitaxel in Advanced Gastric CancerConditions: Solid Tumor; Stomach CancerIntervention: Drug: AZD8186 in combination with paclitaxel Sponsor: Seoul National University Bundang Hospital Recruiting Fri, 28 Jun 2019 12:00:00 EDT [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian CancerCondition: Ovarian NeoplasmIntervention: Drug: Pazopanib and paclitaxel Sponsors: Imperial College London; GlaxoSmithKline Completed Wed, 30 May 2012 12:00:00 EDT Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerIntervention: Drug: Paclitaxel bound albumine Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica Completed Wed, 09 Apr 2014 12:00:00 EDT Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous FistulaConditions: Angioplasty; Stenosis of Arteriovenous FistulaInterventions: Combination Product: Additional angioplasty with paclitaxel-coated balloon; Combination Product: Additional angioplasty with placebo balloon; Procedure: Conventional angioplasty Sponsors: Assistance Publique - Hôpitaux de Paris; Bard Peripheral Vascular, Inc. Active, not recruiting Thu, 28 Apr 2016 12:00:00 EDT Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary LesionsCondition: Coronary Artery DiseaseInterventions: Procedure: Balloon angioplasty; Procedure: Stent implantation Sponsors: B.Braun Surgical SA; Hospital Universitario Infanta Cristina de Badajoz Unknown status Mon, 17 Jan 2011 12:00:00 EST Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerConditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Tumor; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Drug: Elesclomol Sodium; Drug: Paclitaxel Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Mon, 27 Apr 2009 12:00:00 EDT Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaConditions: Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell CarcinomaInterventions: Drug: sintilimab, paclitaxel, carboplatin; Procedure: Surgical resection Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting Fri, 22 Jan 2021 12:00:00 EST
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerConditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity CancerInterventions: Drug: paclitaxel; Drug: ganetespib; Other: laboratory biomarker analysis Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI) Terminated Wed, 16 Oct 2013 12:00:00 EDT Paclitaxel and Cisplatin for Thymic NeoplasmConditions: Thymoma; Thymic CarcinomaIntervention: Drug: paclitaxel and cisplatin Sponsor: Korean Cancer Study Group Terminated Wed, 07 Jan 2009 12:00:00 EST Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)Condition: Locally Advanced Pancreatic CancerInterventions: Drug: Gemcitabine; Radiation: Hypofractionated Ablative Proton Therapy Sponsor: University of Maryland, Baltimore Recruiting Wed, 29 Aug 2018 12:00:00 EDT Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian CancerConditions: Carcinoma; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal CancerIntervention: Drug: AMG 386, paclitaxel and carboplatin Sponsor: Amgen Completed Fri, 03 Dec 2010 12:00:00 EST Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerConditions: Pancreatic Neoplasm; Metastatic Pancreatic Cancer; Locally Advanced Pancreatic AdenocarcinomaIntervention: Drug: Anlotinib+Toripalimab+Nab-paclitaxel Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting Fri, 22 Jan 2021 12:00:00 EST Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCondition: Breast CancerInterventions: Drug: T-DM1; Drug: Trastuzumab; Drug: Lapatinib; Drug: Abraxane; Drug: Paclitaxel; Drug: Pertuzumab Sponsors: The Methodist Hospital Research Institute; Celgene Corporation; Novartis Completed Thu, 27 Feb 2014 12:00:00 EST Weekly Paclitaxel and Trastuzumab in Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: paclitaxel plus trastuzumab Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; Bristol-Myers Squibb; Roche Pharma AG Completed Fri, 26 Aug 2011 12:00:00 EDT Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell CarcinomaCondition: Small Cell CarcinomaInterventions: Drug: Nortriptyline Hydrochloride; Drug: Paclitaxel Sponsors: University of Washington; National Cancer Institute (NCI) Completed Fri, 26 Aug 2016 12:00:00 EDT First Line Chemotherapy for Advanced CancerCondition: Gastric CancerInterventions: Drug: albumin-bounded paclitaxel; Drug: S-1 Sponsor: Chinese Academy of Medical Sciences Terminated Mon, 11 Nov 2013 12:00:00 EST Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerIntervention: Drug: Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy Sponsor: Yonsei University Unknown status Wed, 18 Apr 2018 12:00:00 EDT
Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)Condition: Coronary Artery DiseaseInterventions: Device: Device: Paclitaxel-Coated PTCA Balloon Catheter; Device: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel Sponsor: Boston Scientific Corporation Active, not recruiting Fri, 16 Aug 2019 12:00:00 EDT Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic AdenocarcinomaCondition: Pancreatic AdenocarcinomaInterventions: Drug: AVB-S6-500; Drug: Nab paclitaxel; Drug: Gemcitabine Sponsor: Aravive, Inc. Recruiting Fri, 30 Jul 2021 12:00:00 EDT Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6Conditions: Gastric Cancer Stage IV; Peritoneal Carcinomatosis; Intraperitoneal Paclitaxel; mFOLFOX6Interventions: Drug: Paclitaxel; Drug: mFOLFOX6 regimen Sponsors: Seoul National University Bundang Hospital; Boryung Pharmaceutical Co., Ltd; B. Braun Korea Co., Ltd. Recruiting Tue, 07 Aug 2018 12:00:00 EDT Paclitaxel in Treating Patients With Ovarian Stromal CancerConditions: Adult Type Ovarian Granulosa Cell Tumor; Ovarian Gynandroblastoma; Ovarian Sertoli-Leydig Cell Tumor; Ovarian Sex Cord Tumor With Annular Tubules; Ovarian Steroid Cell TumorIntervention: Drug: Paclitaxel Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Mon, 27 Jan 2003 12:00:00 EST A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCCCondition: Head and Neck Squamous Cell CarcinomaInterventions: Drug: SI-B001; Drug: Paclitaxel Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Recruiting Thu, 23 Sep 2021 12:00:00 EDT Intraperitoneal Therapy For Ovarian Cancer With Carboplatin TrialConditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CarcinomaInterventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous); Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Sponsors: Gynecologic Oncology Trial & Investigation Consortium; Japanese Gynecologic Oncology Group Active, not recruiting Tue, 10 Jan 2012 12:00:00 EST Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial CancerCondition: Transitional Cell CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Biological: Pembrolizumab Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Active, not recruiting Wed, 21 Oct 2015 12:00:00 EDT Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast CancerCondition: Breast CancerInterventions: Drug: nab-paclitaxel regimen1; Drug: nab-paclitaxel regimen2 Sponsor: Beijing Cancer Hospital Recruiting Tue, 10 Dec 2019 12:00:00 EST Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal CancerCondition: Esophageal CancerIntervention: Drug: Paclitaxel Sponsor: Bristol-Myers Squibb Completed Tue, 27 Jun 2006 12:00:00 EDT A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCondition: HER-2 Positive Advanced Gastric CancerInterventions: Drug: HM781-36B(Poziotinib); Drug: Paclitaxel; Drug: Trastuzumab Sponsors: Hanmi Pharmaceutical Company Limited; National OncoVenture Completed Tue, 11 Dec 2012 12:00:00 EST
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract CancerCondition: Unresectable Biliary Tract CancerIntervention: Drug: nab-paclitaxel in combination with gemcitabine + cisplatin Sponsors: AHS Cancer Control Alberta; Celgene Unknown status Wed, 16 Dec 2015 12:00:00 EST Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerConditions: Breast - Female; Male Breast CancerInterventions: Drug: Pembrolizumab; Drug: Paclitaxel Sponsors: Antoinette Tan, MD; Merck Sharp & Dohme Corp. Active, not recruiting Wed, 11 Jan 2017 12:00:00 EST Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESCConditions: Esophageal Cancer Stage IIB; Esophageal Cancer Stage IIIInterventions: Combination Product: Paclitaxel, Cisplatin Plus 5-FU (TCF); Radiation: radiochemotherapy Sponsors: Tianjin Medical University Cancer Institute and Hospital; Shanghai Chest Hospital; Henan Cancer Hospital; The First Affiliated Hospital with Nanjing Medical University; First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Anhui Medical University Not yet recruiting Fri, 08 Dec 2017 12:00:00 EST Alpelisib and Paclitaxel in PIK3CA-altered Gastric CancerConditions: Solid Tumor; Stomach CancerInterventions: Drug: Alpelisib; Drug: Paclitaxel Sponsor: Seoul National University Bundang Hospital Recruiting Tue, 25 Aug 2020 12:00:00 EDT A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)Condition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Sorafenib + Paclitaxel + Carboplatin; Drug: Placebo + Paclitaxel + Carboplatin Sponsor: Bayer Terminated Thu, 15 Nov 2007 12:00:00 EST Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung CancersConditions: Lung Cancer; Untreated Stage IV or Recurrent Squamous Cell Lung CancersInterventions: Drug: albumin-bound paclitaxel; Drug: gemcitabine Sponsors: Memorial Sloan Kettering Cancer Center; Celgene Corporation; Miami Cancer Institute Completed Mon, 17 Aug 2015 12:00:00 EDT Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsConditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Refractory Breast Carcinoma; Triple-Negative Breast CarcinomaInterventions: Drug: Alpelisib; Drug: Nab-paclitaxel Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting Thu, 02 Jan 2020 12:00:00 EST Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line TherapyConditions: Gastric Cancer; Gastroesophageal CancerInterventions: Drug: KH903 + Paclitaxel; Drug: Placebo + Paclitaxel Sponsor: Chengdu Kanghong Biotech Co., Ltd. Not yet recruiting Fri, 18 Sep 2020 12:00:00 EDT Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal AdenocarcinomaCondition: Pancreatic CancerInterventions: Drug: Demcizumab; Drug: Abraxane®; Drug: gemcitabine; Drug: Placebo Sponsors: OncoMed Pharmaceuticals, Inc.; Celgene Corporation Completed Thu, 13 Nov 2014 12:00:00 EST A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Condition: Triple-Negative Breast CancerIntervention: Drug: camrelizumab in combination with nab-paclitaxel and famitinib Sponsor: Fudan University Recruiting Thu, 17 Oct 2019 12:00:00 EDT
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCondition: Advanced Gastric or Gastroesophageal Junction CancerInterventions: Drug: Gentuximab; Drug: Paclitaxel Sponsors: GeneScience Pharmaceuticals Co., Ltd.; Shanghai East Hospital; The First Affiliated Hospital, Zhejiang University School of Medicine; Fujian Tumor Hospital; Sir Run Run Shaw Hospital; The Affiliated Tumor Hospital of Harbin Medical University; Union Hospital of Tongji Medical College, Huazhong University of Science and Technology; Sixth Affiliated Hospital, Sun Yat-sen University; Tongji Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; The First Hospital of Jilin University; The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital of Zhengzhou University Unknown status Mon, 12 Aug 2019 12:00:00 EDT Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast CancerCondition: HER2 Negative Metastatic Breast CancerInterventions: Drug: Cabazitaxel; Drug: Paclitaxel Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust Recruiting Thu, 09 Feb 2017 12:00:00 EST Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus ChemotherapyCondition: Advanced Pancreatic CancerInterventions: Drug: cisplatin+Nab-paclitaxel+GEM; Drug: Nab-paclitaxel+GEM Sponsor: Fudan University Not yet recruiting Wed, 13 Jan 2021 12:00:00 EST Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic CancerConditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic CancerInterventions: Drug: paclitaxel; Drug: bryostatin 1 Sponsor: National Cancer Institute (NCI) Completed Mon, 27 Jan 2003 12:00:00 EST Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic CancerConditions: Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8Interventions: Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: Laith Abushahin; National Cancer Institute (NCI) Recruiting Thu, 03 Oct 2019 12:00:00 EDT Phase II Study of ABI-007 for Gastric CancerCondition: Gastric CancerIntervention: Drug: ABI-007 Sponsor: Taiho Pharmaceutical Co., Ltd. Completed Fri, 18 Apr 2008 12:00:00 EDT Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant TumorsCondition: Advanced Hepatobiliary and Malignant TumorsIntervention: Drug: albumin-bound paclitaxel + oxaliplatin Sponsor: Dong Wang Not yet recruiting Mon, 19 Aug 2019 12:00:00 EDT A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaConditions: Endometrial Cancer; Uterine Cancer; Ovarian Cancer; CarcinosarcomaInterventions: Drug: Paclitaxel; Drug: 300mg DKN-01; Drug: 600mg DKN-01 Sponsor: Leap Therapeutics, Inc. Completed Wed, 10 Jan 2018 12:00:00 EST Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With AvastinCondition: Invasive Breast CancerIntervention: Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin Sponsors: University of Alabama at Birmingham; Ortho Biotech, Inc.; Genentech, Inc. Completed Thu, 13 Mar 2008 12:00:00 EDT A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung CancerConditions: Carcinoma; Non-Squamous Non-Small-Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: CDP791 10mg/kg; Drug: CDP791 20mg/kg Sponsor: UCB Pharma Completed Fri, 09 Sep 2005 12:00:00 EDT
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).Condition: Squamous Cell Carcinoma of the Anal CanalInterventions: Drug: carboplatin; Drug: paclitaxel; Drug: retifanlimab Sponsor: Incyte Corporation Recruiting Wed, 15 Jul 2020 12:00:00 EDT A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Paclitaxel; Drug: Veliparib; Drug: Carboplatin; Drug: Veliparib Placebo Sponsor: AbbVie Active, not recruiting Mon, 16 Jun 2014 12:00:00 EDT Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4Conditions: Restenosis; Stable Angina Pectoris; Acute Coronary SyndromeInterventions: Device: Paclitaxel Eluting Balloon + Scoring Balloon; Device: Paclitaxel Eluting Balloon Sponsors: Deutsches Herzzentrum Muenchen; Biotronik AG Completed Mon, 02 Jul 2012 12:00:00 EDT Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous PaclitaxelCondition: Medical OncologyInterventions: Drug: BAY1161909; Drug: Paclitaxel Sponsor: Bayer Terminated Thu, 15 May 2014 12:00:00 EDT Paclitaxel and Irinotecan in Advanced Gastric CancerCondition: Advanced Gastric CancerIntervention: Drug: Paclitaxel and irinotecan Sponsor: Seoul National University Hospital Completed Thu, 03 Jun 2010 12:00:00 EDT AVB-S6-500/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerCondition: Platinum-resistant Ovarian CancerInterventions: Drug: AVB-S6-500; Drug: Paclitaxel; Other: Placebo Sponsors: Aravive, Inc.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT) Recruiting Thu, 28 Jan 2021 12:00:00 EST The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCCondition: Head and Neck CancerIntervention: Drug: Buparlisib & Paclitaxel Sponsor: Adlai Nortye Biopharma Co., Ltd. Recruiting Wed, 08 Apr 2020 12:00:00 EDT RANGER™ Paclitaxel Coated Balloon vs Standard Balloon AngioplastyConditions: Peripheral Artery Disease; Atherosclerosis; Artery Diseases, Peripheral; Plaque, Atherosclerotic; Occlusive Arterial DiseaseInterventions: Device: RANGER™ Paclitaxel Coated Balloon; Drug: Paclitaxel; Procedure: Standard Balloon Angioplasty Sponsor: Boston Scientific Corporation Active, not recruiting Fri, 24 Feb 2017 12:00:00 EST Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and PaclitaxelConditions: Cancer; Non Small Cell Lung Cancer; Epithelial Ovarian CancerInterventions: Drug: AZD0530; Drug: Carboplatin; Drug: paclitaxel Sponsor: AstraZeneca Withdrawn Fri, 23 Oct 2009 12:00:00 EDT A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Hoffmann-La Roche Completed Mon, 13 Jul 2009 12:00:00 EDT
Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCConditions: Lung Cancer, Non-small Cell; Artificial IntelligenceIntervention: Drug: Camrelizumab + Nab-paclitaxel + Carboplatin Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University Recruiting Wed, 09 Sep 2020 12:00:00 EDT Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube CancerConditions: Ovarian Cancer; Primary PERITONEUM; Fallopian Tube CancerIntervention: Drug: Paclitaxel,Cisplatin, Bevacizumab Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc. Completed Tue, 08 Jan 2008 12:00:00 EST Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)Condition: Breast CancerInterventions: Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa; Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa Sponsors: German Breast Group; Pharmacia; Amgen; Bristol-Myers Squibb Completed Tue, 16 Oct 2007 12:00:00 EDT Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian CancerCondition: Epithelial Ovarian CancerInterventions: Drug: Metformin; Drug: Carboplatin; Drug: Paclitaxel Sponsor: University Medical Center Groningen Completed Tue, 09 Dec 2014 12:00:00 EST CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerCondition: Breast CancerInterventions: Drug: CFI-402257; Drug: Paclitaxel Sponsors: Canadian Cancer Trials Group; Stand Up To Cancer; Canadian Breast Cancer Foundation; Ontario Institute for Cancer Research Recruiting Tue, 26 Jun 2018 12:00:00 EDT Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic CancerConditions: Resectable Pancreatic Cancer; Ductal Adenocarcinoma of the PancreasInterventions: Drug: perioperative nab-paclitaxel/gemcitabine; Drug: adjuvant nab-paclitaxel/gemcitabine Sponsors: AIO-Studien-gGmbH; Celgene; ClinAssess GmbH Active, not recruiting Tue, 28 Jan 2014 12:00:00 EST Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHNConditions: Head and Neck Cancer; Squamous Cell Carcinoma of the Head and NeckInterventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin Sponsor: UNC Lineberger Comprehensive Cancer Center Completed Mon, 28 Apr 2014 12:00:00 EDT Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxelCondition: Pancreatic CancerInterventions: Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsors: Universitaire Ziekenhuizen Leuven; Celgene Corporation Completed Tue, 08 Apr 2014 12:00:00 EDT Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast CancerCondition: Neoplasms, BreastInterventions: Drug: Paclitaxel; Drug: GW572016 (Lapatinib) Sponsor: GlaxoSmithKline Completed Fri, 09 Jan 2004 12:00:00 EST Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung CancerCondition: Lung CancerInterventions: Drug: carboplatin; Drug: paclitaxel; Drug: vadimezan Sponsor: Swiss Group for Clinical Cancer Research Completed Wed, 27 Jan 2010 12:00:00 EST
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Albumin-bound paclitaxel; Drug: Carboplatin; Drug: Herceptin® Sponsor: Celgene Completed Tue, 05 Oct 2004 12:00:00 EDT Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric CancerCondition: Advanced Gastric CancerInterventions: Drug: taxel plus raltitrexed; Drug: taxol Sponsor: Fudan University Unknown status Wed, 26 Feb 2014 12:00:00 EST Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian OriginConditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerInterventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Avastin Sponsors: Massachusetts General Hospital; Genentech, Inc.; National Cancer Institute (NCI) Active, not recruiting Thu, 03 Apr 2008 12:00:00 EDT Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal AdenocarcinomaCondition: Metastatic Pancreatic AdenocarcinomaInterventions: Drug: Gemcitabine; Drug: Paclitaxel Sponsor: UNICANCER Active, not recruiting Thu, 09 May 2019 12:00:00 EDT Scheduling Nab-paclitaxel With GemcitabineCondition: Pancreatic Adenocarcinoma MetastaticInterventions: Drug: Abraxane (nab-paclitaxel); Drug: Gemcitabine Sponsors: CCTU- Cancer Theme; Celgene Completed Fri, 18 May 2018 12:00:00 EDT A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCondition: Small Cell Lung CarcinomaInterventions: Drug: paclitaxel; Biological: IBI318 Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Recruiting Thu, 17 Dec 2020 12:00:00 EST Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct CancerConditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: Emory University; Celgene Recruiting Mon, 09 Jul 2018 12:00:00 EDT Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCondition: Cutaneous Malignant MelanomaInterventions: Drug: Nintedanib; Drug: Nintedanib-Placebo; Drug: Paclitaxel Sponsors: Prof. Dr. med. Dirk Schadendorf; Boehringer Ingelheim; medac GmbH; Alcedis GmbH Completed Thu, 04 Dec 2014 12:00:00 EST Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)Condition: Cancer of Head and NeckInterventions: Drug: Erbitux, Paclitaxel & Carboplatin; Radiation: Radiation Sponsors: University of Maryland, Baltimore; Bristol-Myers Squibb Completed Thu, 22 Jun 2006 12:00:00 EDT Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial CancerCondition: Stage III-IV or Recurrent Endometrial CancerInterventions: Drug: Bevacizumab; Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles Sponsor: Catholic University of the Sacred Heart Unknown status Thu, 17 Jan 2013 12:00:00 EST
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate CancerCondition: Prostate CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel Sponsor: Weill Medical College of Cornell University Terminated Tue, 20 Mar 2012 12:00:00 EDT Paclitaxel Plus Bevacizumab for Older Patients With Breast CancerCondition: Breast CancerInterventions: Drug: Bevacizumab; Drug: Paclitaxel Sponsors: Hellenic Oncology Research Group; University Hospital of Crete Terminated Mon, 10 May 2010 12:00:00 EDT Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung CancerCondition: Small Cell Lung CancerIntervention: Drug: taxol plus everolimus Sponsor: Samsung Medical Center Completed Wed, 03 Mar 2010 12:00:00 EST Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckConditions: Squamous Cell Carcinoma of the Head and Neck; Basaloid Squamous Cell Carcinoma; Undifferentiated Carcinoma; Adenosquamous Cell CarcinomaInterventions: Drug: Abraxane; Drug: Erbitux; Drug: Carboplatin; Radiation: Intensity Modulated Radiation Therapy Sponsors: Dana-Farber Cancer Institute; Celgene Corporation Terminated Tue, 11 Dec 2007 12:00:00 EST Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)Conditions: Head and Neck Cancer; Squamous Cell CancerIntervention: Drug: Afatinib, Ribavirin, and weekly carboplatin/paclitaxel Sponsors: Memorial Sloan Kettering Cancer Center; National Comprehensive Cancer Network; Boehringer Ingelheim Completed Sun, 04 Nov 2012 12:00:00 EDT Phase I Study of Oral BAY 1217389 in Combination With Intravenous PaclitaxelCondition: Medical OncologyInterventions: Drug: BAY1217389; Drug: Paclitaxel Sponsor: Bayer Completed Thu, 19 Feb 2015 12:00:00 EST Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown PrimaryCondition: Carcinoma of Unknown PrimaryInterventions: Drug: belinostat, carboplatin, paclitaxel; Drug: carboplatin, paclitaxel Sponsors: Onxeo; Spectrum Pharmaceuticals, Inc Completed Wed, 01 Apr 2009 12:00:00 EDT Trial of NanoPac Intratumoral Injection in Lung CancerConditions: Lung Cancer, Nonsmall Cell; Lung Cancer; Lung Cancer, Small Cell; Neoplasm of LungIntervention: Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension Sponsors: NanOlogy, LLC; US Biotest, Inc. Recruiting Thu, 19 Mar 2020 12:00:00 EDT Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: Camrelizumab; Drug: Nab paclitaxel; Drug: Gemcitabine Injection Sponsor: Fudan University Recruiting Tue, 04 Aug 2020 12:00:00 EDT Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced MalignanciesCondition: Advanced CancerInterventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Active, not recruiting Wed, 18 Nov 2009 12:00:00 EST
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerCondition: HER2-Positive Early Stage Breast CancerInterventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Lapatinib; Drug: Pegfilgrastim Sponsors: Memorial Sloan Kettering Cancer Center; GlaxoSmithKline Completed Tue, 09 Apr 2013 12:00:00 EDT A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: MM-141; Drug: Placebo; Drug: Gemcitabine; Drug: Nab-Paclitaxel Sponsor: Merrimack Pharmaceuticals Completed Thu, 26 Mar 2015 12:00:00 EDT Study on Neoadjuvant Chemotherapy for Advanced Gastric CancerCondition: Advanced Gastric CarcinomaIntervention: Drug: paclitaxel liposome Sponsor: Peking University Unknown status Fri, 13 Jun 2014 12:00:00 EDT Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)Conditions: Neoplasms; Breast Neoplasms; Breast CancerInterventions: Drug: AZD8931; Drug: Paclitaxel; Drug: Placebo Sponsor: AstraZeneca Completed Wed, 13 May 2009 12:00:00 EDT IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast CarcinomaCondition: Adenocarcinoma Breast Stage IVInterventions: Biological: IMP321 (eftilagimod alpha); Drug: Placebo; Drug: Paclitaxel Sponsor: Immutep S.A.S. Completed Wed, 25 Nov 2015 12:00:00 EST Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid TumorsCondition: Solid TumorsInterventions: Drug: Dovitinib; Drug: Dovitinib + Paclitaxel Sponsors: Centro Nacional de Investigaciones Oncologicas CARLOS III; Hospital Universitario de Fuenlabrada; M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge Terminated Thu, 08 Mar 2012 12:00:00 EST Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerCondition: Gastric CancerIntervention: Drug: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 Sponsor: Beijing Friendship Hospital Not yet recruiting Thu, 06 Feb 2020 12:00:00 EST Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCCondition: Triple Negative Breast NeoplasmsInterventions: Drug: Capivasertib; Drug: Paclitaxel; Drug: Placebo Sponsor: AstraZeneca Recruiting Tue, 25 Jun 2019 12:00:00 EDT Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid CancerCondition: Anaplastic Thyroid CancerInterventions: Drug: CA4P; Drug: paclitaxel; Drug: carboplatin Sponsor: Mateon Therapeutics Terminated Thu, 26 Jul 2007 12:00:00 EDT Intravenous Estramustine With Taxol in Hormone Refractory Prostate AdenocarcinomaCondition: Prostate CancerInterventions: Drug: Estramustine; Drug: Taxol Sponsor: M.D. Anderson Cancer Center Completed Thu, 30 May 2002 12:00:00 EDT
Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive DiseaseConditions: Peripheral Arterial Disease; Stenotic Femoro-popliteal Arteries; Occluded Femoro-popliteal Arteries; AtherosclerosisIntervention: Device: Paclitaxel-coated balloon catheter angioplasty Sponsor: Bayer Completed Wed, 04 Nov 2009 12:00:00 EST Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsCondition: Adrenocortical CarcinomaInterventions: Drug: Sorafenib; Drug: Paclitaxel Sponsor: University of Turin, Italy Unknown status Thu, 06 Nov 2008 12:00:00 EST Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric CancerCondition: Stomach CancerInterventions: Drug: nab paclitaxel; Drug: Tegafur; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: Zhejiang Cancer Hospital; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Wed, 23 Oct 2019 12:00:00 EDT Prevention of Restenosis Following RevascularizationCondition: Vascular Disease, PeripheralIntervention: Drug: Nanoparticle Paclitaxel Sponsor: Celgene Corporation Terminated Mon, 20 Aug 2007 12:00:00 EDT Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal CarcinomaCondition: Esophageal CarcinomaInterventions: Drug: Liposomal Paclitaxel; Drug: Nedaplatin Sponsor: Sun Yat-sen University Completed Wed, 10 Aug 2016 12:00:00 EDT A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: paclitaxel; Drug: Reparixin; Drug: placebo Sponsors: Dompé Farmaceutici S.p.A; PRA Health Sciences Completed Tue, 24 Feb 2015 12:00:00 EST Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLCCondition: Lung CancerInterventions: Drug: carboplatin; Drug: nab-paclitaxel; Radiation: Radiation therapy Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI) Terminated Tue, 16 Oct 2007 12:00:00 EDT Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric CancerCondition: Neoplasms, Gastrointestinal TractInterventions: Drug: Lapatinib; Drug: Paclitaxel Sponsor: GlaxoSmithKline Completed Fri, 15 Jun 2007 12:00:00 EDT Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian CarcinomaCondition: Epithelial Ovarian CarcinomaInterventions: Drug: Metformin; Drug: Paclitaxel; Drug: Carboplatin Sponsors: Gynecologic Oncology Associates; University of North Carolina, Chapel Hill Unknown status Fri, 08 May 2015 12:00:00 EDT Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric CancerCondition: Gastric CancerIntervention: Drug: Nab-paclitaxel combined with oxaliplatin and S-1 Sponsors: Jianjun Yang; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Wed, 22 Sep 2021 12:00:00 EDT
Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo LesionsCondition: Coronary DiseaseIntervention: Device: Paclitaxel DCB Sponsor: Beijing Hospital Recruiting Wed, 17 Jul 2019 12:00:00 EDT Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCondition: Triple-Negative Breast CancerInterventions: Drug: JS001; Drug: Nab-Paclitaxel; Drug: Placebo Sponsor: Shanghai Junshi Bioscience Co., Ltd. Recruiting Wed, 11 Sep 2019 12:00:00 EDT Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsConditions: Neoplasms; Pancreatic NeoplasmsInterventions: Drug: LMB-100; Drug: Nab-Paclitaxel; Device: Mesothelin Expression Sponsor: National Cancer Institute (NCI) Active, not recruiting Thu, 23 Jun 2016 12:00:00 EDT Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical CancerCondition: Recurrent Cervical CancerIntervention: Drug: anti-PD-1+Albumin-Bound Paclitaxel Sponsor: Sun Yat-sen University Recruiting Fri, 10 Apr 2020 12:00:00 EDT Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel ObstructionConditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Bowel ObstructionInterventions: Drug: Cisplatin; Drug: Paclitaxel Sponsor: University Health Network, Toronto Terminated Tue, 09 Mar 2010 12:00:00 EST Dose-finding Study in Platinum-Resistant Ovarian CancerCondition: Recurrent Platinum-resistant Ovarian CancerIntervention: Drug: GSK2110183 in combination with carboplatin and paclitaxel Sponsor: Accenture Completed Tue, 31 Jul 2012 12:00:00 EDT Abraxane and Temodar Plus Genasense in Advanced MelanomaCondition: MelanomaInterventions: Drug: Genasense® (oblimersen); Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension); Drug: Temodar® (temozolomide) Sponsor: Genta Incorporated Unknown status Fri, 08 Dec 2006 12:00:00 EST Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal DoxorubicinCondition: Metastatic Breast CancerInterventions: Drug: liposomal Doxorubicin; Drug: Myocet / Paclitaxel Sponsor: Claudia Lorenz-Schlüter Terminated Fri, 06 Jun 2008 12:00:00 EDT Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast CancerCondition: Breast NeoplasmsIntervention: Drug: Nanoparticle albumin bound paclitaxel followed by FEC Sponsors: NSABP Foundation Inc; Celgene Corporation Completed Fri, 13 May 2005 12:00:00 EDT Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerCondition: HER2+ Early or Locally Advanced Breast CancerInterventions: Drug: pyrotinib + trastuzumab + nab-paclitaxel; Drug: pertuzumab + trastuzumab + nab-paclitaxel Sponsors: Tianjin Medical University Cancer Institute and Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting Tue, 25 May 2021 12:00:00 EDT
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCondition: Advanced Gastric AdenocarcinomaInterventions: Drug: Paclitaxel; Drug: Olaparib; Drug: Pembrolizumab Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp & Dohme Corp. Recruiting Tue, 24 Dec 2019 12:00:00 EST A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic CancerConditions: Pancreatic Adenocarcinoma; Metastatic Pancreatic AdenocarcinomaInterventions: Genetic: VCN-01; Drug: Gemcitabine; Drug: Abraxane® Sponsor: VCN Biosciences, S.L. Completed Mon, 27 Jan 2014 12:00:00 EST Pembro/Carbo/Taxol in Endometrial CancerConditions: Endometrial Cancer; Endometrial AdenocarcinomaInterventions: Drug: Pembrolizumab; Drug: Paclitaxel; Drug: Carboplatin Sponsors: Daniela Matei, MD; Merck Sharp & Dohme Corp.; Hoosier Cancer Research Network Active, not recruiting Tue, 15 Sep 2015 12:00:00 EDT Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCondition: Solid TumorsIntervention: Drug: Nilotinib + Paclitaxel Sponsor: National Cancer Institute (NCI) Recruiting Thu, 05 Mar 2015 12:00:00 EST Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)Condition: Small Vessel LesionInterventions: Device: paclitaxel controlled release balloon catheter (VasoguardTM); Device: common balloon catheter (Maverick2) Sponsor: Shandong Branden Med.Device Co.,Ltd Unknown status Wed, 07 Sep 2016 12:00:00 EDT Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving PaclitaxelConditions: Breast Cancer; Ovarian Neoplasm; PainInterventions: Dietary Supplement: Omega-3 fatty acid; Dietary Supplement: Placebo; Drug: Paclitaxel Sponsors: New Mexico Cancer Care Alliance; Alliance Healthcare Foundation Active, not recruiting Mon, 01 Apr 2013 12:00:00 EDT Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell CancerConditions: Esophageal Squamous Cell Cancer; Elderly PatientsIntervention: Other: Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy Sponsor: Shen Lin Unknown status Thu, 19 Dec 2013 12:00:00 EST TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsConditions: Advanced Malignant Solid Neoplasm; KRAS Gene Mutation; Ovarian Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Ovarian CarcinomaInterventions: Drug: Paclitaxel; Other: Pharmacokinetic Study; Drug: Spleen Tyrosine Kinase Inhibitor TAK-659 Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting Wed, 28 Nov 2018 12:00:00 EST A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: tivozanib (AV-951) + paclitaxel Sponsor: AVEO Pharmaceuticals, Inc. Completed Thu, 17 Jul 2008 12:00:00 EDT Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerCondition: Carcinoma Breast Stage IVIntervention: Drug: Abraxane,Cyclophosphamide,Carboplatin Sponsor: Sun Yat-sen University Terminated Tue, 08 Jul 2014 12:00:00 EDT
A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)Conditions: Stable Angina; Unstable AnginaInterventions: Procedure: Paclitaxel-coated Balloon; Device: Paclitaxel-eluting Stent Sponsor: Ospedale San Donato Terminated Fri, 17 Sep 2010 12:00:00 EDT Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)Condition: Metastatic Breast CancerIntervention: Drug: Paclitaxel+Reparixin Sponsors: Dompé Farmaceutici S.p.A; PRA Health Sciences Completed Thu, 05 Dec 2013 12:00:00 EST Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric AdenocarcinomaCondition: Gastric CancerInterventions: Drug: Albumin-bound Paclitaxel plus S-1; Drug: Oxaliplatin plus S-1 Sponsors: Huazhong University of Science and Technology; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting Fri, 11 Jan 2019 12:00:00 EST A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast CancerCondition: Breast CancerInterventions: Drug: Ipatasertib; Drug: Paclitaxel; Drug: Placebo Sponsors: Genentech, Inc.; SOLTI Breast Cancer Research Group Completed Wed, 26 Nov 2014 12:00:00 EST Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung CancerCondition: Non-Squamous Non-Small Cell Lung CancerInterventions: Drug: Paclitaxel / Carboplatin; Drug: bavituximab Sponsor: Peregrine Pharmaceuticals Completed Mon, 12 Jul 2010 12:00:00 EDT Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)Condition: Primary Breast CancerInterventions: Drug: Cabacitaxel; Drug: Paclitaxel Sponsor: German Breast Group Completed Wed, 30 Jan 2013 12:00:00 EST Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting StentsCondition: Coronary Artery Bypass GraftingIntervention: Device: Paclitaxel eluting stent Sponsors: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec; Boston Scientific Corporation; Canadian Institutes of Health Research (CIHR) Terminated Tue, 19 Oct 2010 12:00:00 EDT Trial of NanoPac Focal Therapy for Prostate CancerConditions: Prostate Cancer; Prostate Adenocarcinoma; Prostate Cancer Adenocarcinoma; Prostatic Neoplasm; Urogenital Neoplasms; Genital Neoplasms, Male; Localized CancerIntervention: Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension Sponsors: NanOlogy, LLC; US Biotest, Inc. Terminated Thu, 09 Jan 2020 12:00:00 EST Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast CancerCondition: Advanced Breast CancerIntervention: Drug: gemcitabine , paclitaxel Sponsors: Samsung Medical Center; Korean Cancer Study Group Completed Tue, 20 Nov 2007 12:00:00 EST Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery StenosisCondition: Peripheral Artery DiseaseInterventions: Device: Sirolimus-eluting balloon catheter; Device: Paclitaxel-eluting balloon catheter Sponsor: Acotec Scientific Co., Ltd Not yet recruiting Thu, 29 Jul 2021 12:00:00 EDT
A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric CancerConditions: Solid Tumor; Stage IV Gastric CancerIntervention: Drug: Paclitaxel Sponsor: Daehwa Pharmaceutical Co., Ltd. Completed Wed, 07 Sep 2016 12:00:00 EDT GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCondition: Metastatic Gastric CancerIntervention: Drug: durvalumab, tremelimumab, paclitaxel Sponsors: Asan Medical Center; Hallym University Medical Center; Seoul National University Bundang Hospital Recruiting Fri, 23 Nov 2018 12:00:00 EST Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal CarcinomatosisCondition: Peritoneal CancerInterventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Paclitaxel Sponsor: M.D. Anderson Cancer Center Completed Tue, 26 Jun 2007 12:00:00 EDT A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic MalignanciesConditions: Pharmacokinetics of ASP9853; Non-hematologic MalignanciesInterventions: Drug: ASP9853; Drug: Docetaxel; Drug: Paclitaxel Sponsor: Astellas Pharma Global Development, Inc. Terminated Fri, 12 Oct 2012 12:00:00 EDT Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerCondition: Breast CancerInterventions: Drug: nab paclitaxel; Drug: Cyclophosphamide; Drug: Trastuzumab Sponsors: SCRI Development Innovations, LLC; Celgene Corporation Completed Thu, 06 Mar 2008 12:00:00 EST A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard ChemotherapyCondition: Cervical CancerIntervention: Drug: HLX10+Albumin-Bound Paclitaxel Sponsor: Shanghai Henlius Biotech Active, not recruiting Tue, 05 Nov 2019 12:00:00 EST Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung CancerCondition: Non Small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Bevacizumab; Drug: Paclitaxel Sponsor: Hellenic Oncology Research Group Completed Wed, 17 Sep 2008 12:00:00 EDT Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerConditions: Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast CarcinomaInterventions: Drug: Galunisertib; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI) Active, not recruiting Wed, 03 Feb 2016 12:00:00 EST A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid TumorsCondition: Solid TumorsInterventions: Drug: LCL161; Drug: Paclitaxel Sponsor: Novartis Pharmaceuticals Completed Mon, 15 Nov 2010 12:00:00 EST Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated BalloonCondition: Coronary RestenosisInterventions: Combination Product: Sirolimus coated balloon; Combination Product: Paclitaxel coated balloon Sponsor: InnoRa GmbH Completed Tue, 08 Aug 2017 12:00:00 EDT
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.Condition: Ovarian CancerIntervention: Drug: Paclitaxel (albumin-bound) Sponsors: Chinese Academy of Medical Sciences; CSPC Ouyi Pharmaceutical Co., Ltd. Not yet recruiting Thu, 10 Dec 2020 12:00:00 EST Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBCCondition: Triple Negative Breast CancerInterventions: Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide; Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide Sponsor: Hebei Medical University Fourth Hospital Withdrawn Mon, 26 Aug 2019 12:00:00 EDT Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Conditions: Esophageal Squamous Cell Carcinoma; Stage IIIIntervention: Drug: Pembrolizumab Injection [Keytruda] Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting Fri, 15 May 2020 12:00:00 EDT Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.Condition: Gastric CancerInterventions: Drug: Olaparib; Drug: Paclitaxel; Drug: Placebo Sponsor: AstraZeneca Active, not recruiting Fri, 16 Aug 2013 12:00:00 EDT Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer PatientsCondition: Gastric CancerInterventions: Drug: olaparib; Drug: paclitaxel; Drug: Placebo Sponsor: AstraZeneca Active, not recruiting Fri, 05 Feb 2010 12:00:00 EST Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)Conditions: Recurrent Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer Stage IVInterventions: Drug: Nivolumab + Paclitaxel; Drug: Cetuximab + Paclitaxel Sponsors: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Bristol-Myers Squibb; Apices Soluciones S.L. Recruiting Mon, 24 Feb 2020 12:00:00 EST Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.Condition: Squamous Cell Carcinoma of the Head and NeckInterventions: Drug: Cetuximab; Drug: Paclitaxel Sponsors: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Recruiting Thu, 17 Dec 2020 12:00:00 EST EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian CancerCondition: Ovarian Cancer RecurrentInterventions: Drug: EP-100; Drug: Paclitaxel Sponsor: Esperance Pharmaceuticals Inc Completed Tue, 06 Dec 2011 12:00:00 EST Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerConditions: Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast CancerInterventions: Drug: AZD2281; Drug: Paclitaxel Sponsor: AstraZeneca Completed Tue, 01 Jul 2008 12:00:00 EDT Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced CancerCondition: NeoplasmsInterventions: Drug: Paclitaxel; Drug: Copanlisib (BAY80-6946) Sponsor: Bayer Completed Mon, 08 Aug 2011 12:00:00 EDT
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerConditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Biological: Pelareorep Sponsors: National Cancer Institute (NCI); NRG Oncology Completed Fri, 10 Sep 2010 12:00:00 EDT Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)Condition: Small Cell Lung CancerInterventions: Drug: Alisertib; Drug: Placebo; Drug: Paclitaxel Sponsor: Millennium Pharmaceuticals, Inc. Completed Thu, 16 Jan 2014 12:00:00 EST EGFR-targeted Therapy for Gastric CancerCondition: Adenocarcinoma of the StomachIntervention: Drug: Anti-EGFR antibody in combination with weekly paclitaxel Sponsors: National Cancer Center, Korea; Korean Cancer Study Group Recruiting Wed, 04 Sep 2019 12:00:00 EDT A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal ReceptorsCondition: Breast NeoplasmsInterventions: Drug: Ipatasertib; Drug: Paclitaxel; Drug: Placebo Sponsor: Genentech, Inc. Completed Fri, 13 Jun 2014 12:00:00 EDT Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal ChemotherapyConditions: Gastric Cancer; Chemotherapy Effect; Surgery; Metastasis; SurvivalInterventions: Drug: Paclitaxel; Drug: Lobaplatin Sponsor: Wuhan Union Hospital, China Recruiting Mon, 22 Mar 2021 12:00:00 EDT Paclitaxel Eluting Balloon in St Elevation Myocardial InfarctionCondition: Acute Myocardial InfarctionInterventions: Device: Bare metal Stent plus Paclitaxel Balloon; Device: Bare metal Stent Sponsors: Francisco Javier Goicolea; Effice Servicios Para la Investigacion S.L. Completed Thu, 25 Apr 2013 12:00:00 EDT Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic CancerConditions: Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic AdenocarcinomaInterventions: Drug: nab-paclitaxel; Drug: Gemcitabine; Drug: tegafur Sponsor: Fudan University Recruiting Fri, 03 Jan 2020 12:00:00 EST Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell CancerCondition: Testicular CancerInterventions: Drug: Paclitaxel; Drug: Cisplatin; Drug: Gemcitabine Sponsor: Rigshospitalet, Denmark Terminated Wed, 19 Sep 2007 12:00:00 EDT Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian CancerCondition: Ovarian CancerIntervention: Drug: OMP-54F28, Paclitaxel and Carboplatin Sponsor: OncoMed Pharmaceuticals, Inc. Completed Thu, 20 Mar 2014 12:00:00 EDT Camrelizumab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Resectable NSCLCCondition: Non-small-cell Lung Cancer (NSCLC)Intervention: Drug: camrelizumab combined with albumin-bound paclitaxel and cisplatin Sponsor: Tang-Du Hospital Recruiting Wed, 08 Apr 2020 12:00:00 EDT
STREAMER : STent Restenosis And MEdicaments ReleaseCondition: Critical IschemiaIntervention: Drug: Paclitaxel Sponsor: Hospices Civils de Lyon Completed Mon, 18 Jul 2016 12:00:00 EDT Phase II Trial of Standard Chemotherapy (Carboplatin & Paclitaxel) +Various Proton Beam Therapy (PBT) DosesCondition: Non Small Cell Lung CancerInterventions: Device: Proton Beam Therapy; Drug: Carboplatin; Drug: Paclitaxel Sponsor: Mayo Clinic Recruiting Fri, 28 Apr 2017 12:00:00 EDT TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Condition: Esophageal NeoplasmsInterventions: Drug: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib; Drug: Paclitaxel + Cisplatin + TQB2450 injection Sponsors: Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting Thu, 19 Aug 2021 12:00:00 EDT Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)Condition: In-Stent RestenosisInterventions: Device: Rapamycin eluting stent implantation; Device: Paclitaxel eluting balloon catheter Sponsors: Medical University of Warsaw; KCRI Unknown status Wed, 08 Dec 2010 12:00:00 EST A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast CancerCondition: Advanced Breast CancerInterventions: Drug: Vinflunine+Gemcitabine; Drug: Paclitaxel+Gemcitabine Sponsor: Pierre Fabre Medicament Terminated Tue, 04 Feb 2014 12:00:00 EST Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder CancerConditions: Recurrent Bladder Urothelial Carcinoma; Stage IV Bladder Urothelial CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Other: Quality-of-Life Assessment Sponsors: Mayo Clinic; National Cancer Institute (NCI) Withdrawn Thu, 24 Mar 2016 12:00:00 EDT Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLCCondition: Non-Small Cell Lung Cancer(NSCLC)Interventions: Drug: Paclitaxel Micelles for Injection; Drug: Paclitaxel Injection; Drug: Cisplatin Sponsor: Shanghai Yizhong Biotechnology Co., Ltd. Active, not recruiting Fri, 29 Jan 2016 12:00:00 EST Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: ACP-196; Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsor: Acerta Pharma BV Terminated Wed, 07 Oct 2015 12:00:00 EDT Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated BalloonCondition: DES In-stent StenosisInterventions: Device: Paclitaxel coated balloon (SeQuent Please); Device: Sirolimus coated balloon Sponsor: InnoRa GmbH Completed Mon, 19 Dec 2016 12:00:00 EST Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response AssessmentCondition: Lung CancerInterventions: Drug: Paclitaxel; Drug: Pemetrexed; Drug: Bevacizumab Sponsor: Memorial Sloan Kettering Cancer Center Completed Fri, 12 Dec 2008 12:00:00 EST
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.Condition: Gastric CancerInterventions: Drug: Taxol; Drug: Campt, Topotesin Sponsors: Hokkaido Gastrointestinal Cancer Study Group; Hokkaido University Hospital Withdrawn Wed, 21 Sep 2005 12:00:00 EDT Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck CancerCondition: Head and Neck CancerInterventions: Biological: Cetuximab; Drug: Cisplatin; Drug: Nab-Paclitaxel; Radiation: intensity-modulated radiation therapy Sponsor: University of Texas Southwestern Medical Center Completed Thu, 26 Feb 2009 12:00:00 EST Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung CancerCondition: Carcinoma, Non-Small-Cell LungInterventions: Drug: Paclitaxel; Procedure: Radiation Therapy Sponsor: University of Rochester Completed Thu, 15 Sep 2005 12:00:00 EDT Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelCondition: NeoplasmsInterventions: Drug: Nilotinib; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Recruiting Mon, 29 Jun 2020 12:00:00 EDT Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCCCondition: Head and Neck Squamous Cell CarcinomaIntervention: Drug: Camrelizumab, nab-paclitaxel, cisplatin Sponsors: Sun Yat-sen University; Jiangsu HengRui Medicine Co., Ltd. Recruiting Thu, 01 Apr 2021 12:00:00 EDT Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum TherapyCondition: Head and Neck Squamous Cell CarcinomaInterventions: Drug: Buparlisib; Drug: Buparlisib matching Placebo; Drug: Paclitaxel Sponsor: Novartis Pharmaceuticals Terminated Mon, 13 May 2013 12:00:00 EDT Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerConditions: Breast Adenocarcinoma; Invasive Breast Carcinoma; Triple-Negative Breast CarcinomaInterventions: Drug: Atezolizumab; Drug: Nab-paclitaxel Sponsor: M.D. Anderson Cancer Center Active, not recruiting Fri, 21 Aug 2015 12:00:00 EDT Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery LesionsCondition: Coronary AtherosclerosisInterventions: Device: NEVO™ Sirolimus-eluting Coronary Stent System; Device: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System) Sponsors: Cordis Corporation; Conor Medsystems Terminated Fri, 01 Feb 2008 12:00:00 EST Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal CarcinomatosisConditions: Gastric Cancer; Peritoneal Carcinomatosis; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Paclitaxel; Drug: Leucovorin; Drug: Fluorouracil Sponsor: University of California, Irvine Recruiting Sun, 21 Feb 2021 12:00:00 EST ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerConditions: Malignant Ovarian Epithelial Tumor; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Fallopian Tube Carcinoma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal CarcinomaInterventions: Drug: Akt/ERK Inhibitor ONC201; Drug: Paclitaxel; Other: Questionnaire Administration Sponsor: Ira Winer Recruiting Wed, 14 Aug 2019 12:00:00 EDT
Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis SuperficialisCondition: Peripheral Arterial DiseaseInterventions: Device: Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries; Device: Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter Sponsors: Jena University Hospital; iVascular S.L.U.; KKS Netzwerk Active, not recruiting Thu, 03 Sep 2015 12:00:00 EDT CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System EvaluationCondition: Coronary DiseaseIntervention: Device: CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter Sponsor: Conor Medsystems Completed Wed, 17 Jan 2007 12:00:00 EST Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid TumorsConditions: Neoplasm Metastasis; CarcinomaIntervention: Drug: Paclitaxel plus PTK787 Sponsors: Indiana University School of Medicine; Novartis Completed Mon, 11 Aug 2008 12:00:00 EDT A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)Condition: Ovarian CancerInterventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin Sponsor: Merck Sharp & Dohme Corp. Completed Fri, 20 May 2011 12:00:00 EDT Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Neratinib; Drug: Trastuzumab; Drug: Paclitaxel Sponsor: Puma Biotechnology, Inc. Completed Fri, 05 Jun 2009 12:00:00 EDT Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid MalignanciesConditions: Adenocarcinoma; Pancreatic NeoplasmsInterventions: Drug: MLN8237; Drug: nab-Paclitaxel Sponsor: Washington University School of Medicine Completed Mon, 03 Sep 2012 12:00:00 EDT Dose Escalation of Lapatinib With Paclitaxel in Ovarian CancerCondition: Ovarian CancerIntervention: Drug: Lapatinib and Paclitaxel Sponsor: Frederick R. Ueland, M.D. Recruiting Thu, 29 Oct 2020 12:00:00 EDT S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck CancerCondition: Head and Neck CancerInterventions: Drug: gemcitabine; Drug: paclitaxel Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Completed Fri, 07 Jan 2005 12:00:00 EST Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial CarcinomaCondition: Endometrial CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: bevacizumab Sponsors: David O'Malley; Genentech, Inc. Completed Thu, 09 Aug 2007 12:00:00 EDT Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical CancerCondition: Cervical CancerIntervention: Drug: Phyxol(Paclitaxel) Sponsors: Chang Gung Memorial Hospital; Sinphar Pharmaceutical Co., Ltd Unknown status Thu, 15 Jan 2009 12:00:00 EST
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyCondition: Extensive-Stage Small Cell Lung CancerInterventions: Drug: Paclitaxel/Albumin-Bound Paclitaxel; Drug: IBI308 Sponsor: Junling Li Recruiting Wed, 14 Aug 2019 12:00:00 EDT Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyCondition: Nasopharyngeal CancerIntervention: Drug: Nab paclitaxel Sponsor: Sun Yat-sen University Recruiting Tue, 20 Apr 2021 12:00:00 EDT A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast CancerCondition: Breast CancerInterventions: Drug: gemcitabine; Drug: paclitaxel; Drug: bevacizumab Sponsors: Eli Lilly and Company; Genentech, Inc. Completed Wed, 03 May 2006 12:00:00 EDT Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerCondition: Breast CancerInterventions: Drug: Enzalutamide; Drug: Placebo; Drug: Paclitaxel Sponsors: Pfizer; Astellas Pharma Inc; Medivation, Inc. Withdrawn Tue, 11 Oct 2016 12:00:00 EDT Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of EsophagusCondition: Esophageal Squamous Cell CarcinomaInterventions: Other: Paclitaxel plus Cisplatin with radiotherapy; Other: S1 plus Cisplatin with radiotherapy Sponsor: Mianyang Central Hospital Unknown status Mon, 26 Oct 2015 12:00:00 EDT Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianCondition: Platinum-resistant Ovarian CancerInterventions: Drug: Paclitaxel; Drug: Afuresertib Sponsor: Laekna Limited Recruiting Tue, 05 May 2020 12:00:00 EDT Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer SubjectsCondition: Pancreatic CancerInterventions: Drug: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine; Drug: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine; Drug: Part A- VS-4718, nab-paclitaxel, gemcitabine Sponsor: Verastem, Inc. Terminated Mon, 11 Jan 2016 12:00:00 EST Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCondition: Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: bortezomib; Drug: paclitaxel; Other: laboratory biomarker analysis Sponsor: National Cancer Institute (NCI) Completed Wed, 09 Apr 2003 12:00:00 EDT A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric CancerConditions: Gastric Adenocarcinoma; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Ramucirumab; Drug: Paclitaxel Sponsor: Eli Lilly and Company Completed Mon, 03 Aug 2015 12:00:00 EDT Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line TreatmentCondition: Metastatic Breast CancerInterventions: Drug: Paclitaxel and Sorafenib; Drug: Paclitaxel Sponsors: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH; iOMEDICO AG Completed Tue, 22 Mar 2011 12:00:00 EDT
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: ARQ-761; Drug: Gemcitabine; Drug: nab-paclitaxel Sponsor: University of Texas Southwestern Medical Center Suspended Mon, 03 Aug 2015 12:00:00 EDT A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung CancerCondition: Non-small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: MEDI-575 Sponsor: MedImmune LLC Terminated Wed, 29 Dec 2010 12:00:00 EST PD0332991/Paclitaxel in Advanced Breast CancerCondition: Breast CancerInterventions: Drug: PD0332991; Drug: Paclitaxel Sponsor: Abramson Cancer Center of the University of Pennsylvania Completed Tue, 22 Mar 2011 12:00:00 EDT Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerCondition: Advanced Gastric CancerInterventions: Drug: Paclitaxel; Drug: Olaparib; Drug: Durvalumab Sponsors: Do-Youn Oh; AstraZeneca Active, not recruiting Mon, 09 Jul 2018 12:00:00 EDT Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyConditions: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube CancerInterventions: Drug: AVB-S6-500; Drug: Paclitaxel; Drug: Carboplatin; Procedure: Tissue from Diagnostic Laparoscopy; Procedure: Tissue from Core biopsy; Procedure: Interval Debulking; Procedure: Peripheral blood; Procedure: Ascites collection Sponsors: Washington University School of Medicine; Aravive, Inc. Withdrawn Tue, 31 Jul 2018 12:00:00 EDT Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast CancerCondition: Locally Recurrent or Metastatic Breast CancerInterventions: Drug: Imetelstat sodium; Drug: Bevacizumab; Drug: Paclitaxel Sponsor: Geron Corporation Completed Thu, 09 Dec 2010 12:00:00 EST Stromal TARgeting for PAncreatic Cancer (STAR_PAC)Condition: Pancreatic AdenocarcinomaInterventions: Drug: ATRA; Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: Barts & The London NHS Trust; Medical Research Council; Celgene Corporation; Cancer Research UK Cambridge Institute; King's College London; Royal Free Hospital NHS Foundation Trust; Imperial College Healthcare NHS Trust; Institute of Cancer Research, United Kingdom; Cambridge University Hospitals NHS Foundation Trust Completed Wed, 11 Oct 2017 12:00:00 EDT Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous CancerCondition: Endometrial CancerInterventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab Sponsors: Yale University; Genentech, Inc. Active, not recruiting Mon, 06 Jun 2011 12:00:00 EDT Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC PatientsCondition: Metastatic Breast CancerInterventions: Drug: Dasatinib; Drug: Trastuzumab; Drug: Paclitaxel Sponsors: Spanish Breast Cancer Research Group; Bristol-Myers Squibb Completed Wed, 02 Mar 2011 12:00:00 EST Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerCondition: Locally Advanced or Metastatic Gastric AdenocarcinomaInterventions: Drug: Camrelizumab; Drug: Apatinib Mesylate; Drug: nab-paclitaxel Sponsor: The First Affiliated Hospital of Xiamen University Recruiting Thu, 01 Oct 2020 12:00:00 EDT
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid TumorsCondition: Advanced Solid TumorsInterventions: Drug: Paclitaxel; Drug: RO5509554 Sponsor: Hoffmann-La Roche Completed Mon, 19 Dec 2011 12:00:00 EST Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian CancerConditions: Ovarian Cancer; Endometrial Cancer; Recurrent Ovarian Cancer; Recurrent Endometrial CancerInterventions: Drug: BKM120; Drug: Nabpaclitaxel Sponsors: Rutgers, The State University of New Jersey; Rutgers Cancer Institute of New Jersey; National Cancer Institute (NCI) Withdrawn Mon, 21 Apr 2014 12:00:00 EDT Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)Condition: Ovarian Sex-cord Stromal TumorInterventions: Drug: Paclitaxel; Drug: Bevacizumab Sponsors: ARCAGY/ GINECO GROUP; Roche Pharma AG Completed Thu, 17 Jan 2013 12:00:00 EST Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerConditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast CarcinomaInterventions: Drug: Alisertib; Drug: Paclitaxel Sponsor: Millennium Pharmaceuticals, Inc. Completed Wed, 24 Mar 2010 12:00:00 EDT Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)Condition: Breast CancerInterventions: Drug: Gemcitabine,cisplatin; Drug: Gemcitabine, Paclitaxel Sponsors: Fudan University; 307 Hospital of PLA; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; Sun Yat-sen University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Changhai Hospital Completed Tue, 01 Feb 2011 12:00:00 EST Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBCCondition: Neoplasms, BreastIntervention: Drug: Lapatinib/nab-Paclitaxel Sponsor: Novartis Pharmaceuticals Completed Thu, 03 Jul 2008 12:00:00 EDT Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell CancerCondition: Esophageal Squamous Cell CancerIntervention: Other: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy Sponsor: Shen Lin Unknown status Thu, 19 Dec 2013 12:00:00 EST Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast CancerConditions: Inflammatory Breast Cancer; Stage IIA Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer; Stage IIB Breast Cancer; Estrogen Receptor Negative; Progesterone Receptor Negative; HER2/Neu NegativeInterventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: laboratory biomarker analysis Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Active, not recruiting Fri, 03 Feb 2012 12:00:00 EST Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerCondition: Oropharynx Squamous Cell CarcinomaInterventions: Drug: Nivolumab; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Radiation Therapy Sponsors: University of Michigan Rogel Cancer Center; Bristol-Myers Squibb Recruiting Mon, 04 Feb 2019 12:00:00 EST Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach CancerConditions: Esophageal Cancer; Gastric CancerInterventions: Drug: Bryostatin-1; Drug: Paclitaxel (Taxol) Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Completed Fri, 25 Jul 2003 12:00:00 EDT
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Apatinib; Drug: Paclitaxel Sponsor: Tianjin Medical University Cancer Institute and Hospital Unknown status Mon, 20 Nov 2017 12:00:00 EST Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Sorafenib; Drug: Paclitaxel; Drug: Carboplatin Sponsors: SCRI Development Innovations, LLC; Bayer Completed Fri, 20 Oct 2006 12:00:00 EDT The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as OraxolCondition: Solid Tumor, AdultIntervention: Drug: Oraxol Sponsor: Athenex, Inc. Recruiting Wed, 27 Mar 2019 12:00:00 EDT Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)Conditions: Coronary Artery Disease; Coronary Restenosis; Coronary Atherosclerosis; Coronary ArteriosclerosisInterventions: Device: Agent Paclitaxel-coated balloon; Device: SeQuent® Please Paclitaxel-coated Balloon Sponsor: Hemoteq AG Completed Fri, 30 May 2014 12:00:00 EDT A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric AdenocarcinomaCondition: Gastric CancerInterventions: Biological: Ramucirumab (IMC-1211B) DP; Drug: Placebo; Drug: Paclitaxel Sponsor: Eli Lilly and Company Completed Tue, 27 Jul 2010 12:00:00 EDT A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian CancerCondition: Ovarian CancerIntervention: Drug: Paclitaxel, Carboplatin and Vorinostat Sponsors: Herlev Hospital; Odense University Hospital Unknown status Wed, 15 Oct 2008 12:00:00 EDT Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.Condition: Urothelial CancerInterventions: Drug: Nab-Paclitaxel; Drug: Paclitaxel Sponsors: Canadian Cancer Trials Group; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Celgene Completed Mon, 13 Jan 2014 12:00:00 EST A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous HistologyCondition: Squamous Non-Small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: RO5479599 Sponsor: Hoffmann-La Roche Terminated Wed, 30 Jul 2014 12:00:00 EDT A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsCondition: Locally Advanced or Metastatic Solid TumorInterventions: Drug: rebastinib; Drug: Paclitaxel Sponsor: Deciphera Pharmaceuticals LLC Active, not recruiting Thu, 26 Jul 2018 12:00:00 EDT Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric CancerCondition: Gastric CancerIntervention: Drug: S1/Paclitaxel chemotherapy plus Apatinib Sponsors: The First Affiliated Hospital of Zhejiang Chinese Medical University; Jiangsu HengRui Medicine Co., Ltd. Unknown status Thu, 20 Aug 2015 12:00:00 EDT
VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical CancerCondition: Cervical CancerIntervention: Drug: Drug: Cisplatin; nab-paclitaxel Sponsor: Peking University Third Hospital Recruiting Fri, 12 Jul 2019 12:00:00 EDT Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular AccessConditions: Kidney Diseases; ESRDInterventions: Device: Vascular Wrap Paclitaxel-Eluting Mesh; Device: Lifespan® ePTFE Vascular Graft Sponsor: Angiotech Pharmaceuticals Terminated Mon, 19 Mar 2007 12:00:00 EDT Paclitaxel Eluting Balloon for SFA In-stent RestenosisCondition: In-stent Arterial RestenosisIntervention: Device: PTA with drug eluting balloon with paclitaxel Sponsor: University Health Network, Toronto Unknown status Tue, 12 Jun 2012 12:00:00 EDT Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Paclitaxel plus carboplatin; Drug: Paclitaxel and epirubicin Sponsor: Chinese Academy of Medical Sciences Unknown status Thu, 13 Jan 2011 12:00:00 EST Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Tivozanib Hydrochloride; Drug: paclitaxel; Drug: Placebo Sponsors: AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc Terminated Mon, 10 Dec 2012 12:00:00 EST Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine CancerCondition: SarcomaInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Fri, 03 Jun 2005 12:00:00 EDT Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast CancerConditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerInterventions: Drug: mifepristone; Drug: placebo; Drug: nab-paclitaxel Sponsor: University of Chicago Completed Thu, 15 Dec 2011 12:00:00 EST Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and GraftsConditions: Dysfunctional AV Graft; Dysfunctional AV FistulaIntervention: Device: Lutonix Paclitaxel Drug Coated Balloon Sponsor: C. R. Bard Withdrawn Tue, 08 Jul 2014 12:00:00 EDT Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: Afatinib 30Mg Tab; Drug: Afatinib 40Mg Tab; Drug: Gemzar; Drug: Abraxane Sponsors: PD Dr. med. Volker Heinemann; Technische Universität München; University of Cologne Unknown status Tue, 29 Nov 2016 12:00:00 EST Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Genexol-PM; Drug: Paclitaxel Sponsor: National Cancer Center, Korea Withdrawn Mon, 26 Jul 2010 12:00:00 EDT
Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access DysfunctionConditions: Dialysis Access Malfunction; Kidney FailureIntervention: Drug: Paclitaxel Drug Coated Balloon Sponsor: Singapore General Hospital Recruiting Wed, 04 Aug 2021 12:00:00 EDT Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid TumorsConditions: Breast Cancer; Ovarian Cancer; Gynecological Cancer; Head and Neck Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Non-squamous Cell Lung CancerIntervention: Drug: PM01183 + paclitaxel +/- bevacizumab Sponsor: PharmaMar Completed Mon, 15 Apr 2013 12:00:00 EDT Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple MyelomaCondition: Relapse/Refractory Multiple MyelomaInterventions: Drug: Paclitaxel; Drug: Cyclophosphamide; Drug: Dexamethasone Sponsor: Sun Yat-sen University Withdrawn Wed, 07 Dec 2016 12:00:00 EST Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid CancerCondition: Advanced Solid TumorsIntervention: Drug: Paclitaxel+HM30181 Sponsor: Hanmi Pharmaceutical Company Limited Completed Tue, 13 Dec 2011 12:00:00 EST EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Paclitaxel + Carboplatin every 3 weeks; Drug: Carboplatin monotherapy every 3 weeks; Drug: Weekly Paclitaxel and Carboplatin Sponsor: Hospices Civils de Lyon Completed Wed, 04 Dec 2013 12:00:00 EST Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerConditions: Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Drug: Lenvatinib; Drug: Paclitaxel; Biological: Pembrolizumab Sponsor: Floor Backes Not yet recruiting Thu, 04 Mar 2021 12:00:00 EST LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid TumorsCondition: Advanced Solid TumorsIntervention: Drug: Panobinostat (LBH589), Carboplatin and Paclitaxel Sponsors: Southern Europe New Drug Organization; Novartis Unknown status Fri, 09 Jul 2010 12:00:00 EDT The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaConditions: Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic CancerInterventions: Drug: CEND-1; Drug: Gemcitabine Injection; Drug: Nab paclitaxel Sponsors: University of Sydney; Australasian Gastro-Intestinal Trials Group Not yet recruiting Mon, 13 Sep 2021 12:00:00 EDT Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung CancerCondition: Lung Cancer, Non-Small CellInterventions: Drug: pazopanib; Drug: paclitaxel Sponsor: GlaxoSmithKline Completed Fri, 20 Mar 2009 12:00:00 EDT Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerCondition: Breast CancerInterventions: Drug: Apatinib; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Chinese Academy of Medical Sciences Unknown status Thu, 08 Nov 2018 12:00:00 EST
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: FeasibilityConditions: Breast Cancer; Adenocarcinoma of the BreastIntervention: Drug: epirubicin, cyclophosphamide, Paclitaxel, Sponsors: Memorial Sloan Kettering Cancer Center; Amgen; Pfizer Completed Mon, 18 Feb 2008 12:00:00 EST Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain SyndromeCondition: Breast CarcinomaInterventions: Procedure: Cryotherapy; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Completed Mon, 28 Dec 2015 12:00:00 EST A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsConditions: Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Tumor Virus InfectionsInterventions: Drug: CC-486; Drug: Carboplatin; Drug: ABI-007 Sponsor: Celgene Completed Wed, 23 Nov 2011 12:00:00 EST A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaCondition: Malignant MelanomaInterventions: Drug: Sorafenib (BAY 43-9006); Drug: ABI-007(Abraxane) Sponsors: Mt. Sinai Medical Center, Miami; Celgene Corporation; Bayer Completed Thu, 07 Jun 2007 12:00:00 EDT Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerCondition: Breast CancerInterventions: Drug: Albumin-bound paclitaxel combined with carboplatin; Drug: Epirubicin combined with docetaxel Sponsor: Shengjing Hospital Recruiting Wed, 23 Oct 2019 12:00:00 EDT First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCConditions: Metastatic Breast Cancer; Advanced Breast Cancer; Triple Negative Breast CancerInterventions: Drug: Atezolizumab; Drug: Paclitaxel; Drug: Bevacizumab Sponsors: MedSIR; Hoffmann-La Roche Recruiting Fri, 29 May 2020 12:00:00 EDT Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Gemcitabine; Drug: Adriamycine; Drug: Paclitaxel Sponsors: Spanish Breast Cancer Research Group; Eli Lilly and Company; Bristol-Myers Squibb Completed Wed, 10 Aug 2005 12:00:00 EDT A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic MelanomaCondition: MelanomaInterventions: Drug: Tasisulam-sodium; Drug: Paclitaxel Sponsor: Eli Lilly and Company Terminated Sun, 01 Nov 2009 12:00:00 EDT Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCondition: Lung Cancer (NSCLC)Interventions: Biological: Paclitaxel; Biological: Carboplatin; Biological: Ipilimumab; Other: Placebo Sponsor: Bristol-Myers Squibb Completed Fri, 31 Oct 2014 12:00:00 EDT Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic CancerCondition: Metastatic Pancreatic CancerIntervention: Drug: Folfirinox alternating with Gemcitabine-nab-Paclitaxel Sponsor: Lyudmyla Berim Recruiting Thu, 17 Dec 2020 12:00:00 EST
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the KneeConditions: Peripheral Arterial Disease; Cardiovascular Disease; Peripheral Vascular DiseaseIntervention: Other: Paclitaxel administration using the OPC Sponsors: Horizons International Peripheral Group; Advanced Catheter Therapies, Inc. Completed Mon, 08 Jun 2015 12:00:00 EDT Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast CancerCondition: Breast CancerInterventions: Drug: Abraxane; Drug: Carboplatin; Drug: Avastin Sponsors: William Sikov MD; Yale University Completed Mon, 28 Jul 2008 12:00:00 EDT Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian CancerConditions: Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine CancerInterventions: Drug: Olaparib; Drug: Carboplatin; Drug: Paclitaxel Sponsors: Swedish Medical Center; AstraZeneca Unknown status Thu, 26 Jul 2012 12:00:00 EDT Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)Condition: In-stent Coronary Artery RestenosisIntervention: Device: Danubio paclitaxel-eluting balloon Sponsors: MINVASYS; European Cardiovascular Research Center Completed Mon, 05 Dec 2011 12:00:00 EST Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast CancerConditions: Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast CancerInterventions: Drug: suramin; Drug: paclitaxel; Other: pharmacological study Sponsor: National Cancer Institute (NCI) Completed Thu, 06 Feb 2003 12:00:00 EST Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent CancerCondition: Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: irinotecan hydrochloride; Drug: paclitaxel Sponsors: University of Chicago; National Cancer Institute (NCI) Completed Thu, 29 Apr 2004 12:00:00 EDT Balloon Elution and Late Loss Optimization (BELLO) StudyCondition: Coronary Artery DiseaseInterventions: Device: IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon); Device: Taxus (Paclitaxel eluting stent) Sponsor: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS Unknown status Mon, 15 Mar 2010 12:00:00 EDT Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line ChemotherapyCondition: Advanced Gastric CancerInterventions: Drug: AZD5363; Drug: paclitaxel Sponsor: Samsung Medical Center Completed Fri, 22 May 2015 12:00:00 EDT Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas CancerCondition: Pancreatic NeoplasmInterventions: Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsors: Hacettepe University; Celgene Completed Thu, 17 Jan 2019 12:00:00 EST Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma CancerConditions: Fallopian Tube Carcinoma; Infectious Disorder; Neutropenia; Ovarian Carcinosarcoma; Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian CancerInterventions: Procedure: Adjuvant Therapy; Drug: Carboplatin; Drug: Paclitaxel; Biological: Pegfilgrastim Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Completed Fri, 14 Jul 2006 12:00:00 EDT
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic CancerCondition: Pancreatic Cancer Non-resectableInterventions: Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX; Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Sponsor: FibroGen Recruiting Tue, 07 May 2019 12:00:00 EDT Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal CancerConditions: Gastro-oesophageal Junction Cancer; Gastric CancerInterventions: Drug: AZD4547; Drug: paclitaxel Sponsor: AstraZeneca Terminated Mon, 24 Oct 2011 12:00:00 EDT A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaConditions: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic AdenocarcinomaInterventions: Drug: zolbetuximab; Drug: nab-paclitaxel; Drug: gemcitabine Sponsor: Astellas Pharma Global Development, Inc. Recruiting Fri, 25 Jan 2019 12:00:00 EST Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in MelanomaCondition: MelanomaInterventions: Drug: Elesclomol (STA-4783); Drug: Paclitaxel Sponsor: Synta Pharmaceuticals Corp. Terminated Thu, 30 Aug 2007 12:00:00 EDT Clinical Study of Decitabine and Paclitaxel Combination TherapyCondition: Advanced Breast CancerInterventions: Drug: Decitabine; Drug: Paclitaxel Sponsor: Dong Wha Pharmaceutical Co. Ltd. Unknown status Thu, 14 Sep 2017 12:00:00 EDT Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal StenosesCondition: Peripheral Arterial Disease (PAD)Interventions: Device: Zilver® Paclitaxel-Eluting Peripheral Stent; Device: Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating; Device: Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating Sponsor: Cook Group Incorporated Active, not recruiting Tue, 18 Oct 2016 12:00:00 EDT A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal CancerCondition: Stage III Esophageal Squamous Cell CarcinomaInterventions: Drug: Paclitaxel and Cisplatin; Drug: Paclitaxel and Fluorouracil; Drug: Paclitaxel and Carboplatin; Radiation: Radiotherapy Sponsors: Fudan University; Huadong Hospital; Wuxi No. 4 People's Hospital; Jiangsu Cancer Institute & Hospital; The First Affiliated Hospital of Xiamen University; Jiangxi Provincial Cancer Hospital; Shanxi Province Cancer Hospital; Gansu Cancer Hospital Active, not recruiting Tue, 02 Jun 2015 12:00:00 EDT Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Condition: Recurrent/Metastatic Gastric CancerIntervention: Drug: Trastuzumab + Ramucirumab + Paclitaxel Sponsor: Yonsei University Active, not recruiting Mon, 17 May 2021 12:00:00 EDT Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerCondition: HER2-positive Gastric CancerIntervention: Drug: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur Sponsor: Shengjing Hospital Recruiting Thu, 07 Oct 2021 12:00:00 EDT Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid TumorsConditions: Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid NeoplasmInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Sapanisertib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting Tue, 13 Feb 2018 12:00:00 EST
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung CancerCondition: Carcinoma, Non-Small-Cell LungInterventions: Radiation: Proton beam radiation therapy (PBT); Drug: Paclitaxel; Drug: Carboplatin Sponsor: Washington University School of Medicine Completed Tue, 24 Jun 2014 12:00:00 EDT Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian CancerCondition: Ovarian CancerInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group Completed Mon, 27 Jan 2003 12:00:00 EST A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerConditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal CancerIntervention: Drug: carboplatin and paclitaxel Sponsor: Korean Gynecologic Oncology Group Unknown status Wed, 04 Apr 2012 12:00:00 EDT Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By SurgeryConditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung CancerInterventions: Drug: vorinostat; Drug: paclitaxel; Radiation: radiation therapy Sponsors: University of Washington; National Cancer Institute (NCI) Terminated Mon, 21 Apr 2008 12:00:00 EDT Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerConditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Completed Tue, 30 Oct 2012 12:00:00 EDT Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerConditions: Breast Cancer; HER2 Positive; Combination ChemotherapyInterventions: Drug: Pyrotinib Maleate Tablets; Drug: Albumin Paclitaxel; Drug: Trastuzumab Sponsors: West China Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting Tue, 05 Nov 2019 12:00:00 EST ABI-007 in Taxol Resistant Patients With Metastatic Breast CancerConditions: Breast Neoplasms; Metastases, NeoplasmIntervention: Drug: ABI-007 Sponsor: Celgene Corporation Completed Thu, 03 Oct 2002 12:00:00 EDT Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by SurgeryConditions: Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7Interventions: Drug: Gemcitabine Hydrochloride; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug: Metformin Hydrochloride; Dietary Supplement: Therapeutic Dietary Intervention; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Active, not recruiting Mon, 12 Jan 2015 12:00:00 EST Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast CancerCondition: Breast CancerInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: University of Alabama at Birmingham; National Cancer Institute (NCI) Completed Tue, 09 Nov 2004 12:00:00 EST A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast CancerCondition: Stage IV (Metastatic) Breast CancerInterventions: Drug: ABI-007; Drug: vinorelbine; Drug: Trastuzumab; Biological: G-CSF Sponsor: Celgene Terminated Thu, 01 Sep 2005 12:00:00 EDT
Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBCCondition: Neoplasms, BreastIntervention: Drug: Lapatinib in combination with weekly paclitaxel Sponsor: GlaxoSmithKline Completed Mon, 07 Jun 2010 12:00:00 EDT Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerConditions: Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Drug: Onalespib; Drug: Paclitaxel; Other: Pharmacological Study Sponsor: National Cancer Institute (NCI) Active, not recruiting Wed, 17 Jun 2015 12:00:00 EDT Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid TumorsConditions: Advanced Solid Tumors; Ovarian Cancer; Small Cell Lung CancerInterventions: Drug: Alisertib; Drug: Paclitaxel Sponsor: Millennium Pharmaceuticals, Inc. Terminated Fri, 20 Feb 2015 12:00:00 EST Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: bevacizumab; Drug: Paclitaxel Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group; NSABP Foundation Inc Completed Mon, 27 Jan 2003 12:00:00 EST A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)Condition: Esophageal Squamous Cell CarcinomaIntervention: Drug: Camrelizumab, Albumin Paclitaxel, Carboplatin Sponsors: Hunan Cancer Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting Tue, 23 Feb 2021 12:00:00 EST Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial InfarctionCondition: Acute Myocardial InfarctionInterventions: Device: Bare metal Stent plus Paclitaxel Balloon; Device: Drug Eluting Stent Sponsors: Fundacion Investigacion Interhospitalaria Cardiovascular; Effice Servicios Para la Investigacion S.L. Terminated Wed, 01 Aug 2018 12:00:00 EDT Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid TumorsConditions: Locally Advanced Solid Tumors; Metastatic Solid Tumors; Pancreatic AdenocarcinomaInterventions: Genetic: VCN-01; Drug: Gemcitabine; Drug: Abraxane® Sponsor: VCN Biosciences, S.L. Completed Mon, 27 Jan 2014 12:00:00 EST Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCCondition: Locally Advanced Pancreatic CancerInterventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Device: RenovoCath Sponsor: RenovoRx Recruiting Tue, 22 Aug 2017 12:00:00 EDT Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic MelanomaCondition: MelanomaInterventions: Drug: Temozolomide; Drug: Abraxane; Drug: Cisplatin; Biological: Interleukin-2; Biological: Interferon alpha 2b Sponsor: M.D. Anderson Cancer Center Completed Thu, 03 Sep 2009 12:00:00 EDT A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer PatientsCondition: Human Epithelial Receptor (HER)-2 Positive Breast CancerInterventions: Drug: Trastuzumab; Drug: Paclitaxel Sponsor: Biocad Completed Wed, 09 Jan 2013 12:00:00 EST
Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric CancerCondition: Recurrent/Metastatic Gastric CancerIntervention: Drug: M7824+paclitaxel Sponsor: Yonsei University Not yet recruiting Thu, 08 Apr 2021 12:00:00 EDT Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)Condition: Coronary DiseaseIntervention: Device: Danubio paclitaxel-eluting balloon Sponsors: MINVASYS; European Cardiovascular Research Center Completed Mon, 05 Dec 2011 12:00:00 EST OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary ArteryCondition: Coronary Artery DiseaseInterventions: Device: OCT-guided paclitaxel drug-coated balloon angioplasty; Device: Angiography-guided paclitaxel drug-coated balloon angioplasty Sponsor: Beijing Anzhen Hospital Recruiting Wed, 19 Feb 2020 12:00:00 EST A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerConditions: High Grade Serous Ovarian; Fallopian Tube; Primary Peritoneal CancerInterventions: Drug: Carboplatin and Paclitaxel; Drug: Nivolumab; Procedure: Cytoreductive surgery; Drug: Ipilimumab Sponsors: Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb Recruiting Thu, 10 Aug 2017 12:00:00 EDT Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsCondition: Breast Cancer FemaleInterventions: Drug: paclitaxel; Drug: Iniparib (SAR2405550 -BSI-201) Sponsors: Sanofi; SOLTI Breast Cancer Research Group Completed Fri, 17 Sep 2010 12:00:00 EDT Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCCondition: Non-Small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Nab-paclitaxel; Drug: MK-3475 (Phase I); Drug: MK-3475 (Phase II) Sponsors: Nisha Mohindra, MD; Hoosier Cancer Research Network; Merck Sharp & Dohme Corp.; Celgene Corporation Active, not recruiting Fri, 06 Mar 2015 12:00:00 EST Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung CancerCondition: Advanced Non-small Cell Lung CancerInterventions: Drug: Endostar(Recombinant Human Endostatin Injection); Drug: paclitaxel-carboplatin Sponsor: Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd Completed Wed, 02 Jul 2008 12:00:00 EDT Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast CancerConditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8Interventions: Drug: Nilotinib; Drug: Nilotinib Hydrochloride Monohydrate; Drug: Paclitaxel; Other: Placebo; Other: Questionnaire Administration Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI) Recruiting Fri, 20 Dec 2019 12:00:00 EST Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)Condition: Bladder Carcinoma in Situ (CIS)Intervention: Drug: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID) Sponsor: Fidia Farmaceutici s.p.a. Not yet recruiting Fri, 27 Aug 2021 12:00:00 EDT Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung CancerCondition: Lung CancerInterventions: Drug: carboplatin; Drug: paclitaxel; Drug: thalidomide; Radiation: radiation therapy Sponsor: National Cancer Institute (NCI) Terminated Mon, 27 Jan 2003 12:00:00 EST
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaConditions: Pulmonary Sarcomatoid Carcinoma; Non-small Cell Lung Cancer; Lung Diseases; Thoracic NeoplasmsInterventions: Drug: Toripalimab; Drug: Bevacizumab; Drug: Nab-paclitaxel; Drug: Carboplatin Sponsor: Sichuan Cancer Hospital and Research Institute Recruiting Tue, 26 Jan 2021 12:00:00 EST BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: BYL719; Drug: Gemcitabine; Drug: (nab)-paclitaxel Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Novartis Completed Wed, 04 Jun 2014 12:00:00 EDT Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic PatientsConditions: Coronary Stenosis; Diabetes MellitusInterventions: Device: Paclitaxel Eluting Balloon; Device: paclitaxel eluting stent; Device: bare metal stent Sponsors: Heart Centre Rotenburg; B. Braun Medical SA Completed Thu, 19 Apr 2007 12:00:00 EDT A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck CancerCondition: Carcinoma, Squamous CellInterventions: Drug: paclitaxel poliglumex; Biological: cetuximab; Radiation: radiation therapy (IMRT or 3D-CRT) Sponsors: State University of New York - Upstate Medical University; CTI BioPharma Unknown status Thu, 17 Apr 2008 12:00:00 EDT Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCondition: Thyroid Gland Anaplastic CarcinomaInterventions: Radiation: Intensity-Modulated Radiation Therapy; Drug: Paclitaxel; Drug: Pazopanib Hydrochloride; Other: Placebo Administration Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting Sun, 07 Nov 2010 12:00:00 EDT Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)Condition: Non-small Cell Lung Cancer, Stage IIIInterventions: Radiation: radiation therapy; Drug: Paclitaxel Protein-Bound, and CARBOPLATIN Sponsors: University of Rochester; Celgene Corporation Withdrawn Tue, 19 May 2009 12:00:00 EDT Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK ArteriesCondition: Peripheral Arterial DiseaseIntervention: Device: Self-expandable drug eluting stent Sponsor: Flanders Medical Research Program Completed Thu, 28 Jun 2012 12:00:00 EDT Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast CancerCondition: Breast CancerInterventions: Drug: nab-paclitaxel; Drug: Bevacizumab; Drug: Trastuzumab Sponsors: SCRI Development Innovations, LLC; Celgene Corporation; Genentech, Inc. Completed Thu, 26 Oct 2006 12:00:00 EDT Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerConditions: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid NeoplasmInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Talazoparib Sponsor: National Cancer Institute (NCI) Active, not recruiting Wed, 17 Dec 2014 12:00:00 EST Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung CancerCondition: Lung CancerInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Wed, 26 May 2004 12:00:00 EDT
Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)Condition: Bladder Carcinoma in Situ (CIS)Intervention: Drug: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) Sponsor: Fidia Farmaceutici s.p.a. Completed Mon, 15 Mar 2021 12:00:00 EDT Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsCondition: Advanced Solid TumorInterventions: Drug: paclitaxel; Drug: TAK-228; Drug: TAK-117 Sponsor: Avera McKennan Hospital & University Health Center Active, not recruiting Tue, 16 May 2017 12:00:00 EDT Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckConditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVC Hypopharyngeal Carcinoma AJCC v8; Stage IVC Laryngeal Cancer AJCC v8; Stage IVC Lip and Oral Cavity Cancer AJCC v8Interventions: Drug: Carboplatin; Biological: Cemiplimab; Drug: Paclitaxel Sponsor: Marcelo Bonomi Not yet recruiting Wed, 28 Apr 2021 12:00:00 EDT Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung CancerCondition: Lung CancerInterventions: Biological: interferon alpha; Drug: 13-cis-retinoic acid; Drug: paclitaxel Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI) Completed Fri, 06 Jun 2003 12:00:00 EDT Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCondition: Lung Cancer - Non Small Cell SquamousInterventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Bristol-Myers Squibb Completed Fri, 28 Jan 2011 12:00:00 EST Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaConditions: Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial CancerInterventions: Drug: paclitaxel; Drug: carboplatin; Drug: erlotinib Sponsor: National Cancer Institute (NCI) Completed Wed, 07 May 2003 12:00:00 EDT Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: paclitaxel liposome injection Sponsor: Nanjing Luye Sike Pharmaceutical Co., Ltd. Unknown status Tue, 20 May 2014 12:00:00 EDT Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast CancerCondition: Breast CancerInterventions: Drug: Paclitaxel; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: RAD001 Sponsors: M.D. Anderson Cancer Center; Novartis; National Cancer Institute (NCI) Unknown status Wed, 11 Jul 2007 12:00:00 EDT Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)Conditions: Gastric Neoplasms; Gastroesophageal Junction AdenocarcinomaInterventions: Biological: Pembrolizumab; Drug: Paclitaxel Sponsor: Merck Sharp & Dohme Corp. Terminated Thu, 12 Jan 2017 12:00:00 EST Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaCondition: Gastric CarcinomaIntervention: Drug: Liposomal paclitaxel and capecitabine Sponsor: Nanjing Sike Pharmaceutical Co., Ltd. Unknown status Thu, 20 Mar 2008 12:00:00 EDT
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the PancreasCondition: Metastatic Pancreatic CancerIntervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stand Up To Cancer; Genentech, Inc.; Celgene Corporation Completed Wed, 17 Mar 2010 12:00:00 EDT RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationConditions: Carcinoma, Large Cell; Neuroendocrine TumorsInterventions: Drug: RAD001; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Novartis Pharmaceuticals Completed Thu, 17 Mar 2011 12:00:00 EDT Study of NAC of GA Therapy for Patients With BRPCCondition: Pancreatic Ductal AdenocarcinomaIntervention: Drug: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel Sponsor: Wakayama Medical University Unknown status Thu, 06 Oct 2016 12:00:00 EDT Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian CancerCondition: Ovarian CancerInterventions: Drug: paclitaxel; Drug: pazopanib Sponsor: National Cancer Institute, Naples Completed Thu, 19 Jul 2012 12:00:00 EDT A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic MalignanciesCondition: Non-hematologic MalignancyInterventions: Drug: Sapanisertib; Drug: Paclitaxel Sponsor: Millennium Pharmaceuticals, Inc. Completed Thu, 09 Apr 2015 12:00:00 EDT Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast CancerCondition: ErbB2-Positive Stage I-III Breast CancerIntervention: Drug: paclitaxel/carboplatin/lapatinib Sponsors: National University Hospital, Singapore; National Cancer Centre, Singapore Unknown status Mon, 07 Mar 2011 12:00:00 EST A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)Condition: Triple-Negative Breast CancerInterventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Drug: Atezolizumab Placebo; Drug: Paclitaxel Sponsor: Hoffmann-La Roche Active, not recruiting Mon, 24 Apr 2017 12:00:00 EDT Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )Condition: Head and Neck Squamous Cell CancerIntervention: Drug: Sintilimab and Nab-paclitaxel Sponsor: Shengyu Zhou Unknown status Wed, 05 Jun 2019 12:00:00 EDT Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerConditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Drug: Pazopanib Hydrochloride; Other: Placebo Sponsors: National Cancer Institute (NCI); NRG Oncology Completed Thu, 10 Nov 2011 12:00:00 EST Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma （ARISE）Condition: Pulmonary Adenosquamous CarcinomaInterventions: Drug: Almonertinib; Drug: Paclitaxel and carboplatin Sponsors: Fujian Cancer Hospital; Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting Tue, 21 Apr 2020 12:00:00 EDT
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLCCondition: Stage IV Non-small Cell Lung CancerIntervention: Drug: Belinostat, Carboplatin, Paclitaxel Sponsors: Acrotech Biopharma LLC; Onxeo Completed Tue, 08 Mar 2011 12:00:00 EST Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: TH-302; Drug: Nab-paclitaxel; Drug: Gemcitabine Sponsor: Threshold Pharmaceuticals Terminated Tue, 28 Jan 2014 12:00:00 EST Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by SurgeryCondition: Lung CancerInterventions: Drug: carboplatin; Drug: paclitaxel; Drug: Zactima; Procedure: neoadjuvant therapy Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI) Terminated Wed, 11 Apr 2007 12:00:00 EDT CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)Condition: Non-small Cell Lung CancerInterventions: Drug: CS-1008; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Daiichi Sankyo, Inc. Completed Thu, 08 Oct 2009 12:00:00 EDT PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic CancerCondition: Neoplasms PancreaticInterventions: Drug: FOLFOX-A; Drug: Gemcitabe and Abraxane; Drug: G-CSF Sponsors: Judith Dixon-Hughes; NHS Greater Glasgow and Clyde; University of Glasgow Recruiting Tue, 05 Nov 2019 12:00:00 EST First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)Conditions: Peripheral Artery Disease; Femoropopliteal Artery DiseaseInterventions: Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland); Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland) Sponsors: Balton Sp.zo.o.; American Heart of Poland Completed Thu, 22 May 2014 12:00:00 EDT Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)Condition: Neoplasms, BreastInterventions: Drug: Pazopanib; Drug: Lapatinib; Drug: paclitaxel; Drug: carboplatin Sponsor: GlaxoSmithKline Completed Fri, 13 Oct 2006 12:00:00 EDT Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and SolidsConditions: Endometrial Cancer; Ovarian CancerInterventions: Drug: Ridaforolimus; Drug: Paclitaxel; Drug: carboplatin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme Corp. Completed Wed, 08 Dec 2010 12:00:00 EST Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast CancerCondition: Breast CancerInterventions: Drug: Cohort 1 neo-adjuvant; Drug: Cohort 2 neo-adjuvant; Drug: Cohort 1 adjuvant; Drug: Cohort 2 adjuvant Sponsors: William Sikov MD; Yale University Completed Mon, 18 Feb 2008 12:00:00 EST Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCondition: Advanced Gastric CancerInterventions: Drug: Camrelizumab; Drug: Apatinib Mesylate; Drug: nab-paclitaxel; Drug: S1 Sponsor: Fujian Medical University Recruiting Thu, 12 Dec 2019 12:00:00 EST
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerConditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity CancerInterventions: Drug: carboplatin; Drug: paclitaxel; Procedure: cytoreductive surgery Sponsor: Masonic Cancer Center, University of Minnesota Terminated Wed, 31 May 2006 12:00:00 EDT Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryConditions: Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma; Stage II Oropharyngeal Squamous Cell Carcinoma; Stage III Hypopharyngeal Squamous Cell Carcinoma; Stage III Laryngeal Squamous Cell Carcinoma; Stage III Oral Cavity Squamous Cell Carcinoma; Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Laryngeal Squamous Cell Carcinoma; Stage IV Oral Cavity Squamous Cell Carcinoma; Stage IV Oropharyngeal Squamous Cell Carcinoma; Stage IVA Hypopharyngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Hypopharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Oral Cavity Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Hypopharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Oral Cavity Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell CarcinomaInterventions: Drug: Paclitaxel; Drug: Carboplatin; Biological: Nivolumab Sponsors: Sidney Kimmel Cancer Center at Thomas Jefferson University; Bristol-Myers Squibb Suspended Fri, 17 Nov 2017 12:00:00 EST Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial CancerCondition: Endometrial CancerInterventions: Drug: Carboplatin and Paclitaxel; Radiation: Radiation Therapy Sponsor: Loyola University Recruiting Thu, 02 May 2019 12:00:00 EDT Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer PatientsConditions: Tubular Breast Cancer; Mucinous Breast Cancer; Invasive Ductal Breast Cancer; Inflammatory Breast CancerInterventions: Drug: Paclitaxel; Drug: Cisplatin; Drug: Gonadotropin-releasing hormone agonist; Drug: Letrozole Sponsor: RenJi Hospital Active, not recruiting Thu, 21 Aug 2014 12:00:00 EDT Local Paclitaxel or Balloon Angioplasty Below the KneeConditions: Stenosis; Occlusion; RestenosisInterventions: Device: SequentPlease OTW paclitaxel coated balloon catheter; Device: conventional uncoated balloon for BTK endovascular therapy Sponsors: Prof. Dr. med. Gunnar Tepe; InnoRa GmbH Unknown status Thu, 11 May 2017 12:00:00 EDT Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerCondition: Breast CancerInterventions: Drug: Gemcitabine; Drug: Epirubicin; Drug: Albumin-bound Paclitaxel Sponsors: SCRI Development Innovations, LLC; Eli Lilly and Company; Celgene Corporation Completed Mon, 19 Sep 2005 12:00:00 EDT Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal CancerConditions: Esophagus Cancer; Esophageal Cancer; Cancer of the EsophagusInterventions: Radiation: Intensity Modulated Radiation Therapy; Drug: Carboplatin; Other: MD Anderson Symptom Inventory (MDASI)-Plus module; Other: EuroQol (EQ-5D); Other: SF-12; Other: MOS Social Support Measure; Other: CES-D; Procedure: Blood for ctDNA (optional); Procedure: Blood for SCCA; Drug: Paclitaxel Sponsor: Washington University School of Medicine Recruiting Tue, 06 Aug 2019 12:00:00 EDT Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteCondition: Neoplasm, Unknown PrimaryInterventions: Drug: paclitaxel; Drug: carboplatin; Drug: bevacizumab; Drug: erlotinib Sponsors: SCRI Development Innovations, LLC; Genentech, Inc. Completed Fri, 04 Aug 2006 12:00:00 EDT Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)Conditions: Squamous Cell Carcinoma of the Head and Neck; Carcinoma, Squamous Cell of the Head and Neck; Cancer of Head and Neck; Cancer of the Head and Neck; Head and Neck Cancer; Neoplasms, Head and NeckInterventions: Drug: nab-Paclitaxel; Drug: Cisplatin; Biological: Cetuximab; Radiation: Intensity-Modulated Radiation Therapy Sponsors: Washington University School of Medicine; Celgene Corporation Active, not recruiting Fri, 09 Oct 2015 12:00:00 EDT Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaConditions: Gastroesophageal Junction Adenocarcinoma; Adenocarcinoma of the StomachInterventions: Drug: Avelumab; Drug: Ramucirumab; Drug: Paclitaxel Sponsor: P. C. Thuss-Patience Recruiting Wed, 29 May 2019 12:00:00 EDT
Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) CatheterCondition: In-Stent RestenosisInterventions: Device: SeQuent® Please; Device: SeQuent® II Sponsor: Klinikum Coburg Unknown status Tue, 20 Oct 2009 12:00:00 EDT Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By SurgeryCondition: Esophageal CancerInterventions: Drug: cisplatin; Drug: gefitinib; Drug: paclitaxel; Procedure: adjuvant therapy; Radiation: radiation therapy Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; National Cancer Institute (NCI) Terminated Wed, 27 Jun 2007 12:00:00 EDT Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLCCondition: NSCLCInterventions: Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin; Drug: IBI305 in Combination with Paclitaxel/Carboplatin Sponsors: Innovent Biologics (Suzhou) Co. Ltd.; WuXi CDS Clinical Research (Shanghai) Co.Ltd. Completed Thu, 03 Nov 2016 12:00:00 EDT Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast CancerCondition: Breast CancerInterventions: Drug: Carboplatin; Drug: Bevacizumab; Drug: Paclitaxel Sponsors: Hellenic Oncology Research Group; University Hospital of Crete Completed Thu, 05 Jun 2008 12:00:00 EDT Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryConditions: Adult Solid Neoplasm; Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast CarcinomaInterventions: Drug: Cilengitide; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Pharmacological Study Sponsor: National Cancer Institute (NCI) Completed Thu, 13 Jan 2011 12:00:00 EST ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerConditions: Advanced Solid Tumor; Metastatic Breast CancerIntervention: Drug: Abraxane Sponsor: Orinove, Inc. Recruiting Wed, 15 May 2019 12:00:00 EDT Sutent + Taxol for Advanced Esophageal CancerCondition: Esophageal CancerInterventions: Drug: Sunitinib malate; Drug: Paclitaxel Sponsors: Hoosier Cancer Research Network; Pfizer Completed Fri, 08 Aug 2008 12:00:00 EDT Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical CancerCondition: Cervical CancerInterventions: Drug: Bevacizumab; Drug: Carboplatin; Drug: Paclitaxel Sponsor: Hoffmann-La Roche Completed Wed, 10 Jun 2015 12:00:00 EDT Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerConditions: Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7Interventions: Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Pharmacological Study; Drug: Selumetinib Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; AstraZeneca Completed Tue, 21 Jul 2015 12:00:00 EDT Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaConditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IV MelanomaInterventions: Drug: carboplatin; Drug: paclitaxel; Drug: bortezomib Sponsor: National Cancer Institute (NCI) Completed Tue, 07 Feb 2006 12:00:00 EST
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)Condition: Ovarian CancerInterventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab Sponsors: Massachusetts General Hospital; Women and Infants Hospital of Rhode Island Completed Fri, 12 Aug 2005 12:00:00 EDT 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid TumorCondition: Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: tanespimycin; Drug: paclitaxel; Other: laboratory biomarker analysis; Other: pharmacological study Sponsor: National Cancer Institute (NCI) Completed Mon, 12 Jul 2004 12:00:00 EDT Paclitaxel and CBT-1(Registered Trademark) to Treat Solid TumorsConditions: Cervical; Ovarian; Lung; Breast; RenalInterventions: Drug: paclitaxel; Drug: CBT-1(Registered Trademark); Radiation: Tc 99m sestamibi Sponsor: National Cancer Institute (NCI) Completed Fri, 04 Sep 2009 12:00:00 EDT Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder CancerCondition: Urinary Bladder NeoplasmsInterventions: Drug: Gemcitabine; Drug: Paclitaxel; Drug: Cisplatin Sponsor: The University of Texas Health Science Center, Houston Terminated Fri, 25 Sep 2015 12:00:00 EDT Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary CancersConditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder CarcinomaInterventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Completed Thu, 19 Mar 2015 12:00:00 EDT A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian CancerConditions: Epithelial Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal CarcinomaInterventions: Drug: weekly paclitaxel; Drug: weekly cisplatin; Device: oncothermia Sponsor: Seoul National University Hospital Unknown status Thu, 22 Jan 2015 12:00:00 EST Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer TherapiesCondition: Metastatic Cancer PancreasInterventions: Drug: PF-03084014; Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: Pfizer; Academic GI Cancer Consortium (AGICC) Terminated Wed, 09 Apr 2014 12:00:00 EDT A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerCondition: Triple Negative Breast CancerInterventions: Drug: Paclitaxel + Carboplatin; Drug: Paclitaxel only Sponsor: Tata Memorial Hospital Active, not recruiting Tue, 30 May 2017 12:00:00 EDT Analysis of Linked Health Insurance Claims and Clinical Registries to Determine Device Surveillance With Paclitaxel-coated Medical DevicesConditions: Paclitaxel Adverse Reaction; Outcome, FatalIntervention: Device: Drug-coated device Sponsors: Universitätsklinikum Hamburg-Eppendorf; GermanVasc; BARMER; MDEpiNet Verband Deutschland e.V. Not yet recruiting Thu, 24 Dec 2020 12:00:00 EST Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.Conditions: Metastatic Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma; Inoperable Disease; Localized Pancreatic AdenocarcinomaInterventions: Drug: SCO-101; Drug: Gemcitabine; Drug: Nab paclitaxel Sponsors: Scandion Oncology A/S; Alcedis GmbH Recruiting Thu, 03 Dec 2020 12:00:00 EST
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast CancerConditions: Breast Cancer; Carcinoma of the BreastInterventions: Drug: Paclitaxel; Drug: Trastuzumab Sponsors: Eric P Winer, MD; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech, Inc. Active, not recruiting Thu, 11 Oct 2007 12:00:00 EDT A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerCondition: Breast CancerInterventions: Drug: Ipatasertib; Drug: Paclitaxel; Drug: Placebo Sponsor: Hoffmann-La Roche Active, not recruiting Thu, 09 Nov 2017 12:00:00 EST Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary OvarianConditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube CancerInterventions: Drug: carboplatin; Drug: Bevacizumab; Drug: Paclitaxel Sponsors: Ritu Salani; Genentech, Inc. Completed Wed, 13 Oct 2010 12:00:00 EDT Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerConditions: Metastatic Esophageal Adenocarcinoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Recurrent Esophageal Adenocarcinoma; Recurrent Esophageal Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Gastroesophageal Junction Adenocarcinoma; Stage IV Esophageal Cancer AJCC v7Interventions: Biological: Cixutumumab; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Pharmacological Study Sponsor: National Cancer Institute (NCI) Active, not recruiting Fri, 11 Jun 2010 12:00:00 EDT Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma; Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Fallopian Tube Cancer; Fallopian Tube Neoplasms; Primary Peritoneal Carcinoma; Primary Peritoneal Serous AdenocarcinomaInterventions: Drug: Paclitaxel; Drug: TAK228 Sponsors: Imperial College London; Takeda Pharmaceuticals International, Inc.; North Eastern German Society of Gynaecological Oncology Recruiting Mon, 27 Aug 2018 12:00:00 EDT Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting StentCondition: Coronary Artery DiseaseInterventions: Device: CoroflexTM Please; Device: Paclitaxel-eluting stent Sponsor: CardioVascular Research Foundation, Korea Completed Thu, 15 Oct 2009 12:00:00 EDT Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast CancerCondition: Breast CancerInterventions: Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide; Drug: Docetaxel followed by anthracycline and cyclophosphamide Sponsor: Xijing Hospital Recruiting Mon, 02 Dec 2019 12:00:00 EST Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-RestenosisCondition: In-stent Stenosis of Infrapopliteal ArteriesInterventions: Device: paclitaxel-coated balloon; Device: non-coated balloon Sponsors: Herz-Zentrums Bad Krozingen; University Heart Center Freiburg - Bad Krozingen Withdrawn Wed, 20 Jul 2011 12:00:00 EDT Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCondition: Melanoma (Skin)Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Tue, 28 Nov 2006 12:00:00 EST A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.Condition: Women With Primary Breast CancerIntervention: Drug: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Completed Tue, 26 Aug 2014 12:00:00 EDT
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerConditions: Gastric Cancer; Gastroesophageal Junction CancerInterventions: Drug: BBI608; Drug: Paclitaxel; Other: Placebo Sponsor: Sumitomo Dainippon Pharma Oncology, Inc Completed Tue, 01 Jul 2014 12:00:00 EDT Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerConditions: Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung CancerInterventions: Drug: imatinib mesylate; Drug: paclitaxel Sponsors: University of Washington; National Cancer Institute (NCI) Completed Thu, 07 Dec 2006 12:00:00 EST Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic CancerCondition: Pancreatic CancerInterventions: Drug: Enzalutamide; Drug: Gemcitabine; Drug: Nab-paclitaxel Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Astellas Pharma Inc Completed Wed, 14 May 2014 12:00:00 EDT A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Condition: Non-Small Cell Lung CancerInterventions: Biological: Olaratumab; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Eli Lilly and Company Completed Thu, 11 Jun 2009 12:00:00 EDT Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid TumorsCondition: NeoplasmsIntervention: Drug: carboplatin + SU011248 (sunitinib) + paclitaxel Sponsor: Pfizer Completed Mon, 06 Aug 2007 12:00:00 EDT Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCondition: Metastatic Pancreatic AdenocarcinomaInterventions: Drug: Ibrutinib; Drug: Paclitaxel; Drug: Gemcitabine Sponsors: Margaret Tempero; Stand Up To Cancer; Lustgarten Foundation Completed Tue, 29 Sep 2015 12:00:00 EDT Real-world Data (RWD) of Ramucirumab Plus PaclitaxelConditions: Gastric Cancer; Gastroesophageal Junction AdenocarcinomaInterventions: Drug: Ramucirumab and paclitaxel; Drug: Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy Sponsor: Hallym University Medical Center Not yet recruiting Mon, 07 Jun 2021 12:00:00 EDT LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid TumorsCondition: Solid TumorsIntervention: Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab Sponsors: SCRI Development Innovations, LLC; Novartis Completed Fri, 09 Nov 2007 12:00:00 EST Paclitaxel/Carboplatin With or Without Cetuximab in CUPConditions: Neoplasms, Unknown Primary; CarcinomaInterventions: Drug: paclitaxel/carboplatin; Drug: cetuximab Sponsors: Heidelberg University; Merck KGaA, Darmstadt, Germany Unknown status Thu, 07 May 2009 12:00:00 EDT Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerCondition: Non-small Cell Lung CancerInterventions: Drug: carboplatin; Drug: Nab-paclitaxel; Drug: Bevacizumab Sponsors: Massachusetts General Hospital; Dana-Farber Cancer Institute; Celgene Corporation; Genentech, Inc. Completed Tue, 25 Mar 2008 12:00:00 EDT
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast CancerConditions: Breast Cancer; Metastatic Breast CancerInterventions: Drug: Gemcitabine; Drug: Paclitaxel; Drug: Bevacizumab Sponsors: George Albert Fisher; Genentech, Inc.; Eli Lilly and Company Completed Thu, 23 Nov 2006 12:00:00 EST A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerConditions: Gastroesophageal Junction Adenocarcinoma; Gastric AdenocarcinomaInterventions: Drug: Ramucirumab; Drug: Paclitaxel; Drug: Placebo Sponsor: Eli Lilly and Company Completed Tue, 13 Sep 2016 12:00:00 EDT Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerCondition: Squamous Non-Small Cell Lung CancerInterventions: Drug: Carboplatin; Drug: Veliparib; Drug: Paclitaxel; Drug: Placebo to veliparib Sponsor: AbbVie Completed Tue, 08 Apr 2014 12:00:00 EDT Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast CancerCondition: Breast CancerIntervention: Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet Sponsor: Hospital Universitario Madrid Sanchinarro Unknown status Thu, 24 Mar 2011 12:00:00 EDT Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With ImmunotherapyConditions: Metastatic Lung Non-Small Cell Squamous Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Lung Non-Squamous Non-Small Cell CarcinomaInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat Sponsor: National Cancer Institute (NCI) Active, not recruiting Wed, 29 May 2019 12:00:00 EDT Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast CancerCondition: Breast CancerInterventions: Drug: carboplatin+ paclitaxel; Drug: paclitaxel Sponsor: Tao OUYANG Completed Fri, 12 Jun 2009 12:00:00 EDT Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCondition: Advanced Gastric AdenocarcinomaInterventions: Drug: AZD1775; Drug: paclitaxel Sponsor: Samsung Medical Center Unknown status Tue, 19 May 2015 12:00:00 EDT Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer PatientsCondition: Non-small Cell Lung Cancer (NSCLC)Intervention: Biological: bevacizumab, carboplatin and paclitaxel Sponsor: Grupo de Investigación y Divulgación Oncológica Unknown status Mon, 11 Nov 2013 12:00:00 EST Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerConditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous CellInterventions: Drug: Paclitaxel for Injection（Albumin Bound）; Drug: carboplatin; Radiation: thoracic radiation therapy Sponsor: First People's Hospital of Hangzhou Unknown status Mon, 19 Dec 2011 12:00:00 EST Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerCondition: Ovarian CancerInterventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin; Drug: Drug: carboplatin Sponsor: AstraZeneca Active, not recruiting Fri, 05 Mar 2010 12:00:00 EST
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast CancerCondition: Breast CancerInterventions: Drug: HBI-8000; Drug: Trastuzumab; Drug: Paclitaxel Sponsor: HUYA Bioscience International Withdrawn Tue, 06 Oct 2015 12:00:00 EDT PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerCondition: Metastatic Pancreatic CancerInterventions: Drug: PEGPH20; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: Dexamethasone; Drug: Enoxaparin Sponsor: Halozyme Therapeutics Completed Thu, 25 Apr 2013 12:00:00 EDT ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLCondition: Breast Cancer MetastaticInterventions: Drug: Abemaciclib; Drug: Paclitaxel; Drug: Letrozole; Drug: Fulvestrant Sponsors: MedSIR; Eli Lilly and Company Recruiting Mon, 26 Oct 2020 12:00:00 EDT Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung CancerCondition: Non-Small Cell Lung CancerIntervention: Drug: ABI-007 Sponsor: Celgene Corporation Completed Fri, 05 Dec 2003 12:00:00 EST Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.Condition: Esophageal Squamous Cell CarcinomaIntervention: Drug: Anlotinib Hydrochloride, Paclitaxel, cisplatin Sponsors: Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active, not recruiting Wed, 21 Aug 2019 12:00:00 EDT A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung CancerCondition: Small Cell Lung CancerInterventions: Drug: Paclitaxel; Drug: Bevacizumab Sponsors: Hoosier Cancer Research Network; Genentech, Inc.; Walther Cancer Institute Completed Mon, 24 Apr 2006 12:00:00 EDT Evaluation of Votrient in AngiosarcomaCondition: AngiosarcomaIntervention: Drug: Pazopanib + Paclitaxel Sponsors: Heidelberg University; Universitätsmedizin Mannheim; Helios Klinikum Berlin-Buch; University Hospital Dresden; Universitätsklinikum Hamburg-Eppendorf; University Hospital, Essen; Hannover Medical School; Klinikum der Universitaet Muenchen, Grosshadern; Medical University of Vienna; Medical University of Graz; Medical University Innsbruck; Novartis Pharmaceuticals Terminated Fri, 08 Aug 2014 12:00:00 EDT PacLitaxel Eluting Balloon Application In Sfa In Stent RestenosisCondition: Peripheral Arterial DiseaseIntervention: Procedure: PacLitaxel Eluting Balloon Application Sponsor: Nantes University Hospital Completed Mon, 30 Apr 2012 12:00:00 EDT Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II TrialCondition: Breast CancerInterventions: Drug: Paclitaxel; Drug: Vinorelbine; Drug: Herceptin; Drug: Filgrastim Sponsors: University of Washington; Amgen; Bristol-Myers Squibb; GlaxoSmithKline Terminated Wed, 10 Jul 2002 12:00:00 EDT BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid TumorsCondition: Solid TumorsInterventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin; Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin; Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1); Drug: BKM120, Paclitaxel + Carboplatin Sponsors: Memorial Sloan Kettering Cancer Center; Novartis Pharmaceuticals; Sai Life Sciences Completed Wed, 16 Feb 2011 12:00:00 EST
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast CancerCondition: Breast CancerInterventions: Other: Doxorubicin followed by Paclitaxel; Other: Paclitaxel followed by Doxorubicin Sponsors: Massachusetts General Hospital; National Cancer Institute (NCI) Completed Tue, 09 Nov 2004 12:00:00 EST Paclitaxel-bevacizumab in Advanced Lung CancerCondition: Non-squamous Non-small Cell Lung CancerInterventions: Drug: Docetaxel; Drug: Paclitaxel; Drug: Bevacizumab Sponsor: Intergroupe Francophone de Cancerologie Thoracique Completed Wed, 09 Jan 2013 12:00:00 EST Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Apatinib; Drug: Etoposide; Drug: Paclitaxel Sponsor: Jiangsu HengRui Medicine Co., Ltd. Recruiting Thu, 27 Jun 2019 12:00:00 EDT Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCondition: Metastatic Pancreatic AdenocarcinomaInterventions: Drug: APX005M; Drug: Nivolumab; Drug: Nab-Paclitaxel; Drug: Gemcitabine Sponsors: Parker Institute for Cancer Immunotherapy; Bristol-Myers Squibb; Apexigen, Inc.; Cancer Research Institute, New York City Active, not recruiting Tue, 11 Jul 2017 12:00:00 EDT TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerConditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal CancerInterventions: Drug: AMG 386; Drug: AMG 386 Placebo; Drug: Paclitaxel Sponsor: Amgen Completed Fri, 17 Sep 2010 12:00:00 EDT Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast CancerCondition: Breast CancerInterventions: Drug: bevacizumab; Drug: carboplatin; Drug: nab-paclitaxel; Procedure: Surgery; Drug: Adjuvant chemotherapy Sponsors: Ohio State University Comprehensive Cancer Center; Celgene Corporation; Genentech, Inc. Completed Fri, 09 May 2008 12:00:00 EDT A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: GDC-0941; Drug: Placebo; Drug: Paclitaxel Sponsor: Genentech, Inc. Completed Tue, 04 Dec 2012 12:00:00 EST A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With PaclitaxelCondition: Anaplastic Thyroid CancerInterventions: Drug: CS-7017; Drug: Paclitaxel Sponsor: Daiichi Sankyo, Inc. Terminated Tue, 29 Jan 2008 12:00:00 EST Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell CarcinomaCondition: Esophageal Squamous Cell CarcinomaInterventions: Drug: Cisplatin Combined With S-1; Drug: Cisplatin Combined With Paclitaxel Sponsor: Fudan University Unknown status Tue, 09 Feb 2016 12:00:00 EST A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerCondition: Advanced/Metastatic Non-Small Cell Lung CancerInterventions: Drug: Ixabepilone, 32 mg/m^2; Drug: Paclitaxel, 200 mg/m^2; Drug: Carboplatin (area under the concentration curve [AUC] 6) Sponsor: R-Pharm Completed Tue, 29 Jul 2008 12:00:00 EDT
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic CancerCondition: Recurrent Pancreatic CancerInterventions: Drug: Tislelizumab; Drug: Nab paclitaxel; Drug: Gemcitabine Sponsor: Changhai Hospital Recruiting Wed, 26 May 2021 12:00:00 EDT Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCondition: Carcinosarcoma, OvarianInterventions: Drug: Galunisertib; Drug: Paclitaxel; Drug: Carboplatin Sponsors: University of Oklahoma; Eli Lilly and Company Active, not recruiting Sun, 02 Jul 2017 12:00:00 EDT Neoadjuvant Therapy for Ovarian CancerConditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube CancerInterventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab Sponsors: Jason D. Wright; Genentech, Inc. Completed Tue, 22 Jun 2010 12:00:00 EDT Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsCondition: Breast CancerInterventions: Drug: Vinorelbine plus Epirubicin; Drug: Paclitaxel plus Epirubicin Sponsor: Fudan University Completed Fri, 11 Dec 2015 12:00:00 EST A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung CancerCondition: Non Small Cell Lung CancerInterventions: Biological: Ramucirumab; Drug: Paclitaxel; Drug: Carboplatin Sponsor: Eli Lilly and Company Completed Fri, 15 Aug 2008 12:00:00 EDT Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary ArteriesCondition: Coronary Artery DiseaseInterventions: Device: Genous stent implantation with paclitaxel-eluting balloon dilation; Device: Genous stent implantation Sponsors: University of Ulm; B. Braun Melsungen AG; OrbusNeich Completed Tue, 12 Aug 2008 12:00:00 EDT Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid TumorsCondition: Unspecified Adult Solid Tumor, Protocol SpecificInterventions: Drug: Carboplatin; Drug: Abraxane Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI) Completed Thu, 23 Aug 2007 12:00:00 EDT AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic CancerConditions: Borderline Resectable Pancreatic Cancer; Locally Advanced Pancreatic AdenocarcinomaInterventions: Drug: Nab paclitaxel plus gemcitabine; Drug: mFOLFIRINOX Sponsor: Fudan University Recruiting Thu, 05 Nov 2020 12:00:00 EST Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')Condition: Breast CancerIntervention: Drug: Pembrolizumab 200mg +Paclitaxel 80mg/m2 Sponsor: Yonsei University Not yet recruiting Wed, 30 Jun 2021 12:00:00 EDT First Line TIP in Poor Prognosis TGCTs.Condition: Germ Cell TumorInterventions: Drug: Paclitaxel; Drug: Ifosfamide; Drug: Cisplatin Sponsor: National Cancer Institute, Slovakia Completed Mon, 13 Apr 2015 12:00:00 EDT
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Conditions: Carcinosarcoma; Endometrial NeoplasmsInterventions: Drug: Paclitaxel; Drug: Cediranib; Drug: Olaparib Sponsors: University of Manchester; AstraZeneca; Cardiff University Unknown status Wed, 27 Jun 2018 12:00:00 EDT Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast CancerCondition: HER-2 Positive Breast CancerInterventions: Drug: Trastuzumab; Drug: Paclitaxel; Drug: Epirubicin; Drug: Carboplatin Sponsors: Zhimin Shao; Roche Pharma AG Unknown status Mon, 05 Sep 2011 12:00:00 EDT Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Condition: Metastatic Pancreatic Ductal AdenocarcinomaInterventions: Biological: NIS793; Biological: Spartalizumab; Drug: gemcitabine; Drug: nab-paclitaxel Sponsor: Novartis Pharmaceuticals Recruiting Mon, 18 May 2020 12:00:00 EDT Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)Conditions: Triple Negative Breast Cancer; TNBC - Triple-Negative Breast CancerInterventions: Drug: Paclitaxel; Drug: CB-839 Sponsor: Calithera Biosciences, Inc Completed Mon, 20 Feb 2017 12:00:00 EST NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerCondition: HER2-positive Newly Diagnosed, Primary Breast CancerInterventions: Drug: BKM120; Drug: Trastuzumab; Drug: Paclitaxel; Drug: BKM120 Placebo Sponsors: Novartis Pharmaceuticals; Breast International Group; German Breast Group; SOLTI Breast Cancer Research Group Completed Fri, 22 Mar 2013 12:00:00 EDT Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic CancerCondition: Advanced Pancreatic CancerInterventions: Drug: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4; Drug: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4; Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4; Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4 Sponsor: PH Research, S.L. Completed Fri, 06 Mar 2015 12:00:00 EST A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension Sponsors: Veeda Oncology; Celgene Corporation Completed Thu, 10 Nov 2005 12:00:00 EST Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast CancerCondition: Breast CancerInterventions: Drug: Sorafenib; Drug: Cisplatin; Drug: Paclitaxel Sponsors: Emory University; Amgen; Bayer Terminated Fri, 03 Sep 2010 12:00:00 EDT Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic AdenocarcinomaCondition: Pancreatic Ductal AdenocarcinomaIntervention: Drug: nab-Paclitaxel + Cisplatin + Gemcitabine Sponsors: HonorHealth Research Institute; Celgene Active, not recruiting Tue, 16 Apr 2019 12:00:00 EDT A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)Condition: Carcinoma, Non-Small Cell LungInterventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel; Drug: Carboplatin plus Paclitaxel Sponsor: Bayer Terminated Fri, 10 Mar 2006 12:00:00 EST
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung CancerConditions: Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung CancerInterventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Vorinostat; Other: Placebo; Other: Laboratory Biomarker Analysis Sponsor: National Cancer Institute (NCI) Terminated Wed, 10 Aug 2011 12:00:00 EDT Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaConditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Head and NeckInterventions: Drug: nab-paclitaxel; Drug: Cisplatin; Drug: Carboplatin; Biological: Cetuximab Sponsors: Washington University School of Medicine; Celgene Corporation Active, not recruiting Tue, 21 Oct 2014 12:00:00 EDT Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)Condition: Head and Neck Squamous Cell CarcinomaInterventions: Drug: Toripalimab, nab-paclitaxel, carboplatin; Drug: Toripalimab; Procedure: Surgical resection Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting Fri, 19 Mar 2021 12:00:00 EDT Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and RadiationCondition: Uterine CarcinomaInterventions: Drug: Paclitaxel/Carboplatin; Radiation: Pelvic radiation therapy Sponsor: Northwell Health Not yet recruiting Tue, 23 Jul 2019 12:00:00 EDT Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial CancerConditions: Endometrial Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus CancerInterventions: Drug: Paclitaxel; Drug: Carboplatin; Radiation: Internal Radiation Therapy; Radiation: External Beam Radiation Therapy; Other: Laboratory Biomarker Analysis Sponsors: Albert Einstein College of Medicine; National Cancer Institute (NCI) Terminated Wed, 30 Dec 2009 12:00:00 EST Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic CancerConditions: Pancreatic Cancer; Stage IV Pancreatic CancerIntervention: Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine Sponsor: OncoMed Pharmaceuticals, Inc. Completed Thu, 30 Jan 2014 12:00:00 EST Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & AbraxaneCondition: Metastatic Pancreatic CancerInterventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel) Sponsors: Cantex Pharmaceuticals; Translational Drug Development Completed Fri, 28 Oct 2011 12:00:00 EDT The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Placebo; Drug: Veliparib; Drug: Carboplatin; Drug: Temozolomide; Drug: Paclitaxel Sponsor: AbbVie Completed Tue, 10 Jan 2012 12:00:00 EST A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerConditions: Cancer Ovaries; Cancer Peritoneal; Cancer, Fallopian TubeInterventions: Drug: OMP-305B83; Drug: Paclitaxel Sponsor: OncoMed Pharmaceuticals, Inc. Completed Wed, 25 Jan 2017 12:00:00 EST Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by SurgeryConditions: Locally Advanced Thymic Carcinoma; Metastatic Thymic Carcinoma; Recurrent Thymic Carcinoma; Unresectable Thymic CarcinomaInterventions: Drug: Carboplatin; Drug: Paclitaxel; Biological: Ramucirumab Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting Wed, 03 Oct 2018 12:00:00 EDT
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinCondition: Non-small Cell Lung CancerInterventions: Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel; Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel Sponsors: BioNumerik Pharmaceuticals, Inc.; Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019. Completed Thu, 27 Aug 2009 12:00:00 EDT A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial CarcinomaCondition: Urothelial CarcinomaIntervention: Drug: Toripalimab plus Nab-Paclitaxel +/- cisplatin Sponsor: Jun Guo Not yet recruiting Thu, 26 Dec 2019 12:00:00 EST Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerCondition: Non-small Cell Lung CancerInterventions: Drug: sildenafil; Drug: placebo; Drug: paclitaxel (taxol); Drug: carboplatin (palaplatin) Sponsor: Hamamatsu University Completed Mon, 15 Sep 2008 12:00:00 EDT Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerCondition: Breast CancerInterventions: Drug: Onartuzumab; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Bevacizumab Placebo; Drug: Onartuzumab Placebo Sponsors: Genentech, Inc.; Hoffmann-La Roche Completed Mon, 23 Aug 2010 12:00:00 EDT ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaConditions: Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian NeoplasmsInterventions: Drug: ABI-007; Drug: Carboplatin Sponsor: Celgene Terminated Tue, 05 Dec 2006 12:00:00 EST A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer CellsCondition: Gastric Cancer With Positive Exfoliative Cancer CellsInterventions: Drug: apatinib; Drug: paclitaxel; Drug: S-1 Sponsor: Hebei Medical University Unknown status Wed, 24 Oct 2018 12:00:00 EDT Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast CancerConditions: Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast CancerInterventions: Drug: imiquimod; Drug: Abraxane; Other: laboratory biomarker analysis; Genetic: RNA analysis; Other: immunoenzyme technique Sponsors: University of Washington; National Cancer Institute (NCI) Completed Wed, 14 Jan 2009 12:00:00 EST Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCondition: Prostate CancerInterventions: Drug: carboplatin; Drug: paclitaxel Sponsors: Jonsson Comprehensive Cancer Center; Bristol-Myers Squibb Completed Mon, 27 Jan 2003 12:00:00 EST Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerConditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerInterventions: Drug: ganetespib; Drug: paclitaxel; Biological: trastuzumab; Biological: pertuzumab Sponsors: Memorial Sloan Kettering Cancer Center; National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University Cancer Institute Completed Wed, 12 Feb 2014 12:00:00 EST Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsConditions: Cancer; Non-Small Cell Lung Cancer; Endometrial Carcinoma; Ovarian CarcinomaInterventions: Drug: XL147 (SAR245408),; Drug: paclitaxel; Drug: carboplatin Sponsor: Sanofi Completed Mon, 22 Sep 2008 12:00:00 EDT
|